EUKARYOTIC TRANSLATION ELONGATION
|
87
|
4.25e-70
|
2.45e-67
|
1.2300
|
-0.512000
|
0.137000
|
-0.204000
|
8.57e-01
|
-6.78e-01
|
1.54e-16
|
2.73e-02
|
1.02e-03
|
1.20e-43
|
7.01e-28
|
RESPONSE OF EIF2AK4 GCN2 TO AMINO ACID DEFICIENCY
|
94
|
8.77e-65
|
2.53e-62
|
1.1400
|
-0.487000
|
0.073800
|
-0.211000
|
7.62e-01
|
-6.60e-01
|
3.28e-16
|
2.17e-01
|
4.01e-04
|
1.89e-37
|
1.80e-28
|
SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE
|
106
|
6.08e-69
|
2.33e-66
|
1.1000
|
-0.481000
|
0.060500
|
-0.206000
|
7.55e-01
|
-6.11e-01
|
1.13e-17
|
2.82e-01
|
2.43e-04
|
2.89e-41
|
1.58e-27
|
ATTENUATION PHASE
|
23
|
8.18e-10
|
1.33e-08
|
1.0900
|
-0.555000
|
-0.474000
|
-0.390000
|
-3.82e-01
|
-5.94e-01
|
4.09e-06
|
8.30e-05
|
1.20e-03
|
1.53e-03
|
8.16e-07
|
ATF6 ATF6 ALPHA ACTIVATES CHAPERONE GENES
|
10
|
4.53e-04
|
2.25e-03
|
1.0800
|
-0.516000
|
-0.662000
|
-0.503000
|
-1.71e-01
|
-4.14e-01
|
4.70e-03
|
2.89e-04
|
5.89e-03
|
3.50e-01
|
2.34e-02
|
EUKARYOTIC TRANSLATION INITIATION
|
114
|
4.37e-62
|
8.39e-60
|
1.0100
|
-0.426000
|
0.106000
|
-0.135000
|
7.44e-01
|
-5.01e-01
|
3.80e-15
|
5.03e-02
|
1.28e-02
|
5.38e-43
|
2.36e-20
|
SELENOAMINO ACID METABOLISM
|
107
|
6.38e-57
|
8.17e-55
|
1.0100
|
-0.423000
|
0.128000
|
-0.158000
|
7.17e-01
|
-5.25e-01
|
4.10e-14
|
2.27e-02
|
4.68e-03
|
1.01e-37
|
5.83e-21
|
NONSENSE MEDIATED DECAY NMD
|
109
|
1.23e-54
|
1.29e-52
|
0.9720
|
-0.385000
|
0.093800
|
-0.120000
|
6.69e-01
|
-5.72e-01
|
3.96e-12
|
9.08e-02
|
3.07e-02
|
1.36e-33
|
5.59e-25
|
COMPLEX I BIOGENESIS
|
56
|
3.98e-28
|
2.29e-26
|
0.9710
|
-0.504000
|
0.051800
|
-0.064400
|
7.22e-01
|
-4.02e-01
|
6.85e-11
|
5.02e-01
|
4.05e-01
|
8.79e-21
|
1.90e-07
|
HSF1 ACTIVATION
|
25
|
1.20e-07
|
1.38e-06
|
0.9420
|
-0.587000
|
-0.399000
|
-0.418000
|
-1.86e-01
|
-4.17e-01
|
3.83e-07
|
5.47e-04
|
2.93e-04
|
1.07e-01
|
3.06e-04
|
ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 43S
|
59
|
6.17e-25
|
3.23e-23
|
0.9080
|
-0.448000
|
0.081500
|
-0.113000
|
6.59e-01
|
-4.12e-01
|
2.57e-09
|
2.79e-01
|
1.34e-01
|
2.03e-18
|
4.51e-08
|
MITOCHONDRIAL TRANSLATION
|
93
|
8.92e-39
|
5.71e-37
|
0.8930
|
-0.317000
|
0.256000
|
-0.035900
|
7.48e-01
|
-2.67e-01
|
1.24e-07
|
2.01e-05
|
5.50e-01
|
9.42e-36
|
8.92e-06
|
RESPIRATORY ELECTRON TRANSPORT
|
102
|
1.10e-43
|
9.74e-42
|
0.8820
|
-0.440000
|
0.084200
|
-0.059100
|
6.97e-01
|
-2.98e-01
|
1.70e-14
|
1.42e-01
|
3.02e-01
|
3.70e-34
|
2.11e-07
|
ADENYLATE CYCLASE ACTIVATING PATHWAY
|
10
|
1.18e-03
|
4.97e-03
|
0.8750
|
0.302000
|
-0.261000
|
0.177000
|
-7.36e-01
|
1.80e-01
|
9.83e-02
|
1.53e-01
|
3.32e-01
|
5.54e-05
|
3.23e-01
|
MITOCHONDRIAL IRON SULFUR CLUSTER BIOGENESIS
|
13
|
2.23e-04
|
1.18e-03
|
0.8670
|
-0.398000
|
0.221000
|
-0.161000
|
6.31e-01
|
-3.49e-01
|
1.29e-02
|
1.69e-01
|
3.14e-01
|
8.26e-05
|
2.95e-02
|
REGULATION OF EXPRESSION OF SLITS AND ROBOS
|
159
|
1.64e-62
|
3.77e-60
|
0.8660
|
-0.413000
|
0.069300
|
-0.075200
|
5.93e-01
|
-4.66e-01
|
2.84e-19
|
1.32e-01
|
1.02e-01
|
3.09e-38
|
3.43e-24
|
FORMATION OF ATP BY CHEMIOSMOTIC COUPLING
|
18
|
1.68e-07
|
1.89e-06
|
0.8570
|
-0.307000
|
-0.018300
|
-0.129000
|
7.44e-01
|
-2.65e-01
|
2.42e-02
|
8.93e-01
|
3.45e-01
|
4.54e-08
|
5.15e-02
|
RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING PROTEINS
|
125
|
1.57e-49
|
1.51e-47
|
0.8410
|
-0.389000
|
0.080400
|
-0.069700
|
6.87e-01
|
-2.70e-01
|
5.65e-14
|
1.21e-01
|
1.79e-01
|
3.01e-40
|
1.81e-07
|
SLBP DEPENDENT PROCESSING OF REPLICATION DEPENDENT HISTONE PRE MRNAS
|
11
|
1.16e-03
|
4.95e-03
|
0.8260
|
-0.442000
|
0.165000
|
0.199000
|
5.37e-01
|
-3.64e-01
|
1.12e-02
|
3.42e-01
|
2.54e-01
|
2.05e-03
|
3.68e-02
|
REGULATION OF COMMISSURAL AXON PATHFINDING BY SLIT AND ROBO
|
10
|
1.07e-03
|
4.64e-03
|
0.8180
|
0.233000
|
-0.103000
|
0.567000
|
-4.90e-01
|
2.08e-01
|
2.02e-01
|
5.72e-01
|
1.91e-03
|
7.29e-03
|
2.56e-01
|
FORMATION OF FIBRIN CLOT CLOTTING CASCADE
|
18
|
8.81e-07
|
8.38e-06
|
0.8110
|
0.169000
|
0.631000
|
-0.293000
|
2.97e-01
|
2.39e-01
|
2.14e-01
|
3.56e-06
|
3.12e-02
|
2.91e-02
|
7.93e-02
|
SIGNALING BY HIPPO
|
20
|
7.87e-07
|
7.75e-06
|
0.8060
|
-0.401000
|
-0.068100
|
-0.418000
|
-5.43e-01
|
1.20e-01
|
1.90e-03
|
5.98e-01
|
1.20e-03
|
2.62e-05
|
3.51e-01
|
RHOBTB2 GTPASE CYCLE
|
23
|
3.79e-05
|
2.44e-04
|
0.7960
|
-0.422000
|
-0.385000
|
-0.236000
|
-2.38e-01
|
-4.42e-01
|
4.66e-04
|
1.39e-03
|
4.98e-02
|
4.84e-02
|
2.45e-04
|
CAMK IV MEDIATED PHOSPHORYLATION OF CREB
|
10
|
8.28e-03
|
2.51e-02
|
0.7810
|
0.349000
|
-0.255000
|
0.496000
|
-1.40e-01
|
3.98e-01
|
5.63e-02
|
1.63e-01
|
6.62e-03
|
4.44e-01
|
2.95e-02
|
CRISTAE FORMATION
|
31
|
1.60e-10
|
2.79e-09
|
0.7810
|
-0.275000
|
0.052000
|
-0.076300
|
6.90e-01
|
-2.22e-01
|
8.11e-03
|
6.17e-01
|
4.62e-01
|
2.84e-11
|
3.23e-02
|
TRANSLATION
|
286
|
8.05e-94
|
9.27e-91
|
0.7800
|
-0.335000
|
0.141000
|
-0.077900
|
6.18e-01
|
-2.98e-01
|
1.99e-22
|
4.36e-05
|
2.38e-02
|
1.27e-72
|
4.67e-18
|
REGULATION OF RUNX1 EXPRESSION AND ACTIVITY
|
17
|
1.83e-04
|
9.97e-04
|
0.7790
|
0.119000
|
-0.429000
|
-0.163000
|
-5.78e-01
|
-2.21e-01
|
3.96e-01
|
2.22e-03
|
2.44e-01
|
3.72e-05
|
1.15e-01
|
ERYTHROPOIETIN ACTIVATES PHOSPHOINOSITIDE 3 KINASE PI3K
|
11
|
5.54e-03
|
1.81e-02
|
0.7770
|
0.151000
|
-0.635000
|
-0.085500
|
-4.02e-01
|
9.19e-02
|
3.85e-01
|
2.64e-04
|
6.24e-01
|
2.09e-02
|
5.98e-01
|
INTRINSIC PATHWAY OF FIBRIN CLOT FORMATION
|
12
|
1.69e-04
|
9.28e-04
|
0.7750
|
0.031400
|
0.599000
|
-0.429000
|
1.65e-01
|
1.69e-01
|
8.51e-01
|
3.25e-04
|
1.00e-02
|
3.22e-01
|
3.12e-01
|
UNBLOCKING OF NMDA RECEPTORS GLUTAMATE BINDING AND ACTIVATION
|
21
|
1.63e-05
|
1.14e-04
|
0.7690
|
0.437000
|
-0.278000
|
0.406000
|
-2.93e-01
|
2.69e-01
|
5.23e-04
|
2.77e-02
|
1.28e-03
|
2.03e-02
|
3.29e-02
|
REDUCTION OF CYTOSOLIC CA LEVELS
|
11
|
1.31e-02
|
3.62e-02
|
0.7630
|
0.446000
|
-0.173000
|
0.272000
|
-3.19e-01
|
4.22e-01
|
1.05e-02
|
3.19e-01
|
1.19e-01
|
6.74e-02
|
1.53e-02
|
TRAF6 MEDIATED IRF7 ACTIVATION
|
15
|
3.31e-03
|
1.18e-02
|
0.7560
|
-0.176000
|
-0.448000
|
-0.385000
|
-4.35e-01
|
4.76e-02
|
2.38e-01
|
2.64e-03
|
9.89e-03
|
3.54e-03
|
7.50e-01
|
TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTORS
|
17
|
4.81e-04
|
2.38e-03
|
0.7470
|
0.441000
|
-0.100000
|
0.554000
|
-1.12e-01
|
1.85e-01
|
1.66e-03
|
4.75e-01
|
7.59e-05
|
4.22e-01
|
1.86e-01
|
LONG TERM POTENTIATION
|
23
|
1.26e-05
|
8.91e-05
|
0.7430
|
0.442000
|
-0.289000
|
0.325000
|
-3.28e-01
|
2.46e-01
|
2.44e-04
|
1.65e-02
|
7.00e-03
|
6.50e-03
|
4.10e-02
|
INFLUENZA INFECTION
|
145
|
1.16e-41
|
8.32e-40
|
0.7420
|
-0.358000
|
-0.018200
|
-0.108000
|
4.81e-01
|
-4.23e-01
|
9.47e-14
|
7.05e-01
|
2.55e-02
|
1.38e-23
|
1.44e-18
|
SYNAPTIC ADHESION LIKE MOLECULES
|
21
|
7.75e-06
|
5.95e-05
|
0.7420
|
0.328000
|
-0.123000
|
0.520000
|
-3.71e-01
|
1.43e-01
|
9.20e-03
|
3.30e-01
|
3.74e-05
|
3.26e-03
|
2.55e-01
|
CELLULAR RESPONSE TO STARVATION
|
145
|
3.07e-43
|
2.35e-41
|
0.7410
|
-0.304000
|
0.054800
|
-0.062200
|
5.71e-01
|
-3.51e-01
|
2.59e-10
|
2.56e-01
|
1.97e-01
|
1.47e-32
|
3.19e-13
|
PKA MEDIATED PHOSPHORYLATION OF CREB
|
19
|
5.46e-05
|
3.33e-04
|
0.7400
|
-0.030900
|
-0.386000
|
0.051600
|
-6.12e-01
|
1.45e-01
|
8.16e-01
|
3.58e-03
|
6.97e-01
|
3.84e-06
|
2.74e-01
|
RRNA PROCESSING
|
194
|
2.68e-56
|
3.08e-54
|
0.7310
|
-0.290000
|
0.062000
|
-0.001710
|
5.44e-01
|
-3.88e-01
|
3.49e-12
|
1.37e-01
|
9.67e-01
|
4.44e-39
|
1.21e-20
|
BIOTIN TRANSPORT AND METABOLISM
|
11
|
7.31e-03
|
2.26e-02
|
0.7300
|
0.111000
|
0.550000
|
0.338000
|
-9.56e-03
|
3.23e-01
|
5.24e-01
|
1.57e-03
|
5.25e-02
|
9.56e-01
|
6.40e-02
|
CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF ADENYLATE CYCLASE
|
11
|
1.13e-02
|
3.21e-02
|
0.7240
|
-0.319000
|
-0.405000
|
-0.151000
|
-4.66e-01
|
1.36e-01
|
6.72e-02
|
2.02e-02
|
3.87e-01
|
7.40e-03
|
4.34e-01
|
NEGATIVE REGULATION OF NOTCH4 SIGNALING
|
54
|
4.60e-16
|
1.89e-14
|
0.7240
|
-0.382000
|
0.050000
|
0.084900
|
5.82e-01
|
-1.70e-01
|
1.18e-06
|
5.25e-01
|
2.81e-01
|
1.31e-13
|
3.05e-02
|
PRESYNAPTIC DEPOLARIZATION AND CALCIUM CHANNEL OPENING
|
11
|
9.16e-03
|
2.75e-02
|
0.7210
|
0.395000
|
-0.232000
|
0.402000
|
-3.86e-01
|
2.24e-02
|
2.34e-02
|
1.83e-01
|
2.11e-02
|
2.67e-02
|
8.98e-01
|
COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDING
|
26
|
1.69e-06
|
1.53e-05
|
0.7190
|
-0.488000
|
-0.134000
|
-0.058300
|
3.70e-01
|
-3.48e-01
|
1.65e-05
|
2.37e-01
|
6.07e-01
|
1.10e-03
|
2.11e-03
|
TRAF3 DEPENDENT IRF ACTIVATION PATHWAY
|
13
|
1.96e-02
|
4.96e-02
|
0.7160
|
-0.211000
|
-0.401000
|
-0.347000
|
-4.33e-01
|
4.33e-03
|
1.89e-01
|
1.23e-02
|
3.04e-02
|
6.84e-03
|
9.78e-01
|
ADENYLATE CYCLASE INHIBITORY PATHWAY
|
13
|
2.99e-03
|
1.09e-02
|
0.7140
|
0.095900
|
-0.221000
|
0.020000
|
-6.62e-01
|
1.13e-01
|
5.49e-01
|
1.67e-01
|
9.01e-01
|
3.53e-05
|
4.80e-01
|
MITOCHONDRIAL PROTEIN IMPORT
|
63
|
2.86e-17
|
1.27e-15
|
0.7120
|
-0.239000
|
0.176000
|
0.044900
|
6.43e-01
|
-6.04e-02
|
1.03e-03
|
1.60e-02
|
5.38e-01
|
9.77e-19
|
4.07e-01
|
MUCOPOLYSACCHARIDOSES
|
11
|
6.18e-03
|
1.95e-02
|
0.7110
|
0.236000
|
0.428000
|
0.438000
|
-1.92e-01
|
1.92e-01
|
1.75e-01
|
1.39e-02
|
1.19e-02
|
2.69e-01
|
2.70e-01
|
NEGATIVE REGULATION OF NMDA RECEPTOR MEDIATED NEURONAL TRANSMISSION
|
21
|
6.46e-05
|
3.87e-04
|
0.7070
|
0.352000
|
-0.350000
|
0.343000
|
-2.43e-01
|
2.77e-01
|
5.26e-03
|
5.56e-03
|
6.54e-03
|
5.37e-02
|
2.81e-02
|
ATF6 ATF6 ALPHA ACTIVATES CHAPERONES
|
12
|
4.70e-02
|
9.94e-02
|
0.7040
|
-0.333000
|
-0.404000
|
-0.388000
|
-1.37e-01
|
-2.27e-01
|
4.58e-02
|
1.54e-02
|
1.99e-02
|
4.11e-01
|
1.73e-01
|
PURINE CATABOLISM
|
16
|
4.23e-03
|
1.43e-02
|
0.7030
|
-0.042100
|
0.455000
|
0.167000
|
4.89e-01
|
1.36e-01
|
7.71e-01
|
1.64e-03
|
2.47e-01
|
7.02e-04
|
3.46e-01
|
CGMP EFFECTS
|
15
|
4.25e-03
|
1.43e-02
|
0.7020
|
0.466000
|
-0.089800
|
0.494000
|
-5.66e-02
|
1.39e-01
|
1.77e-03
|
5.47e-01
|
9.16e-04
|
7.04e-01
|
3.50e-01
|
RNA POLYMERASE III CHAIN ELONGATION
|
18
|
7.51e-04
|
3.46e-03
|
0.7010
|
0.024600
|
0.279000
|
0.178000
|
6.02e-01
|
1.38e-01
|
8.56e-01
|
4.02e-02
|
1.90e-01
|
9.79e-06
|
3.12e-01
|
NEUROTOXICITY OF CLOSTRIDIUM TOXINS
|
10
|
3.48e-02
|
7.79e-02
|
0.6970
|
0.505000
|
-0.186000
|
0.392000
|
8.36e-03
|
2.09e-01
|
5.73e-03
|
3.09e-01
|
3.20e-02
|
9.63e-01
|
2.52e-01
|
TRANSCRIPTIONAL REGULATION OF PLURIPOTENT STEM CELLS
|
15
|
4.01e-03
|
1.38e-02
|
0.6970
|
-0.020000
|
-0.249000
|
-0.267000
|
-5.83e-01
|
-1.10e-01
|
8.93e-01
|
9.56e-02
|
7.30e-02
|
9.24e-05
|
4.61e-01
|
ABORTIVE ELONGATION OF HIV 1 TRANSCRIPT IN THE ABSENCE OF TAT
|
23
|
1.93e-05
|
1.30e-04
|
0.6910
|
-0.155000
|
0.158000
|
0.310000
|
5.08e-01
|
-2.73e-01
|
1.99e-01
|
1.91e-01
|
1.00e-02
|
2.45e-05
|
2.36e-02
|
INCRETIN SYNTHESIS SECRETION AND INACTIVATION
|
12
|
2.12e-02
|
5.24e-02
|
0.6900
|
-0.559000
|
-0.013400
|
-0.146000
|
1.88e-01
|
-3.28e-01
|
8.06e-04
|
9.36e-01
|
3.82e-01
|
2.58e-01
|
4.94e-02
|
SYNTHESIS SECRETION AND INACTIVATION OF GLUCAGON LIKE PEPTIDE 1 GLP 1
|
12
|
2.12e-02
|
5.24e-02
|
0.6900
|
-0.559000
|
-0.013400
|
-0.146000
|
1.88e-01
|
-3.28e-01
|
8.06e-04
|
9.36e-01
|
3.82e-01
|
2.58e-01
|
4.94e-02
|
LYSOSPHINGOLIPID AND LPA RECEPTORS
|
12
|
3.36e-03
|
1.20e-02
|
0.6890
|
-0.118000
|
-0.063800
|
-0.072300
|
-3.35e-01
|
-5.83e-01
|
4.81e-01
|
7.02e-01
|
6.65e-01
|
4.45e-02
|
4.76e-04
|
DNA METHYLATION
|
17
|
9.36e-04
|
4.13e-03
|
0.6890
|
-0.300000
|
0.147000
|
-0.437000
|
3.37e-01
|
-2.41e-01
|
3.25e-02
|
2.95e-01
|
1.80e-03
|
1.60e-02
|
8.59e-02
|
CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES
|
46
|
8.60e-12
|
2.02e-10
|
0.6850
|
-0.366000
|
0.026200
|
-0.014400
|
5.50e-01
|
-1.79e-01
|
1.73e-05
|
7.59e-01
|
8.66e-01
|
1.12e-10
|
3.56e-02
|
AUF1 HNRNP D0 BINDS AND DESTABILIZES MRNA
|
53
|
3.30e-13
|
1.00e-11
|
0.6830
|
-0.424000
|
-0.016600
|
-0.002230
|
4.73e-01
|
-2.52e-01
|
9.27e-08
|
8.34e-01
|
9.78e-01
|
2.66e-09
|
1.49e-03
|
INTERACTION BETWEEN L1 AND ANKYRINS
|
27
|
3.92e-06
|
3.16e-05
|
0.6830
|
0.293000
|
-0.243000
|
0.365000
|
-4.10e-01
|
1.44e-01
|
8.46e-03
|
2.89e-02
|
1.04e-03
|
2.27e-04
|
1.97e-01
|
CA DEPENDENT EVENTS
|
36
|
4.37e-08
|
5.24e-07
|
0.6830
|
0.236000
|
-0.268000
|
0.264000
|
-4.41e-01
|
2.72e-01
|
1.44e-02
|
5.33e-03
|
6.18e-03
|
4.58e-06
|
4.77e-03
|
ABC TRANSPORTERS IN LIPID HOMEOSTASIS
|
13
|
6.72e-03
|
2.10e-02
|
0.6820
|
0.207000
|
-0.006690
|
0.046400
|
-3.12e-01
|
5.68e-01
|
1.96e-01
|
9.67e-01
|
7.72e-01
|
5.12e-02
|
3.87e-04
|
ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE
|
17
|
1.42e-03
|
5.75e-03
|
0.6810
|
0.486000
|
-0.232000
|
0.360000
|
-1.66e-01
|
1.30e-01
|
5.23e-04
|
9.82e-02
|
1.01e-02
|
2.36e-01
|
3.53e-01
|
SCF SKP2 MEDIATED DEGRADATION OF P27 P21
|
58
|
2.07e-14
|
7.21e-13
|
0.6760
|
-0.410000
|
0.076600
|
0.030300
|
5.07e-01
|
-1.58e-01
|
6.64e-08
|
3.13e-01
|
6.90e-01
|
2.47e-11
|
3.79e-02
|
SYNTHESIS OF PIPS AT THE LATE ENDOSOME MEMBRANE
|
11
|
1.76e-02
|
4.51e-02
|
0.6690
|
0.151000
|
0.009130
|
0.059000
|
-3.55e-01
|
5.43e-01
|
3.87e-01
|
9.58e-01
|
7.35e-01
|
4.13e-02
|
1.83e-03
|
DAG AND IP3 SIGNALING
|
40
|
3.33e-08
|
4.08e-07
|
0.6680
|
0.292000
|
-0.264000
|
0.243000
|
-3.75e-01
|
3.02e-01
|
1.38e-03
|
3.88e-03
|
7.92e-03
|
4.03e-05
|
9.46e-04
|
THE CITRIC ACID TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT
|
172
|
1.29e-43
|
1.06e-41
|
0.6680
|
-0.265000
|
0.112000
|
-0.050000
|
5.86e-01
|
-1.29e-01
|
2.01e-09
|
1.11e-02
|
2.59e-01
|
2.95e-40
|
3.54e-03
|
COOPERATION OF PDCL PHLP1 AND TRIC CCT IN G PROTEIN BETA FOLDING
|
34
|
2.84e-07
|
3.03e-06
|
0.6590
|
-0.423000
|
-0.334000
|
-0.055400
|
1.83e-01
|
-3.27e-01
|
1.94e-05
|
7.65e-04
|
5.76e-01
|
6.54e-02
|
9.76e-04
|
STABILIZATION OF P53
|
54
|
4.93e-13
|
1.38e-11
|
0.6580
|
-0.361000
|
-0.030400
|
-0.030900
|
5.11e-01
|
-1.99e-01
|
4.47e-06
|
6.99e-01
|
6.94e-01
|
8.54e-11
|
1.15e-02
|
THE ROLE OF GTSE1 IN G2 M PROGRESSION AFTER G2 CHECKPOINT
|
65
|
1.17e-15
|
4.49e-14
|
0.6570
|
-0.362000
|
0.008960
|
0.032100
|
5.09e-01
|
-2.01e-01
|
4.49e-07
|
9.01e-01
|
6.55e-01
|
1.23e-12
|
5.05e-03
|
ANTIMICROBIAL PEPTIDES
|
13
|
2.90e-03
|
1.07e-02
|
0.6570
|
0.207000
|
0.331000
|
-0.216000
|
4.47e-01
|
1.79e-01
|
1.95e-01
|
3.87e-02
|
1.77e-01
|
5.21e-03
|
2.64e-01
|
REGULATION OF RUNX3 EXPRESSION AND ACTIVITY
|
53
|
4.79e-13
|
1.38e-11
|
0.6560
|
-0.392000
|
-0.027800
|
0.004050
|
4.99e-01
|
-1.65e-01
|
7.87e-07
|
7.27e-01
|
9.59e-01
|
3.31e-10
|
3.74e-02
|
METABOLISM OF POLYAMINES
|
56
|
3.32e-14
|
1.12e-12
|
0.6560
|
-0.307000
|
0.027500
|
0.033700
|
5.71e-01
|
-9.31e-02
|
7.23e-05
|
7.22e-01
|
6.63e-01
|
1.45e-13
|
2.28e-01
|
SEROTONIN NEUROTRANSMITTER RELEASE CYCLE
|
18
|
9.04e-04
|
4.01e-03
|
0.6550
|
0.348000
|
-0.167000
|
0.449000
|
-2.78e-01
|
3.38e-02
|
1.05e-02
|
2.19e-01
|
9.85e-04
|
4.09e-02
|
8.04e-01
|
DEGRADATION OF DVL
|
55
|
1.06e-13
|
3.39e-12
|
0.6550
|
-0.387000
|
-0.037000
|
0.044400
|
4.94e-01
|
-1.78e-01
|
6.90e-07
|
6.35e-01
|
5.69e-01
|
2.33e-10
|
2.24e-02
|
DISEASES ASSOCIATED WITH GLYCOSYLATION PRECURSOR BIOSYNTHESIS
|
18
|
4.16e-03
|
1.41e-02
|
0.6530
|
0.133000
|
0.175000
|
0.440000
|
3.14e-01
|
2.93e-01
|
3.28e-01
|
1.98e-01
|
1.23e-03
|
2.13e-02
|
3.12e-02
|
VOLTAGE GATED POTASSIUM CHANNELS
|
39
|
9.19e-07
|
8.68e-06
|
0.6510
|
0.425000
|
-0.077900
|
0.355000
|
-2.04e-01
|
2.65e-01
|
4.34e-06
|
4.00e-01
|
1.27e-04
|
2.78e-02
|
4.27e-03
|
DETOXIFICATION OF REACTIVE OXYGEN SPECIES
|
31
|
6.48e-06
|
5.01e-05
|
0.6500
|
-0.340000
|
0.205000
|
-0.132000
|
4.57e-01
|
-1.98e-01
|
1.06e-03
|
4.87e-02
|
2.04e-01
|
1.05e-05
|
5.70e-02
|
RECOGNITION AND ASSOCIATION OF DNA GLYCOSYLASE WITH SITE CONTAINING AN AFFECTED PURINE
|
20
|
8.74e-04
|
3.90e-03
|
0.6500
|
-0.364000
|
0.114000
|
-0.147000
|
4.53e-01
|
-2.23e-01
|
4.86e-03
|
3.78e-01
|
2.56e-01
|
4.51e-04
|
8.37e-02
|
NITRIC OXIDE STIMULATES GUANYLATE CYCLASE
|
21
|
7.70e-04
|
3.53e-03
|
0.6490
|
0.491000
|
-0.088200
|
0.343000
|
-2.05e-01
|
1.15e-01
|
9.89e-05
|
4.84e-01
|
6.49e-03
|
1.03e-01
|
3.64e-01
|
TRANSLATION OF REPLICASE AND ASSEMBLY OF THE REPLICATION TRANSCRIPTION COMPLEX
|
12
|
2.38e-02
|
5.78e-02
|
0.6480
|
0.046200
|
0.135000
|
0.451000
|
3.53e-01
|
2.68e-01
|
7.82e-01
|
4.18e-01
|
6.80e-03
|
3.42e-02
|
1.08e-01
|
SYNTHESIS OF IP2 IP AND INS IN THE CYTOSOL
|
13
|
7.61e-03
|
2.34e-02
|
0.6470
|
0.233000
|
0.314000
|
-0.022600
|
-2.48e-01
|
4.51e-01
|
1.45e-01
|
5.02e-02
|
8.88e-01
|
1.22e-01
|
4.84e-03
|
SHC MEDIATED CASCADE FGFR4
|
10
|
2.40e-02
|
5.79e-02
|
0.6450
|
-0.221000
|
-0.113000
|
-0.552000
|
-2.50e-05
|
2.24e-01
|
2.26e-01
|
5.36e-01
|
2.51e-03
|
1.00e+00
|
2.21e-01
|
HSF1 DEPENDENT TRANSACTIVATION
|
33
|
7.73e-05
|
4.54e-04
|
0.6440
|
-0.292000
|
-0.324000
|
-0.193000
|
-2.77e-01
|
-3.33e-01
|
3.75e-03
|
1.28e-03
|
5.51e-02
|
5.98e-03
|
9.34e-04
|
REGULATION OF PYRUVATE DEHYDROGENASE PDH COMPLEX
|
15
|
1.36e-02
|
3.75e-02
|
0.6440
|
0.275000
|
0.239000
|
0.068500
|
9.51e-02
|
5.17e-01
|
6.51e-02
|
1.08e-01
|
6.46e-01
|
5.24e-01
|
5.25e-04
|
CITRIC ACID CYCLE TCA CYCLE
|
22
|
1.01e-04
|
5.80e-04
|
0.6420
|
0.027500
|
0.200000
|
0.053800
|
4.49e-01
|
4.08e-01
|
8.24e-01
|
1.05e-01
|
6.62e-01
|
2.63e-04
|
9.27e-04
|
DEFECTIVE CFTR CAUSES CYSTIC FIBROSIS
|
58
|
5.80e-13
|
1.57e-11
|
0.6390
|
-0.382000
|
0.006550
|
0.000855
|
4.78e-01
|
-1.86e-01
|
4.90e-07
|
9.31e-01
|
9.91e-01
|
3.08e-10
|
1.43e-02
|
COHESIN LOADING ONTO CHROMATIN
|
10
|
8.39e-02
|
1.55e-01
|
0.6380
|
0.049700
|
-0.254000
|
-0.187000
|
-5.39e-01
|
1.20e-01
|
7.85e-01
|
1.64e-01
|
3.05e-01
|
3.16e-03
|
5.10e-01
|
NEUREXINS AND NEUROLIGINS
|
54
|
1.11e-10
|
2.03e-09
|
0.6370
|
0.300000
|
-0.279000
|
0.280000
|
-3.82e-01
|
1.16e-01
|
1.39e-04
|
3.88e-04
|
3.81e-04
|
1.18e-06
|
1.41e-01
|
RECEPTOR TYPE TYROSINE PROTEIN PHOSPHATASES
|
20
|
7.20e-04
|
3.34e-03
|
0.6360
|
0.080200
|
-0.278000
|
0.098100
|
-4.99e-01
|
2.48e-01
|
5.35e-01
|
3.12e-02
|
4.48e-01
|
1.11e-04
|
5.47e-02
|
IONOTROPIC ACTIVITY OF KAINATE RECEPTORS
|
10
|
2.64e-02
|
6.22e-02
|
0.6350
|
0.285000
|
-0.340000
|
0.329000
|
-1.96e-01
|
-2.43e-01
|
1.19e-01
|
6.23e-02
|
7.15e-02
|
2.82e-01
|
1.84e-01
|
FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC
|
19
|
1.04e-03
|
4.56e-03
|
0.6340
|
-0.449000
|
-0.215000
|
-0.083400
|
2.82e-01
|
-2.60e-01
|
7.00e-04
|
1.05e-01
|
5.29e-01
|
3.33e-02
|
5.00e-02
|
ACTIVATION OF THE AP 1 FAMILY OF TRANSCRIPTION FACTORS
|
10
|
5.54e-02
|
1.12e-01
|
0.6330
|
0.050200
|
-0.369000
|
0.181000
|
-4.75e-01
|
6.05e-02
|
7.83e-01
|
4.34e-02
|
3.21e-01
|
9.23e-03
|
7.40e-01
|
TRAFFICKING OF AMPA RECEPTORS
|
31
|
2.21e-05
|
1.47e-04
|
0.6320
|
0.410000
|
-0.093600
|
0.436000
|
-1.31e-01
|
1.27e-01
|
7.82e-05
|
3.67e-01
|
2.71e-05
|
2.05e-01
|
2.19e-01
|
PKA ACTIVATION IN GLUCAGON SIGNALLING
|
16
|
2.12e-03
|
8.33e-03
|
0.6320
|
-0.025200
|
-0.255000
|
0.130000
|
-5.51e-01
|
1.16e-01
|
8.61e-01
|
7.76e-02
|
3.68e-01
|
1.35e-04
|
4.20e-01
|
MET ACTIVATES RAP1 AND RAC1
|
10
|
1.53e-01
|
2.40e-01
|
0.6320
|
-0.248000
|
-0.399000
|
-0.309000
|
-2.88e-01
|
-1.26e-02
|
1.75e-01
|
2.88e-02
|
9.12e-02
|
1.15e-01
|
9.45e-01
|
AMINE LIGAND BINDING RECEPTORS
|
28
|
5.79e-06
|
4.50e-05
|
0.6310
|
0.238000
|
0.040100
|
0.286000
|
-4.43e-01
|
2.51e-01
|
2.95e-02
|
7.14e-01
|
8.87e-03
|
5.01e-05
|
2.17e-02
|
BRANCHED CHAIN AMINO ACID CATABOLISM
|
21
|
1.65e-04
|
9.12e-04
|
0.6310
|
-0.099600
|
0.327000
|
-0.074200
|
2.99e-01
|
4.31e-01
|
4.29e-01
|
9.45e-03
|
5.56e-01
|
1.77e-02
|
6.22e-04
|
SIGNALING BY ROBO RECEPTORS
|
204
|
1.06e-40
|
7.18e-39
|
0.6270
|
-0.333000
|
0.026200
|
-0.045900
|
3.92e-01
|
-3.55e-01
|
2.32e-16
|
5.19e-01
|
2.60e-01
|
5.37e-22
|
2.23e-18
|
SIGNALING BY NOTCH1 HD DOMAIN MUTANTS IN CANCER
|
15
|
5.00e-03
|
1.66e-02
|
0.6270
|
-0.268000
|
-0.156000
|
0.015100
|
-3.28e-01
|
-4.35e-01
|
7.25e-02
|
2.94e-01
|
9.19e-01
|
2.79e-02
|
3.51e-03
|
SIGNALING BY FGFR4 IN DISEASE
|
10
|
1.91e-01
|
2.82e-01
|
0.6230
|
-0.207000
|
-0.428000
|
-0.269000
|
-2.66e-01
|
-1.39e-01
|
2.57e-01
|
1.91e-02
|
1.41e-01
|
1.45e-01
|
4.46e-01
|
MITOCHONDRIAL FATTY ACID BETA OXIDATION
|
33
|
1.51e-06
|
1.38e-05
|
0.6230
|
-0.089100
|
0.392000
|
-0.214000
|
4.16e-01
|
9.12e-02
|
3.76e-01
|
9.78e-05
|
3.36e-02
|
3.59e-05
|
3.65e-01
|
INHIBITION OF DNA RECOMBINATION AT TELOMERE
|
33
|
4.70e-06
|
3.71e-05
|
0.6220
|
-0.263000
|
0.093900
|
-0.098900
|
4.71e-01
|
-2.78e-01
|
8.92e-03
|
3.51e-01
|
3.25e-01
|
2.85e-06
|
5.65e-03
|
SYNTHESIS OF PIPS AT THE GOLGI MEMBRANE
|
15
|
1.42e-02
|
3.86e-02
|
0.6200
|
0.249000
|
-0.014700
|
0.349000
|
-2.69e-01
|
3.58e-01
|
9.55e-02
|
9.22e-01
|
1.94e-02
|
7.08e-02
|
1.63e-02
|
PROCESSING OF SMDT1
|
16
|
9.31e-03
|
2.78e-02
|
0.6200
|
-0.019600
|
0.310000
|
-0.005890
|
5.34e-01
|
5.61e-02
|
8.92e-01
|
3.19e-02
|
9.67e-01
|
2.19e-04
|
6.98e-01
|
DEGRADATION OF AXIN
|
53
|
5.62e-11
|
1.10e-09
|
0.6170
|
-0.381000
|
0.015600
|
0.000221
|
4.58e-01
|
-1.60e-01
|
1.56e-06
|
8.44e-01
|
9.98e-01
|
8.27e-09
|
4.44e-02
|
EFFECTS OF PIP2 HYDROLYSIS
|
27
|
3.00e-04
|
1.55e-03
|
0.6140
|
0.417000
|
-0.166000
|
0.250000
|
-1.52e-01
|
3.00e-01
|
1.78e-04
|
1.35e-01
|
2.48e-02
|
1.71e-01
|
6.89e-03
|
ASPARTATE AND ASPARAGINE METABOLISM
|
11
|
8.22e-02
|
1.52e-01
|
0.6100
|
0.140000
|
0.333000
|
0.075300
|
1.26e-01
|
4.69e-01
|
4.23e-01
|
5.55e-02
|
6.65e-01
|
4.68e-01
|
7.09e-03
|
RETROGRADE NEUROTROPHIN SIGNALLING
|
12
|
5.98e-02
|
1.20e-01
|
0.6100
|
0.207000
|
0.168000
|
0.446000
|
-7.89e-02
|
3.09e-01
|
2.14e-01
|
3.14e-01
|
7.50e-03
|
6.36e-01
|
6.37e-02
|
LOSS OF FUNCTION OF MECP2 IN RETT SYNDROME
|
13
|
1.48e-02
|
3.96e-02
|
0.6080
|
0.105000
|
-0.458000
|
0.273000
|
-2.61e-01
|
-7.86e-02
|
5.14e-01
|
4.29e-03
|
8.81e-02
|
1.03e-01
|
6.24e-01
|
SEMA3A PLEXIN REPULSION SIGNALING BY INHIBITING INTEGRIN ADHESION
|
14
|
7.37e-03
|
2.28e-02
|
0.6070
|
0.025300
|
-0.439000
|
0.157000
|
-2.55e-01
|
2.91e-01
|
8.70e-01
|
4.43e-03
|
3.08e-01
|
9.90e-02
|
5.94e-02
|
NF KB ACTIVATION THROUGH FADD RIP 1 PATHWAY MEDIATED BY CASPASE 8 AND 10
|
11
|
4.17e-02
|
9.01e-02
|
0.6050
|
0.070100
|
-0.082200
|
-0.401000
|
-4.07e-01
|
1.68e-01
|
6.87e-01
|
6.37e-01
|
2.13e-02
|
1.94e-02
|
3.35e-01
|
SYNTHESIS OF PIPS AT THE EARLY ENDOSOME MEMBRANE
|
16
|
7.70e-03
|
2.36e-02
|
0.6040
|
0.179000
|
-0.012100
|
0.035400
|
-3.88e-01
|
4.26e-01
|
2.14e-01
|
9.33e-01
|
8.07e-01
|
7.28e-03
|
3.21e-03
|
G PROTEIN ACTIVATION
|
21
|
1.41e-03
|
5.75e-03
|
0.6030
|
-0.377000
|
-0.237000
|
0.020200
|
1.36e-01
|
-3.83e-01
|
2.81e-03
|
6.05e-02
|
8.73e-01
|
2.79e-01
|
2.36e-03
|
RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF HSCS
|
80
|
6.68e-14
|
2.20e-12
|
0.6020
|
-0.375000
|
0.055900
|
-0.129000
|
3.88e-01
|
-2.27e-01
|
6.70e-09
|
3.88e-01
|
4.57e-02
|
2.09e-09
|
4.61e-04
|
PYROPTOSIS
|
20
|
1.20e-03
|
5.05e-03
|
0.5970
|
-0.285000
|
0.023200
|
0.025900
|
4.90e-01
|
-1.85e-01
|
2.74e-02
|
8.57e-01
|
8.41e-01
|
1.49e-04
|
1.51e-01
|
ASSEMBLY OF THE PRE REPLICATIVE COMPLEX
|
64
|
5.87e-13
|
1.57e-11
|
0.5970
|
-0.294000
|
0.054600
|
0.072000
|
5.02e-01
|
-9.72e-02
|
4.77e-05
|
4.50e-01
|
3.20e-01
|
3.71e-12
|
1.79e-01
|
FORMATION OF THE EARLY ELONGATION COMPLEX
|
33
|
1.04e-05
|
7.64e-05
|
0.5960
|
-0.155000
|
0.177000
|
0.276000
|
4.37e-01
|
-1.81e-01
|
1.25e-01
|
7.85e-02
|
6.01e-03
|
1.38e-05
|
7.20e-02
|
DECTIN 1 MEDIATED NONCANONICAL NF KB SIGNALING
|
58
|
1.81e-11
|
4.01e-10
|
0.5960
|
-0.325000
|
0.007530
|
0.013700
|
4.76e-01
|
-1.51e-01
|
1.92e-05
|
9.21e-01
|
8.57e-01
|
3.65e-10
|
4.73e-02
|
APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY G1
|
70
|
2.02e-13
|
6.30e-12
|
0.5930
|
-0.343000
|
0.067900
|
0.030500
|
4.60e-01
|
-1.31e-01
|
6.93e-07
|
3.26e-01
|
6.60e-01
|
2.79e-11
|
5.91e-02
|
HEDGEHOG LIGAND BIOGENESIS
|
61
|
4.92e-11
|
1.00e-09
|
0.5930
|
-0.400000
|
-0.002100
|
-0.040600
|
3.86e-01
|
-2.04e-01
|
6.59e-08
|
9.77e-01
|
5.83e-01
|
1.89e-07
|
5.87e-03
|
CONSTITUTIVE SIGNALING BY EGFRVIII
|
15
|
8.43e-02
|
1.55e-01
|
0.5930
|
-0.218000
|
-0.368000
|
-0.277000
|
-2.21e-01
|
-2.08e-01
|
1.43e-01
|
1.37e-02
|
6.30e-02
|
1.38e-01
|
1.64e-01
|
PROTEIN PROTEIN INTERACTIONS AT SYNAPSES
|
85
|
4.17e-15
|
1.55e-13
|
0.5920
|
0.227000
|
-0.234000
|
0.262000
|
-3.91e-01
|
1.50e-01
|
2.94e-04
|
1.91e-04
|
3.06e-05
|
4.60e-10
|
1.72e-02
|
SIGNALING BY CTNNB1 PHOSPHO SITE MUTANTS
|
15
|
2.74e-03
|
1.02e-02
|
0.5920
|
-0.161000
|
-0.131000
|
0.000706
|
-3.99e-01
|
3.85e-01
|
2.81e-01
|
3.78e-01
|
9.96e-01
|
7.52e-03
|
9.88e-03
|
DEGRADATION OF GLI1 BY THE PROTEASOME
|
57
|
7.04e-11
|
1.31e-09
|
0.5910
|
-0.365000
|
0.014600
|
-0.010500
|
4.43e-01
|
-1.42e-01
|
1.90e-06
|
8.49e-01
|
8.91e-01
|
7.44e-09
|
6.32e-02
|
RORA ACTIVATES GENE EXPRESSION
|
18
|
8.13e-03
|
2.47e-02
|
0.5910
|
0.313000
|
-0.285000
|
-0.032600
|
-3.81e-01
|
1.53e-01
|
2.16e-02
|
3.60e-02
|
8.11e-01
|
5.17e-03
|
2.62e-01
|
APOPTOSIS INDUCED DNA FRAGMENTATION
|
10
|
4.86e-02
|
1.02e-01
|
0.5890
|
0.103000
|
0.401000
|
-0.267000
|
1.36e-01
|
2.92e-01
|
5.72e-01
|
2.83e-02
|
1.43e-01
|
4.56e-01
|
1.10e-01
|
REGULATION OF MECP2 EXPRESSION AND ACTIVITY
|
29
|
1.30e-04
|
7.36e-04
|
0.5870
|
0.190000
|
-0.338000
|
0.117000
|
-4.25e-01
|
-1.68e-02
|
7.60e-02
|
1.65e-03
|
2.75e-01
|
7.36e-05
|
8.76e-01
|
DOPAMINE NEUROTRANSMITTER RELEASE CYCLE
|
23
|
6.23e-04
|
2.94e-03
|
0.5870
|
0.280000
|
-0.228000
|
0.376000
|
-2.69e-01
|
3.23e-02
|
2.02e-02
|
5.86e-02
|
1.79e-03
|
2.58e-02
|
7.89e-01
|
RRNA PROCESSING IN THE MITOCHONDRION
|
10
|
9.35e-02
|
1.68e-01
|
0.5870
|
0.023500
|
0.093100
|
0.359000
|
3.61e-01
|
2.76e-01
|
8.97e-01
|
6.10e-01
|
4.91e-02
|
4.80e-02
|
1.31e-01
|
PURINE SALVAGE
|
12
|
2.98e-02
|
6.87e-02
|
0.5860
|
-0.261000
|
0.194000
|
0.190000
|
4.28e-01
|
1.36e-01
|
1.18e-01
|
2.46e-01
|
2.54e-01
|
1.03e-02
|
4.14e-01
|
METABOLISM OF AMINO ACIDS AND DERIVATIVES
|
304
|
5.08e-58
|
7.31e-56
|
0.5860
|
-0.244000
|
0.138000
|
-0.079800
|
5.01e-01
|
-8.52e-02
|
3.01e-13
|
3.46e-05
|
1.71e-02
|
4.48e-51
|
1.08e-02
|
MRNA SPLICING MINOR PATHWAY
|
52
|
4.20e-09
|
6.21e-08
|
0.5830
|
-0.280000
|
0.101000
|
0.152000
|
3.22e-01
|
-3.54e-01
|
4.77e-04
|
2.07e-01
|
5.86e-02
|
6.03e-05
|
1.03e-05
|
CHEMOKINE RECEPTORS BIND CHEMOKINES
|
12
|
8.58e-02
|
1.57e-01
|
0.5830
|
-0.121000
|
-0.318000
|
-0.056000
|
-1.98e-01
|
-4.26e-01
|
4.68e-01
|
5.65e-02
|
7.37e-01
|
2.36e-01
|
1.07e-02
|
LGI ADAM INTERACTIONS
|
14
|
2.75e-02
|
6.42e-02
|
0.5800
|
0.342000
|
-0.121000
|
0.452000
|
-3.17e-02
|
-1.24e-02
|
2.68e-02
|
4.33e-01
|
3.43e-03
|
8.37e-01
|
9.36e-01
|
SIGNALING BY FGFR3 FUSIONS IN CANCER
|
10
|
1.98e-01
|
2.90e-01
|
0.5790
|
-0.213000
|
-0.293000
|
-0.405000
|
-1.97e-01
|
3.06e-02
|
2.42e-01
|
1.08e-01
|
2.65e-02
|
2.82e-01
|
8.67e-01
|
MECP2 REGULATES NEURONAL RECEPTORS AND CHANNELS
|
18
|
8.64e-03
|
2.61e-02
|
0.5790
|
0.309000
|
-0.246000
|
0.213000
|
-3.64e-01
|
4.63e-02
|
2.34e-02
|
7.10e-02
|
1.19e-01
|
7.55e-03
|
7.34e-01
|
GRB2 SOS PROVIDES LINKAGE TO MAPK SIGNALING FOR INTEGRINS
|
12
|
1.30e-01
|
2.13e-01
|
0.5790
|
-0.308000
|
-0.330000
|
-0.156000
|
-3.09e-01
|
-1.02e-01
|
6.43e-02
|
4.76e-02
|
3.49e-01
|
6.35e-02
|
5.42e-01
|
RHOBTB GTPASE CYCLE
|
35
|
6.29e-04
|
2.96e-03
|
0.5760
|
-0.318000
|
-0.287000
|
-0.208000
|
-2.05e-01
|
-2.52e-01
|
1.14e-03
|
3.36e-03
|
3.35e-02
|
3.56e-02
|
9.92e-03
|
NUCLEOTIDE LIKE PURINERGIC RECEPTORS
|
12
|
1.38e-01
|
2.23e-01
|
0.5760
|
-0.220000
|
-0.123000
|
-0.440000
|
-2.24e-01
|
-1.56e-01
|
1.87e-01
|
4.62e-01
|
8.31e-03
|
1.79e-01
|
3.50e-01
|
STING MEDIATED INDUCTION OF HOST IMMUNE RESPONSES
|
14
|
1.18e-01
|
2.01e-01
|
0.5740
|
-0.154000
|
-0.290000
|
-0.286000
|
-2.68e-01
|
-2.60e-01
|
3.18e-01
|
6.04e-02
|
6.36e-02
|
8.26e-02
|
9.22e-02
|
SODIUM CALCIUM EXCHANGERS
|
10
|
1.52e-01
|
2.40e-01
|
0.5740
|
0.257000
|
-0.127000
|
0.180000
|
-3.86e-01
|
2.56e-01
|
1.60e-01
|
4.87e-01
|
3.25e-01
|
3.44e-02
|
1.61e-01
|
FGFR2 ALTERNATIVE SPLICING
|
25
|
5.67e-04
|
2.71e-03
|
0.5720
|
-0.208000
|
-0.055100
|
0.023000
|
2.82e-01
|
-4.48e-01
|
7.22e-02
|
6.34e-01
|
8.42e-01
|
1.46e-02
|
1.07e-04
|
SIGNALING BY FGFR2 IIIA TM
|
19
|
3.78e-03
|
1.31e-02
|
0.5710
|
-0.099700
|
0.078000
|
0.010400
|
4.82e-01
|
-2.79e-01
|
4.52e-01
|
5.56e-01
|
9.37e-01
|
2.77e-04
|
3.54e-02
|
REGULATION OF INNATE IMMUNE RESPONSES TO CYTOSOLIC DNA
|
13
|
1.28e-01
|
2.11e-01
|
0.5710
|
-0.383000
|
-0.212000
|
-0.148000
|
-3.25e-02
|
-3.33e-01
|
1.67e-02
|
1.86e-01
|
3.54e-01
|
8.39e-01
|
3.76e-02
|
AKT PHOSPHORYLATES TARGETS IN THE NUCLEUS
|
10
|
1.27e-01
|
2.10e-01
|
0.5700
|
0.159000
|
-0.478000
|
0.016300
|
-2.62e-01
|
-4.47e-02
|
3.83e-01
|
8.84e-03
|
9.29e-01
|
1.52e-01
|
8.07e-01
|
ACTIVATED PKN1 STIMULATES TRANSCRIPTION OF AR ANDROGEN RECEPTOR REGULATED GENES KLK2 AND KLK3
|
19
|
1.09e-02
|
3.14e-02
|
0.5700
|
-0.365000
|
0.184000
|
-0.277000
|
2.52e-01
|
-1.32e-01
|
5.91e-03
|
1.65e-01
|
3.69e-02
|
5.70e-02
|
3.18e-01
|
INTERFERON ALPHA BETA SIGNALING
|
53
|
2.30e-07
|
2.52e-06
|
0.5700
|
-0.150000
|
-0.298000
|
-0.308000
|
-1.08e-02
|
-3.44e-01
|
5.84e-02
|
1.73e-04
|
1.08e-04
|
8.92e-01
|
1.51e-05
|
ERYTHROPOIETIN ACTIVATES RAS
|
13
|
2.41e-02
|
5.79e-02
|
0.5680
|
-0.118000
|
-0.436000
|
-0.231000
|
-1.17e-01
|
2.27e-01
|
4.61e-01
|
6.47e-03
|
1.49e-01
|
4.66e-01
|
1.57e-01
|
G1 S DNA DAMAGE CHECKPOINTS
|
64
|
1.89e-11
|
4.12e-10
|
0.5680
|
-0.316000
|
-0.009870
|
-0.051100
|
4.48e-01
|
-1.40e-01
|
1.27e-05
|
8.91e-01
|
4.80e-01
|
5.76e-10
|
5.34e-02
|
PINK1 PRKN MEDIATED MITOPHAGY
|
22
|
7.20e-04
|
3.34e-03
|
0.5680
|
-0.213000
|
0.025500
|
0.070500
|
5.11e-01
|
-9.99e-02
|
8.34e-02
|
8.36e-01
|
5.67e-01
|
3.34e-05
|
4.17e-01
|
WNT5A DEPENDENT INTERNALIZATION OF FZD4
|
15
|
2.75e-02
|
6.42e-02
|
0.5660
|
0.193000
|
-0.015700
|
0.506000
|
-1.55e-02
|
1.63e-01
|
1.95e-01
|
9.16e-01
|
6.92e-04
|
9.17e-01
|
2.73e-01
|
SIRT1 NEGATIVELY REGULATES RRNA EXPRESSION
|
22
|
3.44e-03
|
1.22e-02
|
0.5640
|
-0.286000
|
0.123000
|
-0.335000
|
2.95e-01
|
-1.50e-01
|
2.04e-02
|
3.17e-01
|
6.49e-03
|
1.67e-02
|
2.24e-01
|
PROSTACYCLIN SIGNALLING THROUGH PROSTACYCLIN RECEPTOR
|
16
|
1.52e-02
|
4.05e-02
|
0.5630
|
-0.369000
|
-0.095100
|
0.037000
|
3.09e-01
|
-2.74e-01
|
1.06e-02
|
5.10e-01
|
7.98e-01
|
3.23e-02
|
5.75e-02
|
REGULATION OF HMOX1 EXPRESSION AND ACTIVITY
|
63
|
2.18e-10
|
3.69e-09
|
0.5630
|
-0.312000
|
0.074500
|
-0.004310
|
4.42e-01
|
-1.37e-01
|
1.90e-05
|
3.07e-01
|
9.53e-01
|
1.32e-09
|
6.08e-02
|
SIGNALING BY BMP
|
25
|
2.15e-03
|
8.42e-03
|
0.5620
|
-0.095100
|
-0.197000
|
-0.260000
|
-4.35e-01
|
1.07e-01
|
4.10e-01
|
8.87e-02
|
2.42e-02
|
1.67e-04
|
3.57e-01
|
CONDENSATION OF PROPHASE CHROMOSOMES
|
25
|
1.38e-03
|
5.66e-03
|
0.5610
|
-0.304000
|
0.133000
|
-0.377000
|
2.22e-01
|
-1.13e-01
|
8.44e-03
|
2.51e-01
|
1.10e-03
|
5.43e-02
|
3.26e-01
|
DEACTIVATION OF THE BETA CATENIN TRANSACTIVATING COMPLEX
|
41
|
1.23e-05
|
8.76e-05
|
0.5600
|
-0.197000
|
-0.152000
|
-0.203000
|
-4.21e-01
|
-1.82e-01
|
2.90e-02
|
9.13e-02
|
2.49e-02
|
3.06e-06
|
4.36e-02
|
GOLGI CISTERNAE PERICENTRIOLAR STACK REORGANIZATION
|
11
|
1.17e-01
|
1.99e-01
|
0.5590
|
0.137000
|
0.055800
|
0.280000
|
2.56e-01
|
3.84e-01
|
4.32e-01
|
7.49e-01
|
1.08e-01
|
1.42e-01
|
2.75e-02
|
PI 3K CASCADE FGFR4
|
10
|
9.71e-02
|
1.73e-01
|
0.5590
|
-0.034000
|
-0.093000
|
-0.501000
|
-1.90e-01
|
1.26e-01
|
8.52e-01
|
6.11e-01
|
6.10e-03
|
2.97e-01
|
4.89e-01
|
HEME SIGNALING
|
44
|
3.77e-06
|
3.08e-05
|
0.5590
|
0.271000
|
-0.267000
|
0.117000
|
-3.59e-01
|
1.61e-01
|
1.90e-03
|
2.15e-03
|
1.81e-01
|
3.87e-05
|
6.48e-02
|
ORC1 REMOVAL FROM CHROMATIN
|
66
|
4.95e-11
|
1.00e-09
|
0.5560
|
-0.311000
|
0.067300
|
0.014500
|
4.44e-01
|
-1.05e-01
|
1.26e-05
|
3.45e-01
|
8.39e-01
|
4.50e-10
|
1.40e-01
|
RHOBTB3 ATPASE CYCLE
|
10
|
3.96e-02
|
8.69e-02
|
0.5560
|
-0.314000
|
0.113000
|
-0.213000
|
-9.32e-02
|
3.79e-01
|
8.53e-02
|
5.36e-01
|
2.44e-01
|
6.10e-01
|
3.81e-02
|
DSCAM INTERACTIONS
|
10
|
1.28e-01
|
2.11e-01
|
0.5550
|
0.304000
|
-0.273000
|
0.343000
|
-1.52e-01
|
1.57e-02
|
9.55e-02
|
1.35e-01
|
6.05e-02
|
4.05e-01
|
9.31e-01
|
CALNEXIN CALRETICULIN CYCLE
|
26
|
5.00e-03
|
1.66e-02
|
0.5550
|
-0.365000
|
-0.286000
|
-0.229000
|
-1.87e-01
|
-7.28e-02
|
1.27e-03
|
1.17e-02
|
4.30e-02
|
9.85e-02
|
5.21e-01
|
ERK MAPK TARGETS
|
22
|
3.85e-03
|
1.33e-02
|
0.5540
|
0.220000
|
-0.229000
|
0.262000
|
-1.98e-01
|
3.13e-01
|
7.46e-02
|
6.29e-02
|
3.31e-02
|
1.08e-01
|
1.10e-02
|
CONSTITUTIVE SIGNALING BY OVEREXPRESSED ERBB2
|
11
|
1.43e-01
|
2.29e-01
|
0.5530
|
-0.308000
|
-0.284000
|
-0.361000
|
-6.12e-03
|
1.03e-02
|
7.68e-02
|
1.03e-01
|
3.84e-02
|
9.72e-01
|
9.53e-01
|
RNA POLYMERASE I PROMOTER ESCAPE
|
45
|
3.07e-06
|
2.57e-05
|
0.5530
|
-0.293000
|
0.138000
|
-0.050800
|
3.89e-01
|
-2.15e-01
|
6.61e-04
|
1.09e-01
|
5.56e-01
|
6.29e-06
|
1.26e-02
|
ANTIGEN PROCESSING CROSS PRESENTATION
|
91
|
5.24e-15
|
1.89e-13
|
0.5520
|
-0.305000
|
-0.051400
|
-0.185000
|
3.85e-01
|
-1.64e-01
|
4.97e-07
|
3.97e-01
|
2.32e-03
|
2.18e-10
|
6.96e-03
|
DEGRADATION OF CYSTEINE AND HOMOCYSTEINE
|
13
|
2.51e-02
|
5.98e-02
|
0.5510
|
-0.075000
|
0.134000
|
-0.006940
|
3.71e-01
|
3.77e-01
|
6.40e-01
|
4.04e-01
|
9.65e-01
|
2.05e-02
|
1.85e-02
|
CHOLESTEROL BIOSYNTHESIS
|
24
|
2.06e-04
|
1.11e-03
|
0.5500
|
-0.487000
|
-0.216000
|
0.008680
|
-1.25e-01
|
-5.51e-02
|
3.58e-05
|
6.69e-02
|
9.41e-01
|
2.91e-01
|
6.41e-01
|
SIGNALING BY ERBB2 ECD MUTANTS
|
16
|
1.23e-01
|
2.06e-01
|
0.5480
|
-0.265000
|
-0.304000
|
-0.269000
|
-1.81e-01
|
-1.80e-01
|
6.63e-02
|
3.52e-02
|
6.24e-02
|
2.11e-01
|
2.13e-01
|
PCNA DEPENDENT LONG PATCH BASE EXCISION REPAIR
|
20
|
1.10e-02
|
3.15e-02
|
0.5470
|
-0.167000
|
0.214000
|
0.120000
|
4.57e-01
|
-5.19e-02
|
1.97e-01
|
9.82e-02
|
3.52e-01
|
4.03e-04
|
6.88e-01
|
UNWINDING OF DNA
|
12
|
1.92e-01
|
2.82e-01
|
0.5470
|
0.113000
|
0.243000
|
0.250000
|
2.72e-01
|
3.01e-01
|
4.97e-01
|
1.45e-01
|
1.34e-01
|
1.03e-01
|
7.10e-02
|
ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MHC
|
22
|
2.80e-02
|
6.51e-02
|
0.5450
|
-0.337000
|
-0.223000
|
-0.293000
|
-1.92e-01
|
-1.04e-01
|
6.23e-03
|
6.96e-02
|
1.74e-02
|
1.20e-01
|
4.00e-01
|
MISCELLANEOUS TRANSPORT AND BINDING EVENTS
|
20
|
1.45e-02
|
3.91e-02
|
0.5440
|
0.296000
|
-0.186000
|
0.028700
|
-3.20e-01
|
2.67e-01
|
2.21e-02
|
1.50e-01
|
8.24e-01
|
1.33e-02
|
3.90e-02
|
NEGATIVE REGULATION OF TCF DEPENDENT SIGNALING BY WNT LIGAND ANTAGONISTS
|
10
|
4.61e-02
|
9.77e-02
|
0.5440
|
-0.045800
|
0.169000
|
0.012000
|
-3.89e-01
|
3.37e-01
|
8.02e-01
|
3.54e-01
|
9.48e-01
|
3.34e-02
|
6.50e-02
|
CELLULAR RESPONSE TO HYPOXIA
|
71
|
4.32e-11
|
9.05e-10
|
0.5430
|
-0.322000
|
0.025600
|
-0.018500
|
4.08e-01
|
-1.53e-01
|
2.71e-06
|
7.09e-01
|
7.87e-01
|
2.74e-09
|
2.54e-02
|
COMPLEMENT CASCADE
|
23
|
1.65e-05
|
1.14e-04
|
0.5430
|
0.186000
|
0.247000
|
-0.399000
|
1.58e-01
|
-1.22e-01
|
1.22e-01
|
4.02e-02
|
9.29e-04
|
1.89e-01
|
3.13e-01
|
INTERLEUKIN 6 SIGNALING
|
10
|
1.49e-01
|
2.37e-01
|
0.5420
|
0.294000
|
-0.263000
|
-0.143000
|
-2.70e-01
|
2.11e-01
|
1.08e-01
|
1.51e-01
|
4.32e-01
|
1.39e-01
|
2.47e-01
|
GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATION
|
31
|
2.85e-04
|
1.48e-03
|
0.5420
|
-0.306000
|
0.084700
|
-0.082400
|
4.03e-01
|
-1.52e-01
|
3.17e-03
|
4.14e-01
|
4.27e-01
|
1.02e-04
|
1.44e-01
|
G PROTEIN MEDIATED EVENTS
|
51
|
5.24e-07
|
5.39e-06
|
0.5410
|
0.157000
|
-0.227000
|
0.115000
|
-3.72e-01
|
2.55e-01
|
5.28e-02
|
5.10e-03
|
1.57e-01
|
4.35e-06
|
1.63e-03
|
FCGR3A MEDIATED IL10 SYNTHESIS
|
32
|
4.51e-04
|
2.25e-03
|
0.5390
|
-0.051600
|
-0.292000
|
-0.114000
|
-4.02e-01
|
1.68e-01
|
6.13e-01
|
4.27e-03
|
2.66e-01
|
8.28e-05
|
9.93e-02
|
SEMA3A PAK DEPENDENT AXON REPULSION
|
16
|
3.89e-02
|
8.59e-02
|
0.5390
|
-0.140000
|
-0.401000
|
-0.003780
|
-3.30e-01
|
4.04e-02
|
3.34e-01
|
5.45e-03
|
9.79e-01
|
2.25e-02
|
7.80e-01
|
OLFACTORY SIGNALING PATHWAY
|
22
|
1.43e-04
|
7.98e-04
|
0.5390
|
0.152000
|
-0.098200
|
-0.298000
|
-3.31e-02
|
-4.10e-01
|
2.17e-01
|
4.26e-01
|
1.54e-02
|
7.88e-01
|
8.82e-04
|
CELLULAR HEXOSE TRANSPORT
|
10
|
3.32e-01
|
4.28e-01
|
0.5360
|
0.214000
|
0.213000
|
0.330000
|
3.23e-02
|
2.94e-01
|
2.42e-01
|
2.45e-01
|
7.06e-02
|
8.60e-01
|
1.08e-01
|
BETA CATENIN PHOSPHORYLATION CASCADE
|
16
|
5.92e-03
|
1.90e-02
|
0.5350
|
-0.118000
|
-0.094900
|
0.058900
|
-3.44e-01
|
3.76e-01
|
4.14e-01
|
5.11e-01
|
6.83e-01
|
1.71e-02
|
9.20e-03
|
GP1B IX V ACTIVATION SIGNALLING
|
10
|
1.83e-01
|
2.74e-01
|
0.5330
|
0.275000
|
0.338000
|
0.259000
|
-1.14e-01
|
1.18e-01
|
1.33e-01
|
6.41e-02
|
1.56e-01
|
5.31e-01
|
5.17e-01
|
CROSSLINKING OF COLLAGEN FIBRILS
|
14
|
4.14e-02
|
8.96e-02
|
0.5330
|
0.270000
|
0.137000
|
0.392000
|
-1.95e-01
|
3.98e-03
|
7.98e-02
|
3.76e-01
|
1.11e-02
|
2.06e-01
|
9.79e-01
|
THROMBOXANE SIGNALLING THROUGH TP RECEPTOR
|
21
|
3.46e-03
|
1.22e-02
|
0.5320
|
-0.322000
|
-0.262000
|
0.030500
|
2.11e-01
|
-2.57e-01
|
1.07e-02
|
3.79e-02
|
8.09e-01
|
9.48e-02
|
4.15e-02
|
MITOTIC TELOPHASE CYTOKINESIS
|
13
|
1.11e-01
|
1.92e-01
|
0.5300
|
0.064100
|
-0.201000
|
-0.131000
|
-4.69e-01
|
2.89e-03
|
6.89e-01
|
2.10e-01
|
4.13e-01
|
3.44e-03
|
9.86e-01
|
NEPHRIN FAMILY INTERACTIONS
|
21
|
1.09e-02
|
3.15e-02
|
0.5290
|
0.305000
|
-0.093500
|
0.177000
|
-3.62e-01
|
1.27e-01
|
1.56e-02
|
4.58e-01
|
1.60e-01
|
4.09e-03
|
3.14e-01
|
GLUTAMATE NEUROTRANSMITTER RELEASE CYCLE
|
23
|
2.66e-03
|
1.00e-02
|
0.5290
|
0.290000
|
-0.306000
|
0.268000
|
-7.39e-02
|
1.58e-01
|
1.60e-02
|
1.11e-02
|
2.63e-02
|
5.40e-01
|
1.91e-01
|
TRAFFICKING AND PROCESSING OF ENDOSOMAL TLR
|
11
|
8.05e-02
|
1.49e-01
|
0.5280
|
-0.132000
|
0.155000
|
-0.443000
|
2.04e-01
|
-1.52e-02
|
4.49e-01
|
3.74e-01
|
1.10e-02
|
2.42e-01
|
9.30e-01
|
CLASS C 3 METABOTROPIC GLUTAMATE PHEROMONE RECEPTORS
|
11
|
7.24e-02
|
1.37e-01
|
0.5280
|
0.087000
|
-0.103000
|
0.243000
|
-4.48e-01
|
3.25e-02
|
6.17e-01
|
5.55e-01
|
1.63e-01
|
1.00e-02
|
8.52e-01
|
INITIAL TRIGGERING OF COMPLEMENT
|
10
|
2.02e-02
|
5.04e-02
|
0.5280
|
0.316000
|
0.195000
|
-0.263000
|
1.42e-01
|
-2.29e-01
|
8.39e-02
|
2.87e-01
|
1.50e-01
|
4.36e-01
|
2.10e-01
|
CRMPS IN SEMA3A SIGNALING
|
16
|
2.20e-02
|
5.40e-02
|
0.5280
|
0.054700
|
-0.280000
|
0.250000
|
-3.59e-01
|
8.00e-02
|
7.05e-01
|
5.22e-02
|
8.38e-02
|
1.30e-02
|
5.79e-01
|
TRANSLESION SYNTHESIS BY POLK
|
17
|
5.23e-02
|
1.07e-01
|
0.5260
|
-0.123000
|
0.270000
|
0.080900
|
4.09e-01
|
-1.23e-01
|
3.78e-01
|
5.40e-02
|
5.64e-01
|
3.54e-03
|
3.80e-01
|
IRF3 MEDIATED INDUCTION OF TYPE I IFN
|
11
|
2.78e-01
|
3.75e-01
|
0.5260
|
-0.144000
|
-0.172000
|
-0.292000
|
-2.56e-01
|
-2.74e-01
|
4.08e-01
|
3.22e-01
|
9.39e-02
|
1.41e-01
|
1.15e-01
|
DISEASES OF DNA REPAIR
|
11
|
6.38e-02
|
1.26e-01
|
0.5250
|
-0.226000
|
-0.124000
|
0.274000
|
2.34e-02
|
-3.65e-01
|
1.95e-01
|
4.75e-01
|
1.15e-01
|
8.93e-01
|
3.62e-02
|
METABOLISM OF STEROID HORMONES
|
19
|
2.12e-02
|
5.24e-02
|
0.5230
|
-0.340000
|
0.066000
|
-0.031200
|
3.43e-01
|
-1.88e-01
|
1.04e-02
|
6.18e-01
|
8.14e-01
|
9.57e-03
|
1.57e-01
|
GLYOXYLATE METABOLISM AND GLYCINE DEGRADATION
|
24
|
4.28e-03
|
1.44e-02
|
0.5220
|
-0.067200
|
0.234000
|
0.053400
|
3.97e-01
|
2.29e-01
|
5.69e-01
|
4.68e-02
|
6.51e-01
|
7.59e-04
|
5.25e-02
|
PIWI INTERACTING RNA PIRNA BIOGENESIS
|
19
|
1.01e-02
|
2.99e-02
|
0.5200
|
-0.195000
|
-0.123000
|
0.051000
|
3.27e-01
|
-3.29e-01
|
1.41e-01
|
3.55e-01
|
7.00e-01
|
1.37e-02
|
1.31e-02
|
DNA REPLICATION PRE INITIATION
|
78
|
5.15e-12
|
1.32e-10
|
0.5190
|
-0.251000
|
0.046200
|
0.023600
|
4.47e-01
|
-5.92e-02
|
1.24e-04
|
4.81e-01
|
7.18e-01
|
8.58e-12
|
3.67e-01
|
GABA SYNTHESIS RELEASE REUPTAKE AND DEGRADATION
|
18
|
6.36e-02
|
1.26e-01
|
0.5190
|
0.383000
|
0.216000
|
0.159000
|
-4.88e-02
|
2.20e-01
|
4.96e-03
|
1.12e-01
|
2.44e-01
|
7.20e-01
|
1.07e-01
|
SIGNALING BY ACTIVIN
|
12
|
1.15e-01
|
1.97e-01
|
0.5180
|
0.121000
|
-0.160000
|
-0.097800
|
-4.57e-01
|
-1.02e-01
|
4.66e-01
|
3.38e-01
|
5.57e-01
|
6.18e-03
|
5.42e-01
|
P38MAPK EVENTS
|
12
|
3.76e-02
|
8.36e-02
|
0.5180
|
-0.098300
|
-0.451000
|
-0.183000
|
3.52e-02
|
1.43e-01
|
5.56e-01
|
6.83e-03
|
2.73e-01
|
8.33e-01
|
3.90e-01
|
SIGNALING BY WNT IN CANCER
|
30
|
2.11e-05
|
1.42e-04
|
0.5170
|
-0.084700
|
0.059900
|
-0.036800
|
-4.00e-01
|
3.09e-01
|
4.22e-01
|
5.70e-01
|
7.28e-01
|
1.51e-04
|
3.36e-03
|
REGULATION OF PTEN STABILITY AND ACTIVITY
|
66
|
3.31e-10
|
5.53e-09
|
0.5170
|
-0.313000
|
-0.072700
|
-0.006810
|
3.80e-01
|
-1.41e-01
|
1.13e-05
|
3.07e-01
|
9.24e-01
|
9.28e-08
|
4.79e-02
|
OTHER SEMAPHORIN INTERACTIONS
|
19
|
2.06e-02
|
5.14e-02
|
0.5170
|
0.044900
|
-0.228000
|
-0.054300
|
-3.82e-01
|
-2.53e-01
|
7.35e-01
|
8.59e-02
|
6.82e-01
|
3.95e-03
|
5.60e-02
|
GLUCONEOGENESIS
|
27
|
1.05e-03
|
4.60e-03
|
0.5170
|
-0.065600
|
0.142000
|
0.224000
|
3.55e-01
|
2.57e-01
|
5.55e-01
|
2.02e-01
|
4.41e-02
|
1.40e-03
|
2.09e-02
|
RAS ACTIVATION UPON CA2 INFLUX THROUGH NMDA RECEPTOR
|
20
|
1.70e-02
|
4.41e-02
|
0.5160
|
0.225000
|
-0.257000
|
0.257000
|
-1.94e-01
|
2.15e-01
|
8.18e-02
|
4.70e-02
|
4.66e-02
|
1.33e-01
|
9.57e-02
|
NRAGE SIGNALS DEATH THROUGH JNK
|
54
|
1.98e-06
|
1.77e-05
|
0.5150
|
0.227000
|
-0.106000
|
0.087500
|
-3.03e-01
|
3.22e-01
|
3.88e-03
|
1.79e-01
|
2.66e-01
|
1.20e-04
|
4.36e-05
|
CLEC7A DECTIN 1 INDUCES NFAT ACTIVATION
|
11
|
1.09e-01
|
1.89e-01
|
0.5140
|
0.106000
|
-0.130000
|
-0.160000
|
-1.43e-01
|
4.36e-01
|
5.43e-01
|
4.55e-01
|
3.57e-01
|
4.11e-01
|
1.23e-02
|
VXPX CARGO TARGETING TO CILIUM
|
19
|
2.38e-02
|
5.77e-02
|
0.5140
|
0.163000
|
-0.244000
|
0.178000
|
-2.74e-01
|
2.68e-01
|
2.20e-01
|
6.59e-02
|
1.78e-01
|
3.86e-02
|
4.35e-02
|
METHYLATION
|
11
|
1.46e-01
|
2.33e-01
|
0.5140
|
-0.144000
|
0.223000
|
-0.122000
|
4.05e-01
|
1.22e-01
|
4.09e-01
|
2.00e-01
|
4.83e-01
|
2.00e-02
|
4.85e-01
|
MATURATION OF NUCLEOPROTEIN
|
10
|
2.51e-01
|
3.49e-01
|
0.5130
|
-0.230000
|
-0.197000
|
-0.004770
|
-2.30e-01
|
-3.44e-01
|
2.07e-01
|
2.82e-01
|
9.79e-01
|
2.07e-01
|
5.99e-02
|
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 12
|
19
|
3.25e-02
|
7.38e-02
|
0.5130
|
-0.403000
|
-0.175000
|
-0.089100
|
1.22e-01
|
-2.17e-01
|
2.35e-03
|
1.87e-01
|
5.02e-01
|
3.57e-01
|
1.02e-01
|
APC C MEDIATED DEGRADATION OF CELL CYCLE PROTEINS
|
81
|
1.27e-11
|
2.92e-10
|
0.5120
|
-0.287000
|
0.078400
|
0.042100
|
4.08e-01
|
-7.48e-02
|
8.18e-06
|
2.23e-01
|
5.13e-01
|
2.28e-10
|
2.45e-01
|
INTERLEUKIN RECEPTOR SHC SIGNALING
|
20
|
2.30e-02
|
5.62e-02
|
0.5120
|
-0.108000
|
-0.229000
|
-0.084300
|
-4.32e-01
|
5.89e-02
|
4.01e-01
|
7.67e-02
|
5.14e-01
|
8.14e-04
|
6.48e-01
|
CONSTITUTIVE SIGNALING BY LIGAND RESPONSIVE EGFR CANCER VARIANTS
|
19
|
9.35e-02
|
1.68e-01
|
0.5110
|
-0.263000
|
-0.241000
|
-0.202000
|
-4.48e-02
|
-3.01e-01
|
4.71e-02
|
6.92e-02
|
1.27e-01
|
7.36e-01
|
2.31e-02
|
TRANSLESION SYNTHESIS BY POLH
|
19
|
2.58e-02
|
6.10e-02
|
0.5110
|
-0.021600
|
0.160000
|
0.102000
|
4.70e-01
|
-5.93e-02
|
8.70e-01
|
2.28e-01
|
4.42e-01
|
3.91e-04
|
6.54e-01
|
GLUTATHIONE CONJUGATION
|
29
|
3.00e-03
|
1.09e-02
|
0.5090
|
-0.116000
|
0.280000
|
-0.032900
|
4.02e-01
|
-6.90e-02
|
2.81e-01
|
9.16e-03
|
7.59e-01
|
1.79e-04
|
5.20e-01
|
ASYMMETRIC LOCALIZATION OF PCP PROTEINS
|
62
|
1.27e-08
|
1.70e-07
|
0.5090
|
-0.325000
|
0.061600
|
0.012800
|
3.76e-01
|
-8.61e-02
|
9.74e-06
|
4.01e-01
|
8.62e-01
|
2.97e-07
|
2.41e-01
|
BASE EXCISION REPAIR AP SITE FORMATION
|
27
|
3.69e-03
|
1.30e-02
|
0.5080
|
-0.198000
|
0.118000
|
-0.015700
|
3.93e-01
|
-2.25e-01
|
7.46e-02
|
2.91e-01
|
8.88e-01
|
4.12e-04
|
4.33e-02
|
PTK6 REGULATES RHO GTPASES RAS GTPASE AND MAP KINASES
|
13
|
4.21e-02
|
9.02e-02
|
0.5080
|
-0.138000
|
-0.116000
|
-0.236000
|
-1.10e-01
|
3.97e-01
|
3.89e-01
|
4.69e-01
|
1.40e-01
|
4.91e-01
|
1.33e-02
|
SWITCHING OF ORIGINS TO A POST REPLICATIVE STATE
|
85
|
6.62e-12
|
1.66e-10
|
0.5060
|
-0.293000
|
0.084200
|
0.044500
|
3.94e-01
|
-7.32e-02
|
2.93e-06
|
1.80e-01
|
4.79e-01
|
3.42e-10
|
2.44e-01
|
MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES
|
31
|
1.05e-03
|
4.60e-03
|
0.5060
|
0.141000
|
-0.238000
|
0.165000
|
-3.29e-01
|
2.10e-01
|
1.76e-01
|
2.20e-02
|
1.11e-01
|
1.53e-03
|
4.33e-02
|
ACTIVATION OF RAC1
|
13
|
7.38e-02
|
1.39e-01
|
0.5060
|
-0.170000
|
-0.135000
|
-0.039000
|
-4.55e-01
|
-2.51e-03
|
2.90e-01
|
3.98e-01
|
8.08e-01
|
4.49e-03
|
9.88e-01
|
RNA POLYMERASE II TRANSCRIPTION TERMINATION
|
65
|
7.59e-09
|
1.08e-07
|
0.5060
|
-0.256000
|
-0.088300
|
0.109000
|
1.38e-01
|
-3.89e-01
|
3.63e-04
|
2.19e-01
|
1.28e-01
|
5.53e-02
|
5.65e-08
|
ANCHORING FIBRIL FORMATION
|
13
|
1.25e-01
|
2.08e-01
|
0.5050
|
0.219000
|
-0.207000
|
0.300000
|
-2.40e-01
|
1.31e-01
|
1.72e-01
|
1.97e-01
|
6.15e-02
|
1.34e-01
|
4.14e-01
|
ADP SIGNALLING THROUGH P2Y PURINOCEPTOR 1
|
22
|
1.41e-02
|
3.85e-02
|
0.5050
|
-0.313000
|
-0.258000
|
-0.003260
|
6.55e-02
|
-2.93e-01
|
1.10e-02
|
3.63e-02
|
9.79e-01
|
5.95e-01
|
1.73e-02
|
INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES
|
29
|
1.50e-03
|
6.05e-03
|
0.5050
|
-0.369000
|
-0.022900
|
-0.060500
|
2.97e-01
|
-1.62e-01
|
5.90e-04
|
8.31e-01
|
5.73e-01
|
5.61e-03
|
1.32e-01
|
REGULATION OF TLR BY ENDOGENOUS LIGAND
|
10
|
1.61e-01
|
2.50e-01
|
0.5040
|
-0.298000
|
0.080600
|
-0.088200
|
3.80e-01
|
8.16e-02
|
1.02e-01
|
6.59e-01
|
6.29e-01
|
3.75e-02
|
6.55e-01
|
PROLONGED ERK ACTIVATION EVENTS
|
12
|
1.38e-01
|
2.23e-01
|
0.5000
|
0.076000
|
-0.215000
|
0.043100
|
-2.62e-01
|
3.58e-01
|
6.48e-01
|
1.98e-01
|
7.96e-01
|
1.16e-01
|
3.19e-02
|
RHO GTPASES ACTIVATE NADPH OXIDASES
|
19
|
7.32e-02
|
1.38e-01
|
0.5000
|
0.218000
|
0.059100
|
0.270000
|
6.67e-02
|
3.49e-01
|
1.00e-01
|
6.56e-01
|
4.18e-02
|
6.15e-01
|
8.47e-03
|
HIV TRANSCRIPTION ELONGATION
|
42
|
4.48e-05
|
2.85e-04
|
0.5000
|
-0.109000
|
0.149000
|
0.240000
|
3.48e-01
|
-1.92e-01
|
2.22e-01
|
9.54e-02
|
7.08e-03
|
9.54e-05
|
3.16e-02
|
ERKS ARE INACTIVATED
|
13
|
4.14e-02
|
8.96e-02
|
0.4990
|
0.006130
|
-0.233000
|
0.286000
|
-8.99e-02
|
3.24e-01
|
9.69e-01
|
1.45e-01
|
7.43e-02
|
5.75e-01
|
4.32e-02
|
SHC MEDIATED CASCADE FGFR3
|
12
|
5.15e-02
|
1.06e-01
|
0.4990
|
-0.050500
|
-0.043100
|
-0.425000
|
6.21e-02
|
2.45e-01
|
7.62e-01
|
7.96e-01
|
1.09e-02
|
7.10e-01
|
1.41e-01
|
CREB1 PHOSPHORYLATION THROUGH NMDA RECEPTOR MEDIATED ACTIVATION OF RAS SIGNALING
|
28
|
4.19e-03
|
1.42e-02
|
0.4970
|
0.206000
|
-0.237000
|
0.176000
|
-2.52e-01
|
2.33e-01
|
5.90e-02
|
3.03e-02
|
1.07e-01
|
2.10e-02
|
3.28e-02
|
REGULATION OF RUNX2 EXPRESSION AND ACTIVITY
|
67
|
3.15e-09
|
4.78e-08
|
0.4970
|
-0.284000
|
-0.073300
|
0.010000
|
3.56e-01
|
-1.85e-01
|
5.73e-05
|
3.00e-01
|
8.87e-01
|
4.79e-07
|
8.75e-03
|
FRS MEDIATED FGFR4 SIGNALING
|
12
|
7.40e-02
|
1.39e-01
|
0.4970
|
-0.082700
|
-0.032200
|
-0.450000
|
2.09e-05
|
1.92e-01
|
6.20e-01
|
8.47e-01
|
6.96e-03
|
1.00e+00
|
2.49e-01
|
NEGATIVE REGULATORS OF DDX58 IFIH1 SIGNALING
|
34
|
3.67e-03
|
1.29e-02
|
0.4970
|
-0.365000
|
-0.219000
|
-0.178000
|
-1.26e-01
|
-1.35e-01
|
2.32e-04
|
2.70e-02
|
7.26e-02
|
2.03e-01
|
1.74e-01
|
SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYMES
|
29
|
3.98e-03
|
1.38e-02
|
0.4960
|
-0.427000
|
-0.036700
|
-0.160000
|
1.39e-01
|
-1.31e-01
|
6.90e-05
|
7.32e-01
|
1.37e-01
|
1.95e-01
|
2.23e-01
|
SULFUR AMINO ACID METABOLISM
|
23
|
1.72e-03
|
6.90e-03
|
0.4950
|
-0.152000
|
0.113000
|
-0.099900
|
3.46e-01
|
2.82e-01
|
2.06e-01
|
3.48e-01
|
4.07e-01
|
4.03e-03
|
1.94e-02
|
P130CAS LINKAGE TO MAPK SIGNALING FOR INTEGRINS
|
12
|
2.09e-01
|
3.02e-01
|
0.4950
|
-0.273000
|
-0.264000
|
-0.168000
|
-2.63e-01
|
6.43e-02
|
1.02e-01
|
1.14e-01
|
3.15e-01
|
1.15e-01
|
7.00e-01
|
REGULATION OF RAS BY GAPS
|
66
|
1.38e-09
|
2.18e-08
|
0.4950
|
-0.311000
|
-0.080300
|
0.003650
|
3.58e-01
|
-1.17e-01
|
1.25e-05
|
2.59e-01
|
9.59e-01
|
4.88e-07
|
1.01e-01
|
G BETA GAMMA SIGNALLING THROUGH CDC42
|
18
|
2.21e-02
|
5.42e-02
|
0.4940
|
-0.321000
|
-0.149000
|
0.045100
|
2.67e-01
|
-2.11e-01
|
1.83e-02
|
2.72e-01
|
7.40e-01
|
4.97e-02
|
1.21e-01
|
RAS PROCESSING
|
23
|
1.09e-03
|
4.71e-03
|
0.4920
|
-0.199000
|
-0.015800
|
-0.021400
|
4.29e-01
|
1.34e-01
|
9.93e-02
|
8.96e-01
|
8.59e-01
|
3.69e-04
|
2.66e-01
|
BBSOME MEDIATED CARGO TARGETING TO CILIUM
|
23
|
3.99e-02
|
8.75e-02
|
0.4920
|
-0.353000
|
-0.106000
|
-0.164000
|
1.12e-01
|
-2.58e-01
|
3.39e-03
|
3.79e-01
|
1.72e-01
|
3.52e-01
|
3.21e-02
|
POST CHAPERONIN TUBULIN FOLDING PATHWAY
|
17
|
4.18e-02
|
9.01e-02
|
0.4920
|
-0.219000
|
0.131000
|
0.190000
|
3.66e-01
|
-8.06e-02
|
1.18e-01
|
3.52e-01
|
1.76e-01
|
8.93e-03
|
5.65e-01
|
THE CANONICAL RETINOID CYCLE IN RODS TWILIGHT VISION
|
13
|
3.80e-02
|
8.43e-02
|
0.4910
|
0.200000
|
0.404000
|
-0.145000
|
9.46e-02
|
-8.61e-02
|
2.13e-01
|
1.16e-02
|
3.65e-01
|
5.55e-01
|
5.91e-01
|
SIGNALING BY ERBB2 IN CANCER
|
24
|
5.27e-02
|
1.07e-01
|
0.4900
|
-0.175000
|
-0.214000
|
-0.298000
|
-2.54e-01
|
-1.01e-01
|
1.39e-01
|
6.90e-02
|
1.15e-02
|
3.10e-02
|
3.90e-01
|
NCAM SIGNALING FOR NEURITE OUT GROWTH
|
55
|
1.13e-07
|
1.31e-06
|
0.4890
|
0.049500
|
-0.222000
|
0.251000
|
-3.53e-01
|
4.64e-03
|
5.26e-01
|
4.45e-03
|
1.29e-03
|
5.99e-06
|
9.53e-01
|
RUNX2 REGULATES BONE DEVELOPMENT
|
28
|
1.05e-02
|
3.06e-02
|
0.4890
|
-0.155000
|
-0.224000
|
-0.128000
|
-3.79e-01
|
-6.99e-02
|
1.56e-01
|
3.98e-02
|
2.42e-01
|
5.22e-04
|
5.22e-01
|
NCAM1 INTERACTIONS
|
35
|
6.87e-05
|
4.08e-04
|
0.4890
|
0.022700
|
-0.220000
|
0.228000
|
-3.48e-01
|
-1.30e-01
|
8.17e-01
|
2.45e-02
|
1.95e-02
|
3.67e-04
|
1.83e-01
|
RNA POLYMERASE III TRANSCRIPTION TERMINATION
|
23
|
1.15e-02
|
3.24e-02
|
0.4880
|
-0.001530
|
0.137000
|
0.086800
|
4.59e-01
|
2.94e-02
|
9.90e-01
|
2.54e-01
|
4.71e-01
|
1.37e-04
|
8.07e-01
|
GAP FILLING DNA REPAIR SYNTHESIS AND LIGATION IN GG NER
|
24
|
1.40e-02
|
3.83e-02
|
0.4870
|
-0.262000
|
0.128000
|
0.040800
|
3.29e-01
|
-2.05e-01
|
2.62e-02
|
2.79e-01
|
7.30e-01
|
5.25e-03
|
8.20e-02
|
CYCLIN A CDK2 ASSOCIATED EVENTS AT S PHASE ENTRY
|
83
|
5.32e-11
|
1.06e-09
|
0.4860
|
-0.334000
|
0.061900
|
-0.002130
|
3.44e-01
|
-4.74e-02
|
1.41e-07
|
3.30e-01
|
9.73e-01
|
6.05e-08
|
4.55e-01
|
VEGFR2 MEDIATED CELL PROLIFERATION
|
19
|
3.05e-02
|
7.02e-02
|
0.4860
|
0.042600
|
-0.328000
|
-0.116000
|
-2.20e-01
|
2.54e-01
|
7.48e-01
|
1.33e-02
|
3.83e-01
|
9.71e-02
|
5.52e-02
|
ALPHA LINOLENIC OMEGA3 AND LINOLEIC OMEGA6 ACID METABOLISM
|
12
|
9.78e-02
|
1.74e-01
|
0.4850
|
-0.026500
|
0.286000
|
-0.202000
|
2.65e-02
|
3.33e-01
|
8.74e-01
|
8.61e-02
|
2.26e-01
|
8.74e-01
|
4.59e-02
|
RECEPTOR MEDIATED MITOPHAGY
|
11
|
7.95e-02
|
1.48e-01
|
0.4840
|
-0.044500
|
-0.081200
|
0.196000
|
3.01e-01
|
3.10e-01
|
7.99e-01
|
6.41e-01
|
2.60e-01
|
8.42e-02
|
7.47e-02
|
INTERLEUKIN 6 FAMILY SIGNALING
|
18
|
1.63e-02
|
4.30e-02
|
0.4830
|
0.370000
|
-0.099300
|
-0.102000
|
-3.40e-02
|
2.74e-01
|
6.52e-03
|
4.66e-01
|
4.56e-01
|
8.03e-01
|
4.40e-02
|
TIGHT JUNCTION INTERACTIONS
|
14
|
5.10e-02
|
1.05e-01
|
0.4820
|
-0.236000
|
0.199000
|
-0.275000
|
4.75e-02
|
2.44e-01
|
1.27e-01
|
1.98e-01
|
7.46e-02
|
7.59e-01
|
1.13e-01
|
INTERFERON GAMMA SIGNALING
|
75
|
5.45e-07
|
5.55e-06
|
0.4810
|
-0.085900
|
-0.226000
|
-0.318000
|
-1.55e-01
|
-2.19e-01
|
1.99e-01
|
7.20e-04
|
1.95e-06
|
2.06e-02
|
1.04e-03
|
POLYMERASE SWITCHING
|
14
|
1.35e-01
|
2.20e-01
|
0.4810
|
-0.002920
|
0.178000
|
0.050700
|
4.14e-01
|
-1.59e-01
|
9.85e-01
|
2.48e-01
|
7.42e-01
|
7.27e-03
|
3.02e-01
|
ABC TRANSPORTER DISORDERS
|
68
|
1.35e-08
|
1.78e-07
|
0.4810
|
-0.275000
|
0.013800
|
0.034800
|
3.73e-01
|
-1.23e-01
|
8.65e-05
|
8.45e-01
|
6.20e-01
|
1.06e-07
|
7.99e-02
|
CD209 DC SIGN SIGNALING
|
18
|
1.10e-01
|
1.90e-01
|
0.4810
|
-0.086000
|
-0.327000
|
-0.190000
|
-2.78e-01
|
5.94e-02
|
5.27e-01
|
1.63e-02
|
1.63e-01
|
4.14e-02
|
6.62e-01
|
RNA POLYMERASE I TRANSCRIPTION TERMINATION
|
31
|
1.78e-03
|
7.09e-03
|
0.4810
|
-0.110000
|
0.097200
|
0.174000
|
3.50e-01
|
-2.39e-01
|
2.88e-01
|
3.49e-01
|
9.41e-02
|
7.54e-04
|
2.14e-02
|
SYNTHESIS OF PIPS AT THE PLASMA MEMBRANE
|
52
|
1.84e-05
|
1.26e-04
|
0.4800
|
0.250000
|
-0.162000
|
0.029100
|
-2.09e-01
|
3.12e-01
|
1.84e-03
|
4.36e-02
|
7.17e-01
|
9.14e-03
|
9.87e-05
|
PREGNENOLONE BIOSYNTHESIS
|
12
|
1.83e-01
|
2.74e-01
|
0.4800
|
-0.321000
|
-0.070900
|
-0.033900
|
2.94e-01
|
-1.87e-01
|
5.45e-02
|
6.71e-01
|
8.39e-01
|
7.76e-02
|
2.63e-01
|
PROTEIN METHYLATION
|
17
|
5.20e-02
|
1.07e-01
|
0.4800
|
-0.038600
|
0.166000
|
-0.083200
|
3.97e-01
|
-1.92e-01
|
7.83e-01
|
2.36e-01
|
5.53e-01
|
4.65e-03
|
1.70e-01
|
EPHRIN SIGNALING
|
19
|
6.49e-02
|
1.27e-01
|
0.4790
|
-0.011400
|
-0.357000
|
0.014300
|
-3.19e-01
|
2.12e-02
|
9.31e-01
|
7.08e-03
|
9.14e-01
|
1.62e-02
|
8.73e-01
|
REPRESSION OF WNT TARGET GENES
|
14
|
2.41e-02
|
5.79e-02
|
0.4780
|
-0.158000
|
0.141000
|
-0.130000
|
-4.08e-01
|
-1.26e-02
|
3.07e-01
|
3.61e-01
|
3.98e-01
|
8.17e-03
|
9.35e-01
|
APC CDC20 MEDIATED DEGRADATION OF NEK2A
|
25
|
1.19e-02
|
3.34e-02
|
0.4780
|
-0.198000
|
0.182000
|
0.140000
|
3.56e-01
|
-9.87e-02
|
8.73e-02
|
1.16e-01
|
2.25e-01
|
2.04e-03
|
3.93e-01
|
EARLY PHASE OF HIV LIFE CYCLE
|
13
|
1.58e-01
|
2.46e-01
|
0.4780
|
-0.214000
|
0.226000
|
-0.227000
|
9.33e-02
|
-2.67e-01
|
1.82e-01
|
1.59e-01
|
1.57e-01
|
5.60e-01
|
9.50e-02
|
SCAVENGING BY CLASS A RECEPTORS
|
13
|
2.32e-02
|
5.67e-02
|
0.4770
|
0.163000
|
0.147000
|
-0.257000
|
9.57e-02
|
-3.23e-01
|
3.09e-01
|
3.59e-01
|
1.09e-01
|
5.50e-01
|
4.36e-02
|
MRNA CAPPING
|
29
|
3.14e-03
|
1.13e-02
|
0.4770
|
-0.189000
|
0.091400
|
0.131000
|
3.82e-01
|
-1.44e-01
|
7.79e-02
|
3.95e-01
|
2.21e-01
|
3.77e-04
|
1.80e-01
|
RHOV GTPASE CYCLE
|
32
|
2.78e-03
|
1.03e-02
|
0.4750
|
0.055200
|
-0.204000
|
-0.009570
|
-4.25e-01
|
1.85e-02
|
5.89e-01
|
4.62e-02
|
9.25e-01
|
3.14e-05
|
8.56e-01
|
ACTIVATION OF GENE EXPRESSION BY SREBF SREBP
|
43
|
4.98e-04
|
2.44e-03
|
0.4750
|
-0.102000
|
-0.312000
|
-0.062300
|
-3.36e-01
|
2.60e-02
|
2.49e-01
|
3.97e-04
|
4.80e-01
|
1.37e-04
|
7.68e-01
|
NUCLEOBASE CATABOLISM
|
31
|
4.11e-03
|
1.40e-02
|
0.4740
|
-0.087700
|
0.338000
|
0.109000
|
2.47e-01
|
1.74e-01
|
3.98e-01
|
1.13e-03
|
2.95e-01
|
1.73e-02
|
9.30e-02
|
PROTEIN LOCALIZATION
|
157
|
2.20e-19
|
1.10e-17
|
0.4740
|
-0.138000
|
0.141000
|
0.008730
|
4.29e-01
|
3.84e-02
|
2.92e-03
|
2.25e-03
|
8.50e-01
|
1.69e-20
|
4.07e-01
|
RA BIOSYNTHESIS PATHWAY
|
12
|
1.01e-01
|
1.79e-01
|
0.4730
|
-0.047600
|
0.204000
|
-0.359000
|
2.23e-01
|
4.32e-02
|
7.75e-01
|
2.21e-01
|
3.15e-02
|
1.81e-01
|
7.96e-01
|
SIGNALING BY EGFR IN CANCER
|
21
|
1.13e-01
|
1.94e-01
|
0.4730
|
-0.247000
|
-0.171000
|
-0.206000
|
-2.57e-02
|
-3.00e-01
|
5.01e-02
|
1.75e-01
|
1.02e-01
|
8.38e-01
|
1.72e-02
|
GLYCOGEN STORAGE DISEASES
|
12
|
1.22e-01
|
2.05e-01
|
0.4720
|
-0.427000
|
0.040900
|
-0.141000
|
1.11e-01
|
8.14e-02
|
1.04e-02
|
8.06e-01
|
3.99e-01
|
5.06e-01
|
6.26e-01
|
MITOCHONDRIAL CALCIUM ION TRANSPORT
|
23
|
2.16e-02
|
5.33e-02
|
0.4710
|
0.004510
|
0.192000
|
0.015300
|
4.27e-01
|
-4.43e-02
|
9.70e-01
|
1.10e-01
|
8.99e-01
|
3.91e-04
|
7.13e-01
|
BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN GENE EXPRESSION
|
25
|
2.34e-02
|
5.69e-02
|
0.4700
|
0.157000
|
-0.286000
|
-0.037200
|
-3.31e-01
|
5.51e-02
|
1.74e-01
|
1.33e-02
|
7.48e-01
|
4.16e-03
|
6.34e-01
|
PKMTS METHYLATE HISTONE LYSINES
|
47
|
2.53e-04
|
1.32e-03
|
0.4690
|
0.077800
|
-0.311000
|
-0.136000
|
-3.01e-01
|
-9.16e-02
|
3.57e-01
|
2.28e-04
|
1.06e-01
|
3.54e-04
|
2.77e-01
|
GLYCOGEN BREAKDOWN GLYCOGENOLYSIS
|
14
|
1.40e-01
|
2.25e-01
|
0.4680
|
-0.120000
|
-0.104000
|
-0.353000
|
-2.04e-01
|
1.67e-01
|
4.36e-01
|
5.01e-01
|
2.22e-02
|
1.87e-01
|
2.80e-01
|
HDR THROUGH MMEJ ALT NHEJ
|
10
|
1.84e-01
|
2.74e-01
|
0.4680
|
0.371000
|
-0.037300
|
0.207000
|
-6.75e-03
|
-1.91e-01
|
4.19e-02
|
8.38e-01
|
2.56e-01
|
9.71e-01
|
2.96e-01
|
SIGNALING BY ERYTHROPOIETIN
|
24
|
2.41e-02
|
5.79e-02
|
0.4670
|
0.044200
|
-0.387000
|
-0.055400
|
-2.41e-01
|
7.49e-02
|
7.08e-01
|
1.05e-03
|
6.38e-01
|
4.07e-02
|
5.25e-01
|
RESOLUTION OF AP SITES VIA THE MULTIPLE NUCLEOTIDE PATCH REPLACEMENT PATHWAY
|
24
|
2.58e-02
|
6.10e-02
|
0.4670
|
-0.091100
|
0.181000
|
0.138000
|
3.96e-01
|
-3.06e-02
|
4.40e-01
|
1.25e-01
|
2.41e-01
|
7.79e-04
|
7.96e-01
|
TRANSCRIPTIONAL REGULATION BY MECP2
|
58
|
3.62e-06
|
3.00e-05
|
0.4670
|
0.221000
|
-0.221000
|
0.153000
|
-3.10e-01
|
-1.04e-02
|
3.61e-03
|
3.56e-03
|
4.35e-02
|
4.36e-05
|
8.91e-01
|
RHOU GTPASE CYCLE
|
33
|
3.71e-03
|
1.30e-02
|
0.4660
|
0.195000
|
-0.144000
|
0.011100
|
-3.50e-01
|
1.89e-01
|
5.21e-02
|
1.53e-01
|
9.12e-01
|
5.11e-04
|
5.99e-02
|
PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE
|
51
|
1.88e-05
|
1.28e-04
|
0.4650
|
0.047200
|
0.189000
|
0.010500
|
3.35e-01
|
2.59e-01
|
5.60e-01
|
1.99e-02
|
8.97e-01
|
3.60e-05
|
1.41e-03
|
MTORC1 MEDIATED SIGNALLING
|
24
|
4.02e-02
|
8.76e-02
|
0.4650
|
0.018400
|
0.213000
|
0.205000
|
2.96e-01
|
2.02e-01
|
8.76e-01
|
7.06e-02
|
8.17e-02
|
1.20e-02
|
8.64e-02
|
ADHERENS JUNCTIONS INTERACTIONS
|
30
|
1.29e-04
|
7.33e-04
|
0.4650
|
-0.205000
|
-0.035300
|
0.025600
|
-4.10e-01
|
6.66e-02
|
5.26e-02
|
7.38e-01
|
8.08e-01
|
1.03e-04
|
5.28e-01
|
GAMMA CARBOXYLATION HYPUSINE FORMATION AND ARYLSULFATASE ACTIVATION
|
29
|
1.71e-02
|
4.43e-02
|
0.4650
|
0.159000
|
0.219000
|
0.074800
|
2.17e-01
|
3.00e-01
|
1.38e-01
|
4.17e-02
|
4.86e-01
|
4.30e-02
|
5.17e-03
|
SEALING OF THE NUCLEAR ENVELOPE NE BY ESCRT III
|
23
|
1.75e-02
|
4.49e-02
|
0.4640
|
-0.119000
|
0.112000
|
0.261000
|
3.35e-01
|
-9.23e-02
|
3.21e-01
|
3.51e-01
|
3.05e-02
|
5.40e-03
|
4.44e-01
|
PLASMA LIPOPROTEIN REMODELING
|
13
|
2.78e-01
|
3.75e-01
|
0.4640
|
0.290000
|
0.228000
|
0.052800
|
1.58e-01
|
2.26e-01
|
7.00e-02
|
1.54e-01
|
7.42e-01
|
3.23e-01
|
1.58e-01
|
METABOLISM OF ANGIOTENSINOGEN TO ANGIOTENSINS
|
10
|
3.33e-01
|
4.29e-01
|
0.4640
|
0.265000
|
0.356000
|
0.026400
|
5.68e-02
|
1.20e-01
|
1.47e-01
|
5.13e-02
|
8.85e-01
|
7.56e-01
|
5.10e-01
|
PEROXISOMAL LIPID METABOLISM
|
26
|
1.65e-02
|
4.32e-02
|
0.4630
|
0.082300
|
0.263000
|
-0.023200
|
3.02e-01
|
2.17e-01
|
4.68e-01
|
2.01e-02
|
8.38e-01
|
7.78e-03
|
5.54e-02
|
APOPTOTIC FACTOR MEDIATED RESPONSE
|
18
|
2.88e-02
|
6.67e-02
|
0.4620
|
-0.259000
|
-0.068000
|
-0.166000
|
3.38e-01
|
-5.78e-03
|
5.74e-02
|
6.17e-01
|
2.24e-01
|
1.30e-02
|
9.66e-01
|
SIGNAL AMPLIFICATION
|
29
|
1.29e-02
|
3.58e-02
|
0.4610
|
-0.320000
|
-0.257000
|
-0.066600
|
-7.34e-03
|
-2.01e-01
|
2.89e-03
|
1.68e-02
|
5.35e-01
|
9.45e-01
|
6.15e-02
|
MRNA DECAY BY 3 TO 5 EXORIBONUCLEASE
|
15
|
5.30e-02
|
1.08e-01
|
0.4610
|
-0.233000
|
-0.046800
|
0.177000
|
3.46e-01
|
-7.13e-02
|
1.18e-01
|
7.54e-01
|
2.34e-01
|
2.05e-02
|
6.33e-01
|
HIV ELONGATION ARREST AND RECOVERY
|
32
|
1.95e-03
|
7.73e-03
|
0.4610
|
-0.080400
|
0.069200
|
0.193000
|
3.06e-01
|
-2.64e-01
|
4.31e-01
|
4.98e-01
|
5.86e-02
|
2.70e-03
|
9.63e-03
|
ZINC TRANSPORTERS
|
14
|
2.57e-01
|
3.54e-01
|
0.4590
|
0.365000
|
-0.037200
|
0.165000
|
-8.59e-02
|
2.02e-01
|
1.79e-02
|
8.10e-01
|
2.84e-01
|
5.78e-01
|
1.90e-01
|
PHASE 0 RAPID DEPOLARISATION
|
28
|
1.39e-02
|
3.81e-02
|
0.4590
|
0.253000
|
-0.046100
|
0.234000
|
-2.54e-01
|
1.59e-01
|
2.07e-02
|
6.73e-01
|
3.18e-02
|
2.01e-02
|
1.47e-01
|
TICAM1 DEPENDENT ACTIVATION OF IRF3 IRF7
|
12
|
4.21e-01
|
5.17e-01
|
0.4580
|
-0.299000
|
-0.163000
|
-0.226000
|
4.40e-02
|
-2.03e-01
|
7.29e-02
|
3.28e-01
|
1.75e-01
|
7.92e-01
|
2.24e-01
|
MITOPHAGY
|
29
|
1.22e-03
|
5.11e-03
|
0.4580
|
-0.159000
|
-0.011900
|
0.101000
|
4.17e-01
|
-1.47e-02
|
1.40e-01
|
9.11e-01
|
3.45e-01
|
1.00e-04
|
8.91e-01
|
RESOLUTION OF ABASIC SITES AP SITES
|
37
|
1.18e-03
|
4.97e-03
|
0.4580
|
-0.018100
|
0.110000
|
0.235000
|
3.53e-01
|
-1.32e-01
|
8.49e-01
|
2.47e-01
|
1.32e-02
|
2.04e-04
|
1.64e-01
|
VEGFR2 MEDIATED VASCULAR PERMEABILITY
|
26
|
1.90e-02
|
4.82e-02
|
0.4570
|
-0.078700
|
-0.264000
|
-0.172000
|
-2.66e-01
|
1.81e-01
|
4.87e-01
|
1.98e-02
|
1.29e-01
|
1.87e-02
|
1.11e-01
|
PI3K EVENTS IN ERBB2 SIGNALING
|
14
|
2.08e-01
|
3.02e-01
|
0.4570
|
-0.108000
|
-0.084300
|
-0.237000
|
-3.37e-01
|
-1.43e-01
|
4.84e-01
|
5.85e-01
|
1.25e-01
|
2.89e-02
|
3.55e-01
|
MEIOTIC RECOMBINATION
|
35
|
2.66e-03
|
1.00e-02
|
0.4570
|
-0.267000
|
0.205000
|
-0.218000
|
1.95e-01
|
-1.01e-01
|
6.37e-03
|
3.57e-02
|
2.56e-02
|
4.59e-02
|
3.01e-01
|
PRC2 METHYLATES HISTONES AND DNA
|
26
|
2.56e-02
|
6.08e-02
|
0.4570
|
-0.225000
|
0.042500
|
-0.211000
|
2.35e-01
|
-2.37e-01
|
4.70e-02
|
7.08e-01
|
6.32e-02
|
3.78e-02
|
3.62e-02
|
INSERTION OF TAIL ANCHORED PROTEINS INTO THE ENDOPLASMIC RETICULUM MEMBRANE
|
22
|
2.67e-02
|
6.29e-02
|
0.4570
|
-0.046200
|
0.085400
|
0.207000
|
3.93e-01
|
4.29e-02
|
7.08e-01
|
4.88e-01
|
9.28e-02
|
1.43e-03
|
7.28e-01
|
CELLULAR RESPONSE TO CHEMICAL STRESS
|
149
|
3.04e-16
|
1.30e-14
|
0.4560
|
-0.203000
|
0.058800
|
-0.006210
|
3.74e-01
|
-1.53e-01
|
1.84e-05
|
2.16e-01
|
8.96e-01
|
3.36e-15
|
1.33e-03
|
INTERLEUKIN 12 SIGNALING
|
36
|
1.30e-03
|
5.40e-03
|
0.4540
|
-0.275000
|
0.060700
|
-0.073500
|
3.38e-01
|
-8.47e-02
|
4.24e-03
|
5.29e-01
|
4.45e-01
|
4.52e-04
|
3.79e-01
|
ACTIVATION OF SMO
|
16
|
9.98e-02
|
1.77e-01
|
0.4540
|
-0.062200
|
-0.253000
|
-0.010400
|
-2.99e-01
|
2.20e-01
|
6.67e-01
|
7.94e-02
|
9.42e-01
|
3.87e-02
|
1.27e-01
|
IRAK4 DEFICIENCY TLR2 4
|
11
|
1.66e-01
|
2.56e-01
|
0.4540
|
-0.271000
|
0.034800
|
-0.236000
|
1.69e-01
|
2.17e-01
|
1.20e-01
|
8.42e-01
|
1.76e-01
|
3.33e-01
|
2.12e-01
|
SYNTHESIS OF PYROPHOSPHATES IN THE CYTOSOL
|
10
|
1.51e-01
|
2.39e-01
|
0.4530
|
-0.182000
|
0.175000
|
0.240000
|
6.48e-02
|
2.84e-01
|
3.20e-01
|
3.38e-01
|
1.90e-01
|
7.23e-01
|
1.20e-01
|
DNA REPLICATION
|
119
|
4.43e-13
|
1.31e-11
|
0.4530
|
-0.222000
|
0.091800
|
0.029800
|
3.78e-01
|
-5.87e-02
|
2.98e-05
|
8.41e-02
|
5.75e-01
|
1.02e-12
|
2.69e-01
|
REGULATION OF GLYCOLYSIS BY FRUCTOSE 2 6 BISPHOSPHATE METABOLISM
|
10
|
1.31e-01
|
2.14e-01
|
0.4530
|
-0.126000
|
-0.081900
|
0.214000
|
-2.62e-01
|
2.61e-01
|
4.90e-01
|
6.54e-01
|
2.42e-01
|
1.52e-01
|
1.53e-01
|
APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B
|
21
|
5.28e-02
|
1.07e-01
|
0.4520
|
-0.234000
|
0.160000
|
0.059900
|
3.27e-01
|
-1.17e-01
|
6.38e-02
|
2.04e-01
|
6.35e-01
|
9.43e-03
|
3.54e-01
|
DNA DAMAGE RECOGNITION IN GG NER
|
38
|
3.77e-03
|
1.31e-02
|
0.4520
|
0.034000
|
0.188000
|
0.180000
|
3.68e-01
|
8.73e-03
|
7.17e-01
|
4.53e-02
|
5.51e-02
|
8.55e-05
|
9.26e-01
|
ESTROGEN DEPENDENT NUCLEAR EVENTS DOWNSTREAM OF ESR MEMBRANE SIGNALING
|
20
|
9.34e-02
|
1.68e-01
|
0.4520
|
-0.110000
|
-0.261000
|
-0.046900
|
-3.45e-01
|
-4.42e-02
|
3.92e-01
|
4.31e-02
|
7.17e-01
|
7.48e-03
|
7.32e-01
|
TNFR2 NON CANONICAL NF KB PATHWAY
|
76
|
2.14e-08
|
2.81e-07
|
0.4520
|
-0.276000
|
-0.007350
|
-0.028900
|
3.40e-01
|
-1.07e-01
|
3.14e-05
|
9.12e-01
|
6.63e-01
|
3.09e-07
|
1.08e-01
|
CHK1 CHK2 CDS1 MEDIATED INACTIVATION OF CYCLIN B CDK1 COMPLEX
|
10
|
1.87e-01
|
2.77e-01
|
0.4510
|
-0.420000
|
0.034200
|
0.015200
|
1.52e-01
|
4.94e-02
|
2.14e-02
|
8.52e-01
|
9.34e-01
|
4.06e-01
|
7.87e-01
|
CASPASE MEDIATED CLEAVAGE OF CYTOSKELETAL PROTEINS
|
12
|
3.12e-01
|
4.08e-01
|
0.4500
|
0.029800
|
0.198000
|
0.227000
|
1.40e-01
|
3.02e-01
|
8.58e-01
|
2.35e-01
|
1.74e-01
|
4.01e-01
|
7.00e-02
|
METABOLISM OF COFACTORS
|
18
|
8.40e-02
|
1.55e-01
|
0.4480
|
-0.182000
|
0.084000
|
-0.088600
|
3.75e-01
|
-1.08e-01
|
1.81e-01
|
5.37e-01
|
5.15e-01
|
5.89e-03
|
4.27e-01
|
GAP JUNCTION ASSEMBLY
|
20
|
9.31e-02
|
1.68e-01
|
0.4470
|
-0.120000
|
0.312000
|
0.019500
|
2.96e-01
|
-9.85e-03
|
3.51e-01
|
1.56e-02
|
8.80e-01
|
2.20e-02
|
9.39e-01
|
FGFR2 MUTANT RECEPTOR ACTIVATION
|
24
|
1.60e-02
|
4.24e-02
|
0.4460
|
-0.088900
|
0.022700
|
0.038600
|
3.88e-01
|
-1.96e-01
|
4.51e-01
|
8.47e-01
|
7.44e-01
|
9.92e-04
|
9.61e-02
|
REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMENTS
|
84
|
3.47e-09
|
5.19e-08
|
0.4460
|
-0.296000
|
-0.052400
|
0.026900
|
2.85e-01
|
-1.63e-01
|
2.73e-06
|
4.06e-01
|
6.70e-01
|
6.22e-06
|
9.93e-03
|
RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 1 PROMOTER
|
28
|
3.51e-02
|
7.85e-02
|
0.4450
|
0.088500
|
0.226000
|
0.125000
|
3.49e-01
|
3.41e-02
|
4.18e-01
|
3.86e-02
|
2.52e-01
|
1.37e-03
|
7.55e-01
|
FORMATION OF TC NER PRE INCISION COMPLEX
|
53
|
4.39e-05
|
2.81e-04
|
0.4430
|
-0.127000
|
0.135000
|
0.154000
|
3.72e-01
|
-2.92e-03
|
1.09e-01
|
9.04e-02
|
5.32e-02
|
2.76e-06
|
9.71e-01
|
PLATELET SENSITIZATION BY LDL
|
15
|
2.12e-01
|
3.05e-01
|
0.4430
|
-0.142000
|
-0.178000
|
-0.196000
|
-3.05e-01
|
1.14e-01
|
3.41e-01
|
2.32e-01
|
1.89e-01
|
4.05e-02
|
4.46e-01
|
NUCLEOTIDE SALVAGE
|
21
|
4.18e-02
|
9.01e-02
|
0.4430
|
-0.174000
|
0.194000
|
0.169000
|
3.05e-01
|
8.25e-02
|
1.69e-01
|
1.24e-01
|
1.80e-01
|
1.54e-02
|
5.13e-01
|
KERATAN SULFATE DEGRADATION
|
11
|
5.26e-01
|
6.09e-01
|
0.4420
|
0.237000
|
0.274000
|
0.144000
|
1.40e-01
|
1.55e-01
|
1.74e-01
|
1.16e-01
|
4.10e-01
|
4.21e-01
|
3.73e-01
|
DOWNSTREAM SIGNALING OF ACTIVATED FGFR4
|
17
|
1.12e-01
|
1.93e-01
|
0.4410
|
-0.076600
|
-0.135000
|
-0.385000
|
-1.31e-01
|
7.14e-02
|
5.85e-01
|
3.34e-01
|
5.97e-03
|
3.49e-01
|
6.10e-01
|
PI 3K CASCADE FGFR3
|
12
|
1.29e-01
|
2.12e-01
|
0.4410
|
0.106000
|
-0.026400
|
-0.382000
|
-9.66e-02
|
1.64e-01
|
5.27e-01
|
8.74e-01
|
2.20e-02
|
5.62e-01
|
3.24e-01
|
HDMS DEMETHYLATE HISTONES
|
26
|
2.70e-02
|
6.35e-02
|
0.4400
|
0.188000
|
-0.129000
|
-0.030300
|
-2.41e-01
|
2.88e-01
|
9.76e-02
|
2.56e-01
|
7.89e-01
|
3.38e-02
|
1.10e-02
|
DAP12 INTERACTIONS
|
28
|
1.87e-02
|
4.77e-02
|
0.4400
|
-0.301000
|
-0.243000
|
-0.183000
|
6.83e-02
|
-7.84e-02
|
5.89e-03
|
2.63e-02
|
9.41e-02
|
5.31e-01
|
4.73e-01
|
BASE EXCISION REPAIR
|
54
|
6.54e-05
|
3.91e-04
|
0.4390
|
-0.119000
|
0.116000
|
0.066800
|
3.73e-01
|
-1.47e-01
|
1.31e-01
|
1.40e-01
|
3.96e-01
|
2.10e-06
|
6.16e-02
|
RRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL
|
59
|
1.64e-05
|
1.14e-04
|
0.4380
|
-0.211000
|
0.040400
|
0.066300
|
2.94e-01
|
-2.35e-01
|
5.05e-03
|
5.91e-01
|
3.78e-01
|
9.68e-05
|
1.81e-03
|
JOSEPHIN DOMAIN DUBS
|
11
|
2.74e-01
|
3.72e-01
|
0.4370
|
-0.207000
|
-0.020800
|
0.156000
|
2.93e-01
|
-1.94e-01
|
2.35e-01
|
9.05e-01
|
3.71e-01
|
9.25e-02
|
2.66e-01
|
GLUTAMATE AND GLUTAMINE METABOLISM
|
13
|
9.16e-02
|
1.66e-01
|
0.4360
|
-0.049000
|
-0.002500
|
-0.081800
|
2.14e-01
|
3.67e-01
|
7.60e-01
|
9.88e-01
|
6.10e-01
|
1.81e-01
|
2.19e-02
|
VITAMIN B5 PANTOTHENATE METABOLISM
|
14
|
1.26e-01
|
2.09e-01
|
0.4360
|
0.057900
|
0.134000
|
-0.173000
|
-2.31e-02
|
3.72e-01
|
7.08e-01
|
3.87e-01
|
2.63e-01
|
8.81e-01
|
1.60e-02
|
RESPONSE OF EIF2AK1 HRI TO HEME DEFICIENCY
|
14
|
2.43e-01
|
3.41e-01
|
0.4350
|
-0.248000
|
-0.105000
|
-0.194000
|
2.24e-01
|
-1.69e-01
|
1.08e-01
|
4.98e-01
|
2.10e-01
|
1.46e-01
|
2.73e-01
|
ER QUALITY CONTROL COMPARTMENT ERQC
|
21
|
8.92e-02
|
1.62e-01
|
0.4340
|
-0.342000
|
-0.188000
|
-0.163000
|
-9.74e-02
|
-2.56e-02
|
6.73e-03
|
1.37e-01
|
1.95e-01
|
4.40e-01
|
8.39e-01
|
PLATELET CALCIUM HOMEOSTASIS
|
25
|
6.53e-02
|
1.27e-01
|
0.4340
|
0.265000
|
-0.005000
|
0.106000
|
-1.49e-01
|
2.91e-01
|
2.20e-02
|
9.66e-01
|
3.57e-01
|
1.97e-01
|
1.18e-02
|
INSULIN PROCESSING
|
24
|
3.27e-02
|
7.42e-02
|
0.4330
|
0.080000
|
-0.335000
|
0.072900
|
-2.12e-01
|
1.37e-01
|
4.98e-01
|
4.49e-03
|
5.37e-01
|
7.24e-02
|
2.46e-01
|
INTERLEUKIN 7 SIGNALING
|
18
|
8.73e-02
|
1.59e-01
|
0.4330
|
0.306000
|
0.090300
|
0.115000
|
-2.55e-01
|
8.74e-02
|
2.48e-02
|
5.07e-01
|
3.97e-01
|
6.10e-02
|
5.21e-01
|
SIGNALING BY CYTOSOLIC FGFR1 FUSION MUTANTS
|
18
|
1.73e-01
|
2.63e-01
|
0.4330
|
-0.015400
|
-0.213000
|
-0.082100
|
-3.63e-01
|
-5.31e-02
|
9.10e-01
|
1.18e-01
|
5.47e-01
|
7.60e-03
|
6.97e-01
|
PI METABOLISM
|
79
|
1.05e-06
|
9.81e-06
|
0.4320
|
0.192000
|
-0.158000
|
0.076300
|
-2.08e-01
|
2.76e-01
|
3.25e-03
|
1.51e-02
|
2.41e-01
|
1.42e-03
|
2.32e-05
|
SYNTHESIS OF PROSTAGLANDINS PG AND THROMBOXANES TX
|
13
|
2.45e-01
|
3.42e-01
|
0.4320
|
-0.092300
|
0.175000
|
-0.109000
|
3.67e-01
|
1.05e-02
|
5.64e-01
|
2.74e-01
|
4.95e-01
|
2.18e-02
|
9.48e-01
|
DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR
|
78
|
1.04e-08
|
1.41e-07
|
0.4310
|
-0.244000
|
-0.053700
|
0.014500
|
3.41e-01
|
-8.49e-02
|
1.93e-04
|
4.13e-01
|
8.25e-01
|
2.00e-07
|
1.95e-01
|
HIV TRANSCRIPTION INITIATION
|
45
|
5.39e-04
|
2.61e-03
|
0.4310
|
-0.210000
|
0.040700
|
0.029000
|
3.19e-01
|
-1.93e-01
|
1.48e-02
|
6.36e-01
|
7.37e-01
|
2.11e-04
|
2.50e-02
|
NOREPINEPHRINE NEUROTRANSMITTER RELEASE CYCLE
|
17
|
1.06e-01
|
1.85e-01
|
0.4310
|
0.246000
|
-0.185000
|
0.274000
|
-1.14e-01
|
-4.92e-02
|
7.91e-02
|
1.86e-01
|
5.05e-02
|
4.16e-01
|
7.25e-01
|
UCH PROTEINASES
|
89
|
2.76e-08
|
3.46e-07
|
0.4300
|
-0.230000
|
0.054500
|
-0.016200
|
3.37e-01
|
-1.24e-01
|
1.73e-04
|
3.74e-01
|
7.92e-01
|
4.12e-08
|
4.26e-02
|
HEME BIOSYNTHESIS
|
13
|
2.14e-01
|
3.08e-01
|
0.4300
|
0.109000
|
-0.022200
|
0.187000
|
2.24e-01
|
2.96e-01
|
4.95e-01
|
8.90e-01
|
2.43e-01
|
1.62e-01
|
6.51e-02
|
ASSEMBLY AND CELL SURFACE PRESENTATION OF NMDA RECEPTORS
|
35
|
3.10e-03
|
1.12e-02
|
0.4300
|
0.169000
|
-0.172000
|
0.317000
|
-1.15e-01
|
1.13e-01
|
8.32e-02
|
7.80e-02
|
1.19e-03
|
2.40e-01
|
2.49e-01
|
NEF MEDIATED DOWNREGULATION OF MHC CLASS I COMPLEX CELL SURFACE EXPRESSION
|
10
|
4.35e-01
|
5.27e-01
|
0.4270
|
-0.224000
|
-0.295000
|
-0.171000
|
7.47e-02
|
-1.02e-01
|
2.21e-01
|
1.06e-01
|
3.49e-01
|
6.83e-01
|
5.75e-01
|
BUDDING AND MATURATION OF HIV VIRION
|
27
|
1.40e-02
|
3.83e-02
|
0.4260
|
-0.179000
|
0.076300
|
0.180000
|
3.24e-01
|
-7.84e-02
|
1.07e-01
|
4.93e-01
|
1.05e-01
|
3.54e-03
|
4.81e-01
|
RAF INDEPENDENT MAPK1 3 ACTIVATION
|
20
|
6.53e-02
|
1.27e-01
|
0.4260
|
0.101000
|
-0.305000
|
0.057200
|
-1.64e-01
|
2.19e-01
|
4.36e-01
|
1.82e-02
|
6.58e-01
|
2.04e-01
|
8.96e-02
|
REGULATION OF BACH1 ACTIVITY
|
11
|
4.39e-01
|
5.29e-01
|
0.4250
|
-0.021500
|
0.304000
|
0.001780
|
2.77e-01
|
-1.03e-01
|
9.02e-01
|
8.10e-02
|
9.92e-01
|
1.11e-01
|
5.54e-01
|
DEFECTS IN COBALAMIN B12 METABOLISM
|
12
|
1.03e-01
|
1.80e-01
|
0.4240
|
0.025800
|
-0.017300
|
-0.368000
|
2.05e-01
|
3.69e-02
|
8.77e-01
|
9.17e-01
|
2.72e-02
|
2.19e-01
|
8.25e-01
|
SIGNALING BY PDGFR IN DISEASE
|
20
|
1.43e-01
|
2.29e-01
|
0.4240
|
0.014400
|
-0.245000
|
-0.196000
|
-2.68e-01
|
9.58e-02
|
9.11e-01
|
5.81e-02
|
1.29e-01
|
3.79e-02
|
4.58e-01
|
RHO GTPASES ACTIVATE KTN1
|
11
|
2.88e-01
|
3.83e-01
|
0.4230
|
-0.140000
|
0.153000
|
-0.258000
|
2.37e-01
|
1.14e-01
|
4.21e-01
|
3.81e-01
|
1.39e-01
|
1.73e-01
|
5.14e-01
|
SYNTHESIS OF PE
|
13
|
1.02e-01
|
1.80e-01
|
0.4220
|
0.083900
|
-0.187000
|
-0.328000
|
8.90e-03
|
1.69e-01
|
6.01e-01
|
2.43e-01
|
4.05e-02
|
9.56e-01
|
2.93e-01
|
CYTOSOLIC IRON SULFUR CLUSTER ASSEMBLY
|
13
|
7.05e-02
|
1.34e-01
|
0.4220
|
0.013200
|
-0.302000
|
0.203000
|
1.92e-01
|
9.08e-02
|
9.34e-01
|
5.94e-02
|
2.04e-01
|
2.30e-01
|
5.71e-01
|
MRNA SPLICING
|
188
|
1.28e-17
|
5.91e-16
|
0.4220
|
-0.193000
|
0.012300
|
0.064100
|
1.61e-01
|
-3.32e-01
|
5.22e-06
|
7.72e-01
|
1.30e-01
|
1.43e-04
|
4.21e-15
|
FRS MEDIATED FGFR3 SIGNALING
|
14
|
8.41e-02
|
1.55e-01
|
0.4210
|
0.043900
|
0.016300
|
-0.355000
|
5.33e-02
|
2.15e-01
|
7.76e-01
|
9.16e-01
|
2.14e-02
|
7.30e-01
|
1.63e-01
|
N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCLE
|
35
|
1.17e-02
|
3.30e-02
|
0.4210
|
-0.313000
|
-0.219000
|
-0.128000
|
-1.14e-01
|
-4.64e-02
|
1.36e-03
|
2.48e-02
|
1.91e-01
|
2.44e-01
|
6.34e-01
|
GAB1 SIGNALOSOME
|
13
|
4.31e-01
|
5.24e-01
|
0.4210
|
-0.090300
|
-0.161000
|
-0.194000
|
-2.67e-01
|
-1.85e-01
|
5.73e-01
|
3.14e-01
|
2.26e-01
|
9.52e-02
|
2.48e-01
|
DDX58 IFIH1 MEDIATED INDUCTION OF INTERFERON ALPHA BETA
|
63
|
8.25e-04
|
3.74e-03
|
0.4200
|
-0.224000
|
-0.214000
|
-0.238000
|
-1.36e-01
|
-7.13e-02
|
2.07e-03
|
3.37e-03
|
1.10e-03
|
6.23e-02
|
3.28e-01
|
INSULIN RECEPTOR RECYCLING
|
20
|
1.64e-02
|
4.32e-02
|
0.4200
|
-0.045200
|
-0.097500
|
0.190000
|
2.93e-01
|
2.06e-01
|
7.27e-01
|
4.50e-01
|
1.42e-01
|
2.32e-02
|
1.11e-01
|
ION HOMEOSTASIS
|
47
|
2.96e-03
|
1.08e-02
|
0.4190
|
0.315000
|
-0.035800
|
0.154000
|
-4.41e-02
|
2.23e-01
|
1.91e-04
|
6.72e-01
|
6.77e-02
|
6.01e-01
|
8.20e-03
|
SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN
|
12
|
4.40e-01
|
5.29e-01
|
0.4180
|
-0.255000
|
-0.046300
|
-0.256000
|
1.53e-01
|
-1.38e-01
|
1.26e-01
|
7.81e-01
|
1.25e-01
|
3.60e-01
|
4.10e-01
|
CYTOPROTECTION BY HMOX1
|
119
|
2.14e-11
|
4.57e-10
|
0.4180
|
-0.170000
|
0.014400
|
0.021800
|
3.54e-01
|
-1.41e-01
|
1.34e-03
|
7.86e-01
|
6.81e-01
|
2.65e-11
|
7.79e-03
|
METABOLISM OF RNA
|
643
|
1.95e-60
|
3.22e-58
|
0.4170
|
-0.186000
|
0.005320
|
0.048500
|
2.77e-01
|
-2.45e-01
|
9.61e-16
|
8.19e-01
|
3.71e-02
|
6.75e-33
|
3.98e-26
|
ACTIVATION OF NMDA RECEPTORS AND POSTSYNAPTIC EVENTS
|
83
|
2.01e-07
|
2.25e-06
|
0.4160
|
0.127000
|
-0.217000
|
0.205000
|
-1.76e-01
|
1.93e-01
|
4.63e-02
|
6.39e-04
|
1.23e-03
|
5.65e-03
|
2.40e-03
|
SIGNALING BY LEPTIN
|
10
|
4.49e-01
|
5.39e-01
|
0.4160
|
0.336000
|
0.046700
|
-0.027300
|
-8.41e-02
|
2.24e-01
|
6.62e-02
|
7.98e-01
|
8.81e-01
|
6.45e-01
|
2.19e-01
|
PLATELET ADHESION TO EXPOSED COLLAGEN
|
11
|
2.15e-01
|
3.09e-01
|
0.4160
|
-0.003890
|
0.333000
|
-0.245000
|
-3.33e-03
|
4.26e-02
|
9.82e-01
|
5.56e-02
|
1.60e-01
|
9.85e-01
|
8.07e-01
|
SIGNALING BY NOTCH4
|
83
|
3.27e-07
|
3.43e-06
|
0.4160
|
-0.241000
|
0.065200
|
0.010600
|
3.15e-01
|
-1.07e-01
|
1.52e-04
|
3.05e-01
|
8.68e-01
|
7.21e-07
|
9.26e-02
|
CHONDROITIN SULFATE BIOSYNTHESIS
|
18
|
2.52e-01
|
3.51e-01
|
0.4150
|
0.298000
|
0.161000
|
0.159000
|
-6.47e-02
|
1.66e-01
|
2.85e-02
|
2.38e-01
|
2.43e-01
|
6.35e-01
|
2.22e-01
|
OVARIAN TUMOR DOMAIN PROTEASES
|
36
|
3.09e-02
|
7.07e-02
|
0.4120
|
-0.126000
|
-0.268000
|
-0.242000
|
-1.42e-01
|
-6.06e-02
|
1.92e-01
|
5.38e-03
|
1.21e-02
|
1.40e-01
|
5.29e-01
|
TRAF6 MEDIATED NF KB ACTIVATION
|
21
|
1.04e-01
|
1.82e-01
|
0.4120
|
-0.060500
|
-0.191000
|
-0.302000
|
-1.64e-01
|
1.09e-01
|
6.31e-01
|
1.30e-01
|
1.67e-02
|
1.93e-01
|
3.88e-01
|
FCERI MEDIATED MAPK ACTIVATION
|
28
|
4.01e-02
|
8.76e-02
|
0.4120
|
-0.147000
|
-0.299000
|
-0.087700
|
-2.16e-01
|
6.80e-02
|
1.79e-01
|
6.25e-03
|
4.22e-01
|
4.82e-02
|
5.33e-01
|
DEPOSITION OF NEW CENPA CONTAINING NUCLEOSOMES AT THE CENTROMERE
|
34
|
9.98e-03
|
2.95e-02
|
0.4120
|
-0.164000
|
0.113000
|
-0.211000
|
2.64e-01
|
-1.23e-01
|
9.77e-02
|
2.52e-01
|
3.37e-02
|
7.62e-03
|
2.13e-01
|
RHOF GTPASE CYCLE
|
39
|
1.21e-03
|
5.08e-03
|
0.4110
|
0.067200
|
-0.005040
|
-0.117000
|
-3.72e-01
|
1.14e-01
|
4.68e-01
|
9.57e-01
|
2.06e-01
|
5.95e-05
|
2.17e-01
|
RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER
|
28
|
9.60e-03
|
2.85e-02
|
0.4110
|
0.003420
|
0.008230
|
0.150000
|
3.66e-01
|
1.12e-01
|
9.75e-01
|
9.40e-01
|
1.70e-01
|
7.98e-04
|
3.03e-01
|
DUAL INCISION IN GG NER
|
40
|
5.97e-03
|
1.91e-02
|
0.4110
|
-0.066700
|
0.162000
|
0.174000
|
3.20e-01
|
-7.55e-02
|
4.66e-01
|
7.57e-02
|
5.71e-02
|
4.63e-04
|
4.09e-01
|
P75NTR RECRUITS SIGNALLING COMPLEXES
|
12
|
3.96e-01
|
4.94e-01
|
0.4110
|
-0.132000
|
0.019200
|
-0.117000
|
1.62e-01
|
-3.33e-01
|
4.28e-01
|
9.08e-01
|
4.84e-01
|
3.30e-01
|
4.60e-02
|
FORMATION OF THE CORNIFIED ENVELOPE
|
20
|
1.85e-01
|
2.74e-01
|
0.4100
|
0.164000
|
0.187000
|
0.319000
|
4.58e-02
|
5.31e-02
|
2.05e-01
|
1.47e-01
|
1.36e-02
|
7.23e-01
|
6.81e-01
|
KERATINIZATION
|
20
|
1.85e-01
|
2.74e-01
|
0.4100
|
0.164000
|
0.187000
|
0.319000
|
4.58e-02
|
5.31e-02
|
2.05e-01
|
1.47e-01
|
1.36e-02
|
7.23e-01
|
6.81e-01
|
TRANSPORT OF INORGANIC CATIONS ANIONS AND AMINO ACIDS OLIGOPEPTIDES
|
77
|
8.32e-06
|
6.30e-05
|
0.4100
|
0.182000
|
-0.079800
|
0.037100
|
-2.29e-01
|
2.73e-01
|
5.67e-03
|
2.27e-01
|
5.74e-01
|
5.26e-04
|
3.44e-05
|
CONSTITUTIVE SIGNALING BY AKT1 E17K IN CANCER
|
26
|
4.21e-02
|
9.02e-02
|
0.4100
|
0.250000
|
-0.198000
|
0.052100
|
-1.24e-01
|
2.19e-01
|
2.72e-02
|
8.09e-02
|
6.46e-01
|
2.76e-01
|
5.28e-02
|
STRIATED MUSCLE CONTRACTION
|
21
|
2.46e-02
|
5.88e-02
|
0.4090
|
0.153000
|
-0.055000
|
0.143000
|
1.47e-01
|
-3.15e-01
|
2.25e-01
|
6.63e-01
|
2.57e-01
|
2.42e-01
|
1.25e-02
|
REGULATION OF SIGNALING BY CBL
|
22
|
7.26e-02
|
1.37e-01
|
0.4090
|
-0.085800
|
-0.317000
|
-0.047100
|
-1.95e-01
|
1.37e-01
|
4.86e-01
|
9.98e-03
|
7.02e-01
|
1.13e-01
|
2.67e-01
|
IL 6 TYPE CYTOKINE RECEPTOR LIGAND INTERACTIONS
|
12
|
2.81e-01
|
3.76e-01
|
0.4090
|
0.223000
|
-0.066600
|
-0.095500
|
-2.86e-02
|
3.21e-01
|
1.82e-01
|
6.90e-01
|
5.67e-01
|
8.64e-01
|
5.41e-02
|
PERK REGULATES GENE EXPRESSION
|
28
|
9.46e-03
|
2.81e-02
|
0.4090
|
-0.280000
|
-0.224000
|
-0.038800
|
1.74e-01
|
-7.92e-02
|
1.02e-02
|
3.98e-02
|
7.22e-01
|
1.11e-01
|
4.68e-01
|
CLASS I PEROXISOMAL MEMBRANE PROTEIN IMPORT
|
20
|
6.52e-02
|
1.27e-01
|
0.4090
|
-0.087900
|
0.184000
|
-0.018200
|
1.77e-01
|
3.07e-01
|
4.96e-01
|
1.55e-01
|
8.88e-01
|
1.72e-01
|
1.76e-02
|
ELASTIC FIBRE FORMATION
|
36
|
1.38e-03
|
5.66e-03
|
0.4080
|
0.318000
|
0.244000
|
-0.007560
|
-5.35e-02
|
5.32e-02
|
9.59e-04
|
1.14e-02
|
9.37e-01
|
5.78e-01
|
5.81e-01
|
INTERLEUKIN 10 SIGNALING
|
17
|
2.44e-01
|
3.42e-01
|
0.4080
|
-0.040900
|
-0.204000
|
-0.300000
|
-1.79e-01
|
2.71e-02
|
7.70e-01
|
1.45e-01
|
3.25e-02
|
2.01e-01
|
8.47e-01
|
DUAL INCISION IN TC NER
|
64
|
3.48e-05
|
2.25e-04
|
0.4060
|
-0.152000
|
0.120000
|
0.139000
|
3.23e-01
|
-5.85e-02
|
3.53e-02
|
9.69e-02
|
5.41e-02
|
7.82e-06
|
4.19e-01
|
DISASSEMBLY OF THE DESTRUCTION COMPLEX AND RECRUITMENT OF AXIN TO THE MEMBRANE
|
26
|
1.07e-02
|
3.10e-02
|
0.4060
|
-0.050200
|
-0.044600
|
0.071900
|
-2.91e-01
|
2.65e-01
|
6.58e-01
|
6.94e-01
|
5.26e-01
|
1.01e-02
|
1.94e-02
|
FCERI MEDIATED NF KB ACTIVATION
|
76
|
7.60e-07
|
7.55e-06
|
0.4050
|
-0.201000
|
-0.008270
|
-0.020200
|
3.36e-01
|
-1.01e-01
|
2.44e-03
|
9.01e-01
|
7.60e-01
|
4.05e-07
|
1.27e-01
|
SHC1 EVENTS IN EGFR SIGNALING
|
10
|
6.39e-01
|
7.00e-01
|
0.4040
|
-0.237000
|
-0.123000
|
-0.291000
|
2.97e-03
|
-8.79e-02
|
1.95e-01
|
4.99e-01
|
1.11e-01
|
9.87e-01
|
6.30e-01
|
KSRP KHSRP BINDS AND DESTABILIZES MRNA
|
16
|
9.37e-02
|
1.68e-01
|
0.4040
|
-0.081500
|
-0.051500
|
0.313000
|
2.35e-01
|
2.81e-02
|
5.73e-01
|
7.21e-01
|
3.04e-02
|
1.03e-01
|
8.46e-01
|
NOTCH3 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
|
23
|
9.28e-02
|
1.68e-01
|
0.4040
|
-0.055200
|
-0.141000
|
-0.081500
|
-3.33e-01
|
-1.50e-01
|
6.47e-01
|
2.42e-01
|
4.99e-01
|
5.69e-03
|
2.14e-01
|
INTERLEUKIN 20 FAMILY SIGNALING
|
12
|
4.50e-01
|
5.39e-01
|
0.4030
|
0.198000
|
-0.203000
|
0.071400
|
-2.64e-01
|
8.87e-02
|
2.36e-01
|
2.24e-01
|
6.68e-01
|
1.14e-01
|
5.95e-01
|
REGULATION OF IFNA SIGNALING
|
12
|
3.76e-01
|
4.73e-01
|
0.4030
|
0.066500
|
-0.328000
|
-0.092800
|
-1.25e-01
|
-1.62e-01
|
6.90e-01
|
4.91e-02
|
5.78e-01
|
4.54e-01
|
3.30e-01
|
PYRIMIDINE CATABOLISM
|
10
|
5.57e-01
|
6.36e-01
|
0.4030
|
-0.096900
|
0.304000
|
0.099600
|
2.23e-01
|
3.42e-02
|
5.96e-01
|
9.62e-02
|
5.85e-01
|
2.23e-01
|
8.51e-01
|
SYNTHESIS OF IP3 AND IP4 IN THE CYTOSOL
|
25
|
7.05e-02
|
1.34e-01
|
0.4020
|
0.191000
|
0.066000
|
0.004800
|
-1.55e-01
|
3.11e-01
|
9.87e-02
|
5.68e-01
|
9.67e-01
|
1.81e-01
|
7.05e-03
|
NICOTINAMIDE SALVAGING
|
15
|
1.73e-01
|
2.63e-01
|
0.4020
|
-0.231000
|
0.110000
|
0.073600
|
2.21e-02
|
-3.00e-01
|
1.22e-01
|
4.61e-01
|
6.22e-01
|
8.82e-01
|
4.41e-02
|
GENERATION OF SECOND MESSENGER MOLECULES
|
17
|
5.08e-02
|
1.05e-01
|
0.4000
|
0.015800
|
0.220000
|
-0.158000
|
-5.26e-02
|
-2.90e-01
|
9.10e-01
|
1.17e-01
|
2.58e-01
|
7.07e-01
|
3.87e-02
|
SIGNALING BY RETINOIC ACID
|
31
|
1.20e-02
|
3.35e-02
|
0.3990
|
0.087500
|
0.223000
|
-0.123000
|
2.31e-01
|
1.83e-01
|
3.99e-01
|
3.14e-02
|
2.36e-01
|
2.59e-02
|
7.83e-02
|
NOTCH2 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
|
11
|
2.71e-01
|
3.69e-01
|
0.3990
|
0.139000
|
0.186000
|
-0.066900
|
-2.83e-01
|
1.44e-01
|
4.26e-01
|
2.86e-01
|
7.01e-01
|
1.04e-01
|
4.08e-01
|
ROLE OF SECOND MESSENGERS IN NETRIN 1 SIGNALING
|
10
|
4.79e-01
|
5.66e-01
|
0.3990
|
0.298000
|
0.021000
|
0.248000
|
-4.03e-02
|
-7.97e-02
|
1.02e-01
|
9.08e-01
|
1.75e-01
|
8.25e-01
|
6.63e-01
|
RND3 GTPASE CYCLE
|
37
|
5.26e-03
|
1.73e-02
|
0.3990
|
-0.082500
|
-0.095900
|
-0.065700
|
-3.64e-01
|
-7.67e-02
|
3.85e-01
|
3.13e-01
|
4.89e-01
|
1.26e-04
|
4.19e-01
|
CD28 DEPENDENT PI3K AKT SIGNALING
|
20
|
1.36e-01
|
2.21e-01
|
0.3990
|
0.177000
|
-0.131000
|
0.070500
|
-9.05e-02
|
3.12e-01
|
1.71e-01
|
3.10e-01
|
5.85e-01
|
4.84e-01
|
1.58e-02
|
ONCOGENIC MAPK SIGNALING
|
76
|
8.76e-06
|
6.55e-05
|
0.3990
|
0.041600
|
-0.290000
|
0.049200
|
-2.36e-01
|
1.22e-01
|
5.31e-01
|
1.25e-05
|
4.59e-01
|
3.69e-04
|
6.69e-02
|
RHOBTB1 GTPASE CYCLE
|
23
|
2.44e-01
|
3.42e-01
|
0.3990
|
-0.208000
|
-0.214000
|
-0.203000
|
-1.35e-01
|
-1.02e-01
|
8.42e-02
|
7.59e-02
|
9.23e-02
|
2.61e-01
|
3.97e-01
|
AMYLOID FIBER FORMATION
|
54
|
5.16e-04
|
2.51e-03
|
0.3980
|
-0.202000
|
0.031700
|
-0.189000
|
2.57e-01
|
-1.22e-01
|
1.04e-02
|
6.87e-01
|
1.63e-02
|
1.09e-03
|
1.20e-01
|
STIMULI SENSING CHANNELS
|
73
|
5.17e-05
|
3.17e-04
|
0.3970
|
0.313000
|
0.002700
|
0.053500
|
-9.12e-02
|
2.21e-01
|
3.91e-06
|
9.68e-01
|
4.29e-01
|
1.78e-01
|
1.08e-03
|
CYTOCHROME C MEDIATED APOPTOTIC RESPONSE
|
12
|
2.25e-01
|
3.20e-01
|
0.3960
|
-0.191000
|
-0.146000
|
-0.236000
|
1.49e-01
|
1.45e-01
|
2.51e-01
|
3.83e-01
|
1.57e-01
|
3.71e-01
|
3.83e-01
|
CASPASE ACTIVATION VIA DEATH RECEPTORS IN THE PRESENCE OF LIGAND
|
12
|
3.31e-01
|
4.28e-01
|
0.3960
|
-0.091200
|
-0.080200
|
-0.373000
|
4.95e-02
|
-2.28e-02
|
5.85e-01
|
6.31e-01
|
2.53e-02
|
7.67e-01
|
8.91e-01
|
ZBP1 DAI MEDIATED INDUCTION OF TYPE I IFNS
|
18
|
2.02e-01
|
2.94e-01
|
0.3960
|
-0.053300
|
-0.168000
|
-0.338000
|
-1.05e-01
|
-1.44e-02
|
6.95e-01
|
2.18e-01
|
1.29e-02
|
4.43e-01
|
9.16e-01
|
PLASMA LIPOPROTEIN ASSEMBLY
|
11
|
5.08e-01
|
5.94e-01
|
0.3960
|
-0.026000
|
0.340000
|
0.031100
|
1.63e-01
|
1.13e-01
|
8.81e-01
|
5.09e-02
|
8.58e-01
|
3.48e-01
|
5.17e-01
|
DERMATAN SULFATE BIOSYNTHESIS
|
11
|
1.82e-01
|
2.74e-01
|
0.3960
|
0.041800
|
0.299000
|
0.172000
|
-1.36e-01
|
-1.33e-01
|
8.10e-01
|
8.65e-02
|
3.23e-01
|
4.36e-01
|
4.46e-01
|
CD28 DEPENDENT VAV1 PATHWAY
|
11
|
4.27e-01
|
5.21e-01
|
0.3950
|
-0.345000
|
-0.119000
|
-0.028400
|
-9.79e-02
|
-1.14e-01
|
4.78e-02
|
4.96e-01
|
8.70e-01
|
5.74e-01
|
5.11e-01
|
LYSINE CATABOLISM
|
11
|
3.84e-01
|
4.81e-01
|
0.3950
|
0.052800
|
0.316000
|
-0.141000
|
1.02e-01
|
1.52e-01
|
7.62e-01
|
6.93e-02
|
4.19e-01
|
5.57e-01
|
3.82e-01
|
ERBB2 ACTIVATES PTK6 SIGNALING
|
10
|
4.18e-01
|
5.15e-01
|
0.3950
|
-0.021300
|
0.029200
|
-0.221000
|
-3.24e-01
|
-3.04e-02
|
9.07e-01
|
8.73e-01
|
2.27e-01
|
7.62e-02
|
8.68e-01
|
HS GAG BIOSYNTHESIS
|
29
|
4.02e-03
|
1.38e-02
|
0.3940
|
0.002530
|
0.065100
|
0.222000
|
-2.60e-01
|
1.85e-01
|
9.81e-01
|
5.44e-01
|
3.83e-02
|
1.54e-02
|
8.52e-02
|
REGULATION OF CHOLESTEROL BIOSYNTHESIS BY SREBP SREBF
|
56
|
5.67e-04
|
2.71e-03
|
0.3940
|
-0.027300
|
-0.229000
|
-0.022700
|
-2.91e-01
|
1.30e-01
|
7.24e-01
|
3.06e-03
|
7.69e-01
|
1.66e-04
|
9.20e-02
|
TRIGLYCERIDE CATABOLISM
|
14
|
3.01e-01
|
3.96e-01
|
0.3940
|
-0.278000
|
0.047600
|
-0.024900
|
2.67e-01
|
-6.30e-02
|
7.19e-02
|
7.58e-01
|
8.72e-01
|
8.42e-02
|
6.83e-01
|
TRANSCRIPTION COUPLED NUCLEOTIDE EXCISION REPAIR TC NER
|
77
|
7.90e-06
|
6.03e-05
|
0.3930
|
-0.137000
|
0.116000
|
0.124000
|
3.23e-01
|
-4.81e-02
|
3.72e-02
|
7.79e-02
|
6.08e-02
|
9.40e-07
|
4.66e-01
|
GLYCOSPHINGOLIPID METABOLISM
|
37
|
2.93e-03
|
1.08e-02
|
0.3930
|
0.013600
|
0.050100
|
0.033600
|
2.65e-02
|
3.87e-01
|
8.86e-01
|
5.98e-01
|
7.24e-01
|
7.80e-01
|
4.62e-05
|
FORMATION OF APOPTOSOME
|
10
|
3.38e-01
|
4.34e-01
|
0.3920
|
-0.117000
|
-0.193000
|
-0.279000
|
1.39e-01
|
7.51e-02
|
5.22e-01
|
2.92e-01
|
1.26e-01
|
4.46e-01
|
6.81e-01
|
CHAPERONE MEDIATED AUTOPHAGY
|
19
|
1.76e-01
|
2.65e-01
|
0.3920
|
-0.115000
|
0.086200
|
-0.096700
|
2.86e-01
|
-2.05e-01
|
3.85e-01
|
5.16e-01
|
4.65e-01
|
3.09e-02
|
1.22e-01
|
BETA OXIDATION OF VERY LONG CHAIN FATTY ACIDS
|
11
|
4.23e-01
|
5.18e-01
|
0.3910
|
0.191000
|
0.121000
|
0.056000
|
3.13e-01
|
-1.83e-02
|
2.73e-01
|
4.88e-01
|
7.48e-01
|
7.20e-02
|
9.16e-01
|
NEGATIVE EPIGENETIC REGULATION OF RRNA EXPRESSION
|
62
|
2.25e-04
|
1.19e-03
|
0.3910
|
-0.186000
|
0.040300
|
-0.019400
|
2.81e-01
|
-1.91e-01
|
1.11e-02
|
5.83e-01
|
7.92e-01
|
1.28e-04
|
9.23e-03
|
HSP90 CHAPERONE CYCLE FOR STEROID HORMONE RECEPTORS SHR
|
48
|
2.68e-03
|
1.00e-02
|
0.3890
|
-0.313000
|
-0.183000
|
-0.060200
|
9.16e-03
|
-1.27e-01
|
1.77e-04
|
2.80e-02
|
4.71e-01
|
9.13e-01
|
1.29e-01
|
NEURONAL SYSTEM
|
362
|
3.97e-26
|
2.18e-24
|
0.3890
|
0.186000
|
-0.108000
|
0.180000
|
-2.08e-01
|
1.70e-01
|
1.27e-09
|
4.13e-04
|
4.22e-09
|
1.30e-11
|
2.78e-08
|
ION TRANSPORT BY P TYPE ATPASES
|
46
|
5.94e-03
|
1.90e-02
|
0.3890
|
0.192000
|
0.057100
|
0.110000
|
-1.76e-01
|
2.61e-01
|
2.44e-02
|
5.03e-01
|
1.97e-01
|
3.91e-02
|
2.24e-03
|
SYNTHESIS OF VERY LONG CHAIN FATTY ACYL COAS
|
20
|
6.48e-02
|
1.27e-01
|
0.3880
|
-0.079700
|
0.189000
|
-0.171000
|
-9.80e-03
|
2.81e-01
|
5.37e-01
|
1.44e-01
|
1.87e-01
|
9.40e-01
|
2.94e-02
|
PHASE II CONJUGATION OF COMPOUNDS
|
60
|
5.71e-04
|
2.72e-03
|
0.3870
|
-0.125000
|
0.225000
|
-0.014800
|
2.89e-01
|
1.50e-02
|
9.55e-02
|
2.54e-03
|
8.43e-01
|
1.11e-04
|
8.41e-01
|
RUNX1 INTERACTS WITH CO FACTORS WHOSE PRECISE EFFECT ON RUNX1 TARGETS IS NOT KNOWN
|
37
|
1.35e-02
|
3.72e-02
|
0.3870
|
-0.013200
|
-0.291000
|
0.049100
|
-1.69e-01
|
-1.85e-01
|
8.90e-01
|
2.22e-03
|
6.05e-01
|
7.46e-02
|
5.14e-02
|
ENDOSOMAL SORTING COMPLEX REQUIRED FOR TRANSPORT ESCRT
|
30
|
1.43e-02
|
3.89e-02
|
0.3870
|
-0.157000
|
0.052700
|
0.195000
|
2.91e-01
|
6.02e-04
|
1.36e-01
|
6.17e-01
|
6.45e-02
|
5.89e-03
|
9.95e-01
|
MAPK6 MAPK4 SIGNALING
|
83
|
2.13e-06
|
1.88e-05
|
0.3870
|
-0.275000
|
-0.128000
|
-0.019700
|
1.75e-01
|
-1.62e-01
|
1.52e-05
|
4.32e-02
|
7.57e-01
|
5.80e-03
|
1.06e-02
|
NA CL DEPENDENT NEUROTRANSMITTER TRANSPORTERS
|
10
|
5.19e-01
|
6.03e-01
|
0.3870
|
0.237000
|
0.286000
|
-0.001000
|
3.23e-02
|
1.02e-01
|
1.95e-01
|
1.17e-01
|
9.96e-01
|
8.60e-01
|
5.78e-01
|
HEPARAN SULFATE HEPARIN HS GAG METABOLISM
|
51
|
3.12e-04
|
1.58e-03
|
0.3850
|
0.110000
|
0.140000
|
0.247000
|
-1.78e-01
|
1.56e-01
|
1.74e-01
|
8.44e-02
|
2.32e-03
|
2.81e-02
|
5.40e-02
|
RECOGNITION OF DNA DAMAGE BY PCNA CONTAINING REPLICATION COMPLEX
|
28
|
5.07e-02
|
1.05e-01
|
0.3850
|
-0.139000
|
0.139000
|
0.119000
|
3.08e-01
|
1.52e-02
|
2.02e-01
|
2.04e-01
|
2.75e-01
|
4.80e-03
|
8.89e-01
|
B WICH COMPLEX POSITIVELY REGULATES RRNA EXPRESSION
|
45
|
6.19e-03
|
1.95e-02
|
0.3850
|
-0.189000
|
0.029200
|
-0.073700
|
2.49e-01
|
-2.09e-01
|
2.81e-02
|
7.35e-01
|
3.92e-01
|
3.84e-03
|
1.53e-02
|
SYNTHESIS OF BILE ACIDS AND BILE SALTS VIA 7ALPHA HYDROXYCHOLESTEROL
|
12
|
4.10e-01
|
5.08e-01
|
0.3840
|
0.018500
|
0.208000
|
-0.053600
|
1.13e-01
|
2.98e-01
|
9.12e-01
|
2.12e-01
|
7.48e-01
|
4.99e-01
|
7.42e-02
|
ASSEMBLY OF THE HIV VIRION
|
16
|
1.80e-01
|
2.71e-01
|
0.3830
|
-0.212000
|
-0.139000
|
0.064500
|
2.29e-01
|
-1.61e-01
|
1.42e-01
|
3.35e-01
|
6.55e-01
|
1.12e-01
|
2.65e-01
|
NETRIN 1 SIGNALING
|
48
|
2.71e-03
|
1.02e-02
|
0.3830
|
0.176000
|
-0.088600
|
0.213000
|
-2.29e-01
|
1.00e-01
|
3.49e-02
|
2.89e-01
|
1.07e-02
|
6.14e-03
|
2.30e-01
|
SIGNALING BY FGFR1 IN DISEASE
|
32
|
7.42e-02
|
1.39e-01
|
0.3820
|
-0.014700
|
-0.202000
|
-0.174000
|
-2.72e-01
|
2.37e-02
|
8.86e-01
|
4.77e-02
|
8.77e-02
|
7.73e-03
|
8.17e-01
|
TERMINATION OF TRANSLESION DNA SYNTHESIS
|
31
|
3.71e-02
|
8.26e-02
|
0.3820
|
-0.208000
|
0.073800
|
0.062600
|
2.58e-01
|
-1.63e-01
|
4.47e-02
|
4.77e-01
|
5.47e-01
|
1.30e-02
|
1.15e-01
|
MOLECULES ASSOCIATED WITH ELASTIC FIBRES
|
31
|
6.06e-03
|
1.93e-02
|
0.3810
|
0.300000
|
0.217000
|
-0.072500
|
-2.06e-02
|
5.19e-02
|
3.81e-03
|
3.69e-02
|
4.85e-01
|
8.43e-01
|
6.17e-01
|
LATE ENDOSOMAL MICROAUTOPHAGY
|
30
|
3.31e-02
|
7.50e-02
|
0.3810
|
-0.092900
|
0.057300
|
0.133000
|
3.29e-01
|
-8.57e-02
|
3.78e-01
|
5.87e-01
|
2.09e-01
|
1.82e-03
|
4.17e-01
|
NUCLEAR PORE COMPLEX NPC DISASSEMBLY
|
31
|
4.94e-02
|
1.03e-01
|
0.3800
|
0.186000
|
-0.175000
|
0.104000
|
-1.51e-01
|
2.14e-01
|
7.37e-02
|
9.13e-02
|
3.14e-01
|
1.45e-01
|
3.97e-02
|
REGULATED NECROSIS
|
45
|
5.04e-03
|
1.66e-02
|
0.3800
|
-0.224000
|
-0.001270
|
-0.084000
|
2.60e-01
|
-1.39e-01
|
9.24e-03
|
9.88e-01
|
3.30e-01
|
2.53e-03
|
1.07e-01
|
MYOGENESIS
|
24
|
1.14e-01
|
1.95e-01
|
0.3800
|
0.111000
|
-0.130000
|
0.030300
|
-2.14e-01
|
2.62e-01
|
3.49e-01
|
2.71e-01
|
7.97e-01
|
7.02e-02
|
2.63e-02
|
TICAM1 RIP1 MEDIATED IKK COMPLEX RECRUITMENT
|
18
|
1.86e-01
|
2.76e-01
|
0.3800
|
-0.156000
|
-0.144000
|
-0.304000
|
8.01e-02
|
1.09e-03
|
2.52e-01
|
2.91e-01
|
2.53e-02
|
5.56e-01
|
9.94e-01
|
INOSITOL PHOSPHATE METABOLISM
|
46
|
1.71e-03
|
6.88e-03
|
0.3790
|
0.075300
|
0.168000
|
0.047900
|
-1.30e-01
|
3.01e-01
|
3.77e-01
|
4.88e-02
|
5.74e-01
|
1.28e-01
|
4.15e-04
|
SIGNALING BY KIT IN DISEASE
|
20
|
1.84e-01
|
2.74e-01
|
0.3790
|
0.007820
|
-0.333000
|
-0.039700
|
-1.63e-01
|
6.54e-02
|
9.52e-01
|
9.95e-03
|
7.59e-01
|
2.07e-01
|
6.13e-01
|
DAP12 SIGNALING
|
24
|
1.02e-01
|
1.79e-01
|
0.3780
|
-0.293000
|
-0.206000
|
-0.113000
|
2.26e-02
|
-3.69e-02
|
1.29e-02
|
8.07e-02
|
3.36e-01
|
8.48e-01
|
7.55e-01
|
SUMOYLATION OF DNA METHYLATION PROTEINS
|
15
|
3.33e-01
|
4.29e-01
|
0.3780
|
-0.023600
|
-0.269000
|
0.086600
|
-2.03e-01
|
-1.46e-01
|
8.74e-01
|
7.11e-02
|
5.61e-01
|
1.74e-01
|
3.26e-01
|
SYNTHESIS OF PC
|
26
|
1.48e-02
|
3.96e-02
|
0.3780
|
0.158000
|
-0.063300
|
-0.072400
|
1.53e-01
|
2.92e-01
|
1.63e-01
|
5.76e-01
|
5.23e-01
|
1.77e-01
|
9.92e-03
|
DNA STRAND ELONGATION
|
32
|
6.59e-02
|
1.28e-01
|
0.3780
|
0.026800
|
0.186000
|
0.078300
|
3.08e-01
|
8.33e-02
|
7.93e-01
|
6.89e-02
|
4.43e-01
|
2.61e-03
|
4.15e-01
|
PENTOSE PHOSPHATE PATHWAY
|
13
|
3.72e-01
|
4.70e-01
|
0.3780
|
-0.105000
|
0.243000
|
-0.183000
|
1.34e-01
|
-1.47e-01
|
5.11e-01
|
1.30e-01
|
2.55e-01
|
4.04e-01
|
3.60e-01
|
NEUROTRANSMITTER RELEASE CYCLE
|
48
|
6.64e-03
|
2.08e-02
|
0.3770
|
0.286000
|
-0.067700
|
0.082900
|
-9.21e-02
|
2.01e-01
|
5.97e-04
|
4.17e-01
|
3.21e-01
|
2.70e-01
|
1.60e-02
|
PCP CE PATHWAY
|
88
|
5.69e-07
|
5.70e-06
|
0.3770
|
-0.247000
|
0.038600
|
0.057200
|
2.70e-01
|
-6.38e-02
|
6.45e-05
|
5.32e-01
|
3.54e-01
|
1.24e-05
|
3.01e-01
|
AMINO ACIDS REGULATE MTORC1
|
51
|
8.35e-04
|
3.76e-03
|
0.3760
|
0.035200
|
0.019100
|
0.213000
|
2.14e-01
|
2.22e-01
|
6.64e-01
|
8.13e-01
|
8.58e-03
|
8.37e-03
|
6.18e-03
|
SIGNALING BY FLT3 FUSION PROTEINS
|
18
|
3.01e-01
|
3.96e-01
|
0.3760
|
-0.013100
|
-0.197000
|
-0.123000
|
-2.61e-01
|
1.37e-01
|
9.23e-01
|
1.47e-01
|
3.67e-01
|
5.54e-02
|
3.14e-01
|
REGULATION OF HSF1 MEDIATED HEAT SHOCK RESPONSE
|
75
|
6.24e-04
|
2.94e-03
|
0.3750
|
-0.186000
|
-0.207000
|
-0.108000
|
-2.12e-01
|
-8.18e-02
|
5.28e-03
|
1.96e-03
|
1.06e-01
|
1.53e-03
|
2.21e-01
|
SIGNALLING TO RAS
|
17
|
9.78e-02
|
1.74e-01
|
0.3750
|
-0.024400
|
-0.325000
|
-0.106000
|
2.43e-02
|
1.49e-01
|
8.62e-01
|
2.02e-02
|
4.48e-01
|
8.62e-01
|
2.87e-01
|
GLYCOGEN METABOLISM
|
25
|
6.31e-02
|
1.25e-01
|
0.3750
|
-0.186000
|
-0.043700
|
-0.275000
|
-6.07e-02
|
1.57e-01
|
1.08e-01
|
7.05e-01
|
1.74e-02
|
5.99e-01
|
1.73e-01
|
PURINERGIC SIGNALING IN LEISHMANIASIS INFECTION
|
22
|
1.57e-01
|
2.45e-01
|
0.3740
|
-0.170000
|
0.062700
|
-0.320000
|
-1.15e-02
|
-6.87e-02
|
1.67e-01
|
6.11e-01
|
9.37e-03
|
9.25e-01
|
5.77e-01
|
ANTIGEN ACTIVATES B CELL RECEPTOR BCR LEADING TO GENERATION OF SECOND MESSENGERS
|
26
|
9.92e-02
|
1.76e-01
|
0.3740
|
-0.032000
|
-0.212000
|
-0.160000
|
-2.02e-01
|
1.65e-01
|
7.78e-01
|
6.11e-02
|
1.59e-01
|
7.41e-02
|
1.45e-01
|
ENOS ACTIVATION
|
11
|
5.89e-01
|
6.61e-01
|
0.3740
|
-0.181000
|
0.004300
|
-0.322000
|
6.20e-04
|
-6.04e-02
|
3.00e-01
|
9.80e-01
|
6.47e-02
|
9.97e-01
|
7.29e-01
|
PRESYNAPTIC FUNCTION OF KAINATE RECEPTORS
|
19
|
1.12e-01
|
1.93e-01
|
0.3740
|
-0.216000
|
-0.105000
|
0.130000
|
2.09e-01
|
-1.46e-01
|
1.03e-01
|
4.30e-01
|
3.27e-01
|
1.15e-01
|
2.70e-01
|
CASPASE ACTIVATION VIA DEPENDENCE RECEPTORS IN THE ABSENCE OF LIGAND
|
10
|
5.67e-01
|
6.44e-01
|
0.3730
|
0.288000
|
0.048000
|
-0.002820
|
-1.85e-01
|
1.40e-01
|
1.14e-01
|
7.93e-01
|
9.88e-01
|
3.12e-01
|
4.44e-01
|
WNT5A DEPENDENT INTERNALIZATION OF FZD2 FZD5 AND ROR2
|
13
|
3.02e-01
|
3.96e-01
|
0.3720
|
-0.000872
|
0.291000
|
0.224000
|
-2.04e-02
|
6.02e-02
|
9.96e-01
|
6.97e-02
|
1.62e-01
|
8.99e-01
|
7.07e-01
|
MTOR SIGNALLING
|
40
|
9.25e-03
|
2.77e-02
|
0.3720
|
0.029100
|
0.073000
|
0.144000
|
2.03e-01
|
2.66e-01
|
7.50e-01
|
4.24e-01
|
1.16e-01
|
2.66e-02
|
3.65e-03
|
G2 M CHECKPOINTS
|
128
|
7.34e-09
|
1.06e-07
|
0.3720
|
-0.229000
|
-0.000811
|
-0.061000
|
2.59e-01
|
-1.22e-01
|
7.73e-06
|
9.87e-01
|
2.34e-01
|
4.17e-07
|
1.71e-02
|
AKT PHOSPHORYLATES TARGETS IN THE CYTOSOL
|
14
|
2.38e-01
|
3.36e-01
|
0.3720
|
0.203000
|
-0.156000
|
0.058300
|
1.03e-01
|
2.43e-01
|
1.89e-01
|
3.12e-01
|
7.06e-01
|
5.04e-01
|
1.16e-01
|
NOTCH HLH TRANSCRIPTION PATHWAY
|
28
|
4.92e-02
|
1.03e-01
|
0.3720
|
0.148000
|
-0.151000
|
-0.064300
|
-2.73e-01
|
-1.22e-01
|
1.76e-01
|
1.67e-01
|
5.56e-01
|
1.26e-02
|
2.62e-01
|
DEGRADATION OF BETA CATENIN BY THE DESTRUCTION COMPLEX
|
82
|
3.02e-06
|
2.55e-05
|
0.3710
|
-0.294000
|
0.020900
|
0.001290
|
2.19e-01
|
-5.57e-02
|
4.31e-06
|
7.44e-01
|
9.84e-01
|
6.17e-04
|
3.84e-01
|
ERBB2 REGULATES CELL MOTILITY
|
13
|
4.05e-01
|
5.02e-01
|
0.3700
|
-0.118000
|
-0.002600
|
-0.230000
|
-2.55e-01
|
7.13e-02
|
4.62e-01
|
9.87e-01
|
1.51e-01
|
1.12e-01
|
6.56e-01
|
TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION
|
16
|
4.29e-01
|
5.23e-01
|
0.3690
|
-0.313000
|
-0.014600
|
-0.148000
|
4.50e-02
|
-1.18e-01
|
3.02e-02
|
9.20e-01
|
3.06e-01
|
7.55e-01
|
4.16e-01
|
INTERLEUKIN 3 INTERLEUKIN 5 AND GM CSF SIGNALING
|
41
|
1.68e-02
|
4.38e-02
|
0.3690
|
-0.082700
|
-0.191000
|
-0.058700
|
-2.88e-01
|
7.88e-02
|
3.59e-01
|
3.42e-02
|
5.16e-01
|
1.43e-03
|
3.83e-01
|
TELOMERE MAINTENANCE
|
75
|
4.57e-05
|
2.88e-04
|
0.3680
|
-0.100000
|
0.056000
|
-0.054100
|
2.94e-01
|
-1.82e-01
|
1.33e-01
|
4.02e-01
|
4.18e-01
|
1.08e-05
|
6.48e-03
|
ROLE OF LAT2 NTAL LAB ON CALCIUM MOBILIZATION
|
14
|
4.24e-01
|
5.19e-01
|
0.3680
|
-0.106000
|
-0.216000
|
-0.117000
|
-2.06e-01
|
1.46e-01
|
4.93e-01
|
1.62e-01
|
4.48e-01
|
1.81e-01
|
3.43e-01
|
RAC1 GTPASE CYCLE
|
176
|
1.48e-11
|
3.34e-10
|
0.3670
|
0.096200
|
-0.103000
|
-0.051600
|
-2.85e-01
|
1.76e-01
|
2.79e-02
|
1.90e-02
|
2.38e-01
|
6.81e-11
|
6.03e-05
|
INTERLEUKIN 2 FAMILY SIGNALING
|
33
|
7.09e-02
|
1.35e-01
|
0.3670
|
0.010200
|
-0.198000
|
-0.055700
|
-3.00e-01
|
4.79e-02
|
9.19e-01
|
4.92e-02
|
5.80e-01
|
2.90e-03
|
6.34e-01
|
GABA RECEPTOR ACTIVATION
|
53
|
1.16e-03
|
4.95e-03
|
0.3670
|
-0.143000
|
-0.162000
|
-0.035100
|
-2.85e-01
|
7.41e-02
|
7.12e-02
|
4.16e-02
|
6.58e-01
|
3.41e-04
|
3.51e-01
|
GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR GG NER
|
83
|
6.30e-05
|
3.80e-04
|
0.3670
|
-0.086500
|
0.160000
|
0.121000
|
2.94e-01
|
-1.96e-02
|
1.73e-01
|
1.16e-02
|
5.77e-02
|
3.78e-06
|
7.58e-01
|
LAGGING STRAND SYNTHESIS
|
20
|
2.16e-01
|
3.10e-01
|
0.3660
|
-0.025200
|
0.151000
|
-0.024700
|
3.28e-01
|
-4.76e-02
|
8.45e-01
|
2.42e-01
|
8.48e-01
|
1.10e-02
|
7.13e-01
|
FORMATION OF INCISION COMPLEX IN GG NER
|
43
|
1.49e-02
|
3.98e-02
|
0.3660
|
-0.091300
|
0.204000
|
0.151000
|
2.43e-01
|
4.79e-02
|
3.00e-01
|
2.10e-02
|
8.68e-02
|
5.83e-03
|
5.87e-01
|
GASTRIN CREB SIGNALLING PATHWAY VIA PKC AND MAPK
|
16
|
3.40e-01
|
4.36e-01
|
0.3660
|
-0.076300
|
-0.296000
|
-0.039800
|
-1.75e-01
|
8.91e-02
|
5.97e-01
|
4.01e-02
|
7.83e-01
|
2.26e-01
|
5.37e-01
|
INHIBITION OF THE PROTEOLYTIC ACTIVITY OF APC C REQUIRED FOR THE ONSET OF ANAPHASE BY MITOTIC SPINDLE CHECKPOINT COMPONENTS
|
20
|
2.28e-01
|
3.23e-01
|
0.3660
|
-0.125000
|
0.138000
|
0.114000
|
2.93e-01
|
-1.08e-02
|
3.32e-01
|
2.87e-01
|
3.76e-01
|
2.33e-02
|
9.33e-01
|
RUNX2 REGULATES OSTEOBLAST DIFFERENTIATION
|
22
|
2.16e-01
|
3.10e-01
|
0.3660
|
-0.087000
|
-0.169000
|
-0.062700
|
-3.06e-01
|
-1.37e-02
|
4.80e-01
|
1.71e-01
|
6.11e-01
|
1.30e-02
|
9.11e-01
|
FATTY ACID METABOLISM
|
143
|
2.04e-10
|
3.51e-09
|
0.3650
|
0.013100
|
0.222000
|
-0.113000
|
2.17e-01
|
1.55e-01
|
7.87e-01
|
4.46e-06
|
1.97e-02
|
7.63e-06
|
1.42e-03
|
ATF4 ACTIVATES GENES IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS
|
23
|
4.08e-02
|
8.86e-02
|
0.3650
|
-0.212000
|
-0.170000
|
0.057500
|
2.30e-01
|
-5.38e-02
|
7.78e-02
|
1.58e-01
|
6.33e-01
|
5.59e-02
|
6.55e-01
|
N GLYCAN ANTENNAE ELONGATION IN THE MEDIAL TRANS GOLGI
|
23
|
1.08e-01
|
1.88e-01
|
0.3650
|
-0.122000
|
-0.022900
|
-0.183000
|
-2.69e-01
|
1.09e-01
|
3.12e-01
|
8.50e-01
|
1.29e-01
|
2.54e-02
|
3.64e-01
|
METABOLISM OF NUCLEOTIDES
|
92
|
1.91e-06
|
1.72e-05
|
0.3650
|
-0.194000
|
0.162000
|
0.046200
|
2.53e-01
|
5.49e-02
|
1.33e-03
|
7.12e-03
|
4.44e-01
|
2.72e-05
|
3.64e-01
|
SURFACTANT METABOLISM
|
15
|
4.71e-01
|
5.58e-01
|
0.3640
|
-0.206000
|
-0.021500
|
-0.276000
|
-1.13e-01
|
-2.91e-02
|
1.67e-01
|
8.86e-01
|
6.44e-02
|
4.50e-01
|
8.45e-01
|
RAF ACTIVATION
|
34
|
6.17e-03
|
1.95e-02
|
0.3640
|
-0.078300
|
-0.219000
|
0.082600
|
-1.37e-01
|
2.30e-01
|
4.30e-01
|
2.73e-02
|
4.05e-01
|
1.66e-01
|
2.04e-02
|
BLOOD GROUP SYSTEMS BIOSYNTHESIS
|
12
|
3.24e-01
|
4.21e-01
|
0.3640
|
-0.094400
|
0.049300
|
-0.110000
|
4.05e-02
|
3.28e-01
|
5.71e-01
|
7.68e-01
|
5.10e-01
|
8.08e-01
|
4.94e-02
|
INTEGRIN SIGNALING
|
24
|
1.43e-01
|
2.29e-01
|
0.3640
|
-0.043300
|
-0.219000
|
-0.092500
|
-2.14e-01
|
1.68e-01
|
7.14e-01
|
6.32e-02
|
4.33e-01
|
7.00e-02
|
1.54e-01
|
TRANSCRIPTIONAL REGULATION OF GRANULOPOIESIS
|
42
|
1.27e-02
|
3.54e-02
|
0.3640
|
-0.205000
|
0.153000
|
-0.222000
|
3.75e-02
|
-1.27e-01
|
2.16e-02
|
8.67e-02
|
1.26e-02
|
6.74e-01
|
1.56e-01
|
PROCESSING OF CAPPED INTRONLESS PRE MRNA
|
28
|
3.07e-02
|
7.04e-02
|
0.3640
|
-0.156000
|
-0.048600
|
0.201000
|
1.35e-01
|
-2.17e-01
|
1.54e-01
|
6.56e-01
|
6.62e-02
|
2.17e-01
|
4.69e-02
|
THE NLRP3 INFLAMMASOME
|
15
|
4.33e-01
|
5.26e-01
|
0.3630
|
-0.126000
|
-0.006160
|
-0.312000
|
-9.52e-02
|
-9.93e-02
|
3.99e-01
|
9.67e-01
|
3.65e-02
|
5.23e-01
|
5.05e-01
|
ENERGY DEPENDENT REGULATION OF MTOR BY LKB1 AMPK
|
28
|
3.88e-02
|
8.59e-02
|
0.3630
|
0.005690
|
0.041300
|
0.079600
|
1.46e-01
|
3.20e-01
|
9.58e-01
|
7.05e-01
|
4.66e-01
|
1.81e-01
|
3.35e-03
|
CELL CELL JUNCTION ORGANIZATION
|
46
|
1.76e-04
|
9.59e-04
|
0.3620
|
-0.196000
|
0.021400
|
-0.031300
|
-2.79e-01
|
1.18e-01
|
2.15e-02
|
8.02e-01
|
7.14e-01
|
1.07e-03
|
1.68e-01
|
RHOB GTPASE CYCLE
|
67
|
5.67e-04
|
2.71e-03
|
0.3620
|
0.134000
|
-0.085700
|
0.001200
|
-2.49e-01
|
2.10e-01
|
5.76e-02
|
2.25e-01
|
9.86e-01
|
4.30e-04
|
3.01e-03
|
RUNX3 REGULATES NOTCH SIGNALING
|
13
|
2.62e-01
|
3.60e-01
|
0.3620
|
0.127000
|
0.095400
|
-0.186000
|
-2.66e-01
|
2.41e-02
|
4.27e-01
|
5.52e-01
|
2.47e-01
|
9.70e-02
|
8.81e-01
|
PI 3K CASCADE FGFR2
|
14
|
3.61e-01
|
4.58e-01
|
0.3620
|
0.093800
|
-0.198000
|
-0.232000
|
-1.44e-01
|
9.18e-02
|
5.43e-01
|
2.00e-01
|
1.33e-01
|
3.51e-01
|
5.52e-01
|
DARPP 32 EVENTS
|
23
|
4.86e-02
|
1.02e-01
|
0.3620
|
-0.029200
|
-0.080100
|
0.215000
|
-6.54e-02
|
2.71e-01
|
8.08e-01
|
5.06e-01
|
7.47e-02
|
5.87e-01
|
2.46e-02
|
RAP1 SIGNALLING
|
15
|
4.14e-01
|
5.12e-01
|
0.3610
|
0.149000
|
-0.133000
|
0.144000
|
-1.02e-01
|
2.44e-01
|
3.18e-01
|
3.74e-01
|
3.33e-01
|
4.93e-01
|
1.02e-01
|
NUCLEOTIDE EXCISION REPAIR
|
109
|
1.20e-06
|
1.10e-05
|
0.3610
|
-0.091800
|
0.130000
|
0.130000
|
2.95e-01
|
-3.60e-02
|
9.80e-02
|
1.91e-02
|
1.93e-02
|
1.07e-07
|
5.17e-01
|
GLYCOGEN SYNTHESIS
|
14
|
3.62e-01
|
4.59e-01
|
0.3610
|
-0.252000
|
-0.056900
|
-0.224000
|
7.18e-02
|
9.07e-02
|
1.03e-01
|
7.12e-01
|
1.47e-01
|
6.42e-01
|
5.57e-01
|
ACTIVATION OF MATRIX METALLOPROTEINASES
|
14
|
1.20e-01
|
2.03e-01
|
0.3610
|
-0.067300
|
0.192000
|
0.017900
|
-2.95e-01
|
4.09e-02
|
6.63e-01
|
2.14e-01
|
9.08e-01
|
5.63e-02
|
7.91e-01
|
IKK COMPLEX RECRUITMENT MEDIATED BY RIP1
|
20
|
1.43e-01
|
2.28e-01
|
0.3610
|
-0.086400
|
-0.184000
|
-0.291000
|
6.32e-02
|
-6.13e-03
|
5.03e-01
|
1.55e-01
|
2.42e-02
|
6.25e-01
|
9.62e-01
|
INACTIVATION OF CSF3 G CSF SIGNALING
|
24
|
1.62e-01
|
2.51e-01
|
0.3600
|
-0.237000
|
-0.138000
|
-0.213000
|
8.86e-02
|
-3.64e-02
|
4.45e-02
|
2.42e-01
|
7.08e-02
|
4.52e-01
|
7.57e-01
|
SIGNALING BY PDGFRA TRANSMEMBRANE JUXTAMEMBRANE AND KINASE DOMAIN MUTANTS
|
12
|
5.48e-01
|
6.29e-01
|
0.3600
|
0.053000
|
-0.255000
|
-0.125000
|
-1.75e-01
|
1.22e-01
|
7.50e-01
|
1.25e-01
|
4.55e-01
|
2.93e-01
|
4.63e-01
|
THROMBIN SIGNALLING THROUGH PROTEINASE ACTIVATED RECEPTORS PARS
|
26
|
7.80e-02
|
1.46e-01
|
0.3590
|
-0.242000
|
-0.193000
|
0.026300
|
9.11e-02
|
-1.56e-01
|
3.30e-02
|
8.83e-02
|
8.17e-01
|
4.21e-01
|
1.68e-01
|
YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION
|
11
|
5.88e-01
|
6.61e-01
|
0.3590
|
0.137000
|
-0.065200
|
-0.076100
|
-2.77e-01
|
1.53e-01
|
4.30e-01
|
7.08e-01
|
6.62e-01
|
1.12e-01
|
3.79e-01
|
TRANSCRIPTIONAL ACTIVATION OF MITOCHONDRIAL BIOGENESIS
|
54
|
2.26e-03
|
8.72e-03
|
0.3590
|
0.175000
|
-0.257000
|
0.069700
|
-1.56e-01
|
5.60e-02
|
2.64e-02
|
1.11e-03
|
3.76e-01
|
4.70e-02
|
4.77e-01
|
NS1 MEDIATED EFFECTS ON HOST PATHWAYS
|
37
|
2.00e-02
|
5.04e-02
|
0.3590
|
0.029200
|
-0.255000
|
0.100000
|
-1.96e-01
|
1.20e-01
|
7.59e-01
|
7.36e-03
|
2.90e-01
|
3.88e-02
|
2.06e-01
|
DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVITY
|
23
|
1.49e-01
|
2.36e-01
|
0.3590
|
0.054900
|
-0.168000
|
0.116000
|
-2.87e-01
|
4.68e-02
|
6.49e-01
|
1.64e-01
|
3.37e-01
|
1.74e-02
|
6.98e-01
|
NOTCH3 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
|
26
|
7.08e-02
|
1.35e-01
|
0.3590
|
-0.168000
|
-0.050100
|
0.077700
|
-5.31e-02
|
-2.98e-01
|
1.38e-01
|
6.58e-01
|
4.93e-01
|
6.39e-01
|
8.48e-03
|
DOWNSTREAM SIGNALING OF ACTIVATED FGFR3
|
19
|
1.56e-01
|
2.45e-01
|
0.3580
|
0.016000
|
-0.088900
|
-0.322000
|
-7.83e-02
|
1.01e-01
|
9.04e-01
|
5.02e-01
|
1.50e-02
|
5.55e-01
|
4.45e-01
|
CYTOSOLIC TRNA AMINOACYLATION
|
24
|
3.92e-02
|
8.63e-02
|
0.3580
|
-0.141000
|
0.015600
|
0.041700
|
2.47e-01
|
2.13e-01
|
2.32e-01
|
8.95e-01
|
7.24e-01
|
3.61e-02
|
7.13e-02
|
SUMOYLATION OF TRANSCRIPTION FACTORS
|
16
|
5.72e-01
|
6.48e-01
|
0.3570
|
-0.245000
|
-0.078800
|
-0.199000
|
-2.61e-02
|
-1.46e-01
|
8.97e-02
|
5.85e-01
|
1.69e-01
|
8.57e-01
|
3.14e-01
|
EPHB MEDIATED FORWARD SIGNALING
|
42
|
1.11e-02
|
3.17e-02
|
0.3570
|
-0.107000
|
-0.293000
|
0.064500
|
-1.33e-01
|
-8.96e-02
|
2.31e-01
|
1.01e-03
|
4.70e-01
|
1.37e-01
|
3.15e-01
|
TNFS BIND THEIR PHYSIOLOGICAL RECEPTORS
|
10
|
5.88e-01
|
6.61e-01
|
0.3570
|
0.065600
|
-0.045500
|
-0.230000
|
-2.24e-01
|
1.32e-01
|
7.20e-01
|
8.03e-01
|
2.07e-01
|
2.19e-01
|
4.71e-01
|
TRANSFERRIN ENDOCYTOSIS AND RECYCLING
|
26
|
4.03e-02
|
8.78e-02
|
0.3560
|
0.017100
|
-0.008860
|
0.061800
|
2.51e-01
|
2.45e-01
|
8.80e-01
|
9.38e-01
|
5.85e-01
|
2.70e-02
|
3.07e-02
|
HEDGEHOG ON STATE
|
82
|
9.44e-06
|
7.02e-05
|
0.3560
|
-0.294000
|
-0.097500
|
-0.049700
|
1.58e-01
|
-5.95e-02
|
4.27e-06
|
1.27e-01
|
4.37e-01
|
1.37e-02
|
3.52e-01
|
POTASSIUM CHANNELS
|
89
|
4.99e-05
|
3.08e-04
|
0.3550
|
0.149000
|
-0.045700
|
0.235000
|
-1.15e-01
|
1.82e-01
|
1.54e-02
|
4.56e-01
|
1.27e-04
|
6.15e-02
|
3.01e-03
|
PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA
|
237
|
9.24e-16
|
3.67e-14
|
0.3550
|
-0.169000
|
-0.015900
|
0.063900
|
1.36e-01
|
-2.73e-01
|
7.43e-06
|
6.74e-01
|
9.08e-02
|
3.29e-04
|
5.27e-13
|
SYNTHESIS OF LEUKOTRIENES LT AND EOXINS EX
|
12
|
5.10e-01
|
5.96e-01
|
0.3540
|
0.242000
|
-0.004160
|
0.165000
|
1.97e-01
|
2.62e-02
|
1.46e-01
|
9.80e-01
|
3.21e-01
|
2.37e-01
|
8.75e-01
|
TRANSPORT OF CONNEXONS TO THE PLASMA MEMBRANE
|
13
|
5.25e-01
|
6.07e-01
|
0.3540
|
-0.141000
|
0.236000
|
0.079100
|
1.98e-01
|
-6.27e-02
|
3.79e-01
|
1.40e-01
|
6.21e-01
|
2.17e-01
|
6.95e-01
|
TRP CHANNELS
|
18
|
2.09e-01
|
3.02e-01
|
0.3530
|
0.317000
|
-0.053400
|
-0.037000
|
-8.09e-02
|
1.16e-01
|
1.98e-02
|
6.95e-01
|
7.86e-01
|
5.53e-01
|
3.95e-01
|
CIRCADIAN CLOCK
|
67
|
1.16e-03
|
4.95e-03
|
0.3530
|
0.050500
|
-0.237000
|
0.021900
|
-2.41e-01
|
8.53e-02
|
4.75e-01
|
8.01e-04
|
7.56e-01
|
6.36e-04
|
2.27e-01
|
RIP MEDIATED NFKB ACTIVATION VIA ZBP1
|
15
|
1.96e-01
|
2.88e-01
|
0.3530
|
0.101000
|
-0.126000
|
-0.299000
|
-2.58e-02
|
9.11e-02
|
4.99e-01
|
3.97e-01
|
4.48e-02
|
8.63e-01
|
5.41e-01
|
CDC42 GTPASE CYCLE
|
152
|
8.83e-09
|
1.24e-07
|
0.3530
|
0.132000
|
-0.112000
|
0.006080
|
-2.73e-01
|
1.40e-01
|
4.93e-03
|
1.72e-02
|
8.97e-01
|
6.24e-09
|
2.89e-03
|
INTERLEUKIN 12 FAMILY SIGNALING
|
42
|
1.14e-02
|
3.23e-02
|
0.3510
|
-0.193000
|
-0.015600
|
-0.097200
|
2.66e-01
|
-7.61e-02
|
3.08e-02
|
8.61e-01
|
2.76e-01
|
2.91e-03
|
3.94e-01
|
PHOSPHORYLATION OF THE APC C
|
17
|
2.95e-01
|
3.92e-01
|
0.3500
|
-0.223000
|
0.095000
|
0.091800
|
2.29e-01
|
-5.69e-02
|
1.12e-01
|
4.98e-01
|
5.12e-01
|
1.02e-01
|
6.84e-01
|
SIGNALING BY NTRK2 TRKB
|
23
|
1.99e-01
|
2.91e-01
|
0.3490
|
0.060600
|
-0.192000
|
0.094700
|
-2.64e-01
|
5.21e-02
|
6.15e-01
|
1.12e-01
|
4.32e-01
|
2.81e-02
|
6.66e-01
|
S PHASE
|
152
|
4.47e-10
|
7.36e-09
|
0.3480
|
-0.213000
|
0.075500
|
-0.000865
|
2.64e-01
|
-6.60e-03
|
5.72e-06
|
1.09e-01
|
9.85e-01
|
2.00e-08
|
8.88e-01
|
DISEASES OF IMMUNE SYSTEM
|
22
|
1.31e-01
|
2.14e-01
|
0.3480
|
-0.106000
|
-0.081000
|
-0.289000
|
-2.10e-03
|
1.39e-01
|
3.87e-01
|
5.11e-01
|
1.89e-02
|
9.86e-01
|
2.58e-01
|
EXTRA NUCLEAR ESTROGEN SIGNALING
|
65
|
7.65e-03
|
2.35e-02
|
0.3470
|
-0.205000
|
-0.187000
|
-0.124000
|
-1.52e-01
|
-7.05e-02
|
4.25e-03
|
9.18e-03
|
8.38e-02
|
3.45e-02
|
3.26e-01
|
E3 UBIQUITIN LIGASES UBIQUITINATE TARGET PROTEINS
|
48
|
1.74e-02
|
4.48e-02
|
0.3470
|
-0.229000
|
-0.027600
|
-0.165000
|
1.67e-01
|
-1.10e-01
|
6.07e-03
|
7.40e-01
|
4.81e-02
|
4.53e-02
|
1.89e-01
|
COPI MEDIATED ANTEROGRADE TRANSPORT
|
90
|
3.03e-06
|
2.55e-05
|
0.3460
|
0.007690
|
0.000491
|
0.239000
|
1.52e-01
|
1.99e-01
|
9.00e-01
|
9.94e-01
|
8.74e-05
|
1.30e-02
|
1.10e-03
|
SPRY REGULATION OF FGF SIGNALING
|
16
|
3.50e-01
|
4.48e-01
|
0.3460
|
0.081300
|
-0.023400
|
0.326000
|
7.76e-02
|
1.62e-02
|
5.73e-01
|
8.71e-01
|
2.38e-02
|
5.91e-01
|
9.11e-01
|
UPTAKE AND FUNCTION OF ANTHRAX TOXINS
|
11
|
5.56e-01
|
6.36e-01
|
0.3460
|
0.172000
|
-0.146000
|
-0.030800
|
-6.11e-02
|
2.53e-01
|
3.24e-01
|
4.00e-01
|
8.59e-01
|
7.26e-01
|
1.46e-01
|
PYRUVATE METABOLISM
|
27
|
1.28e-01
|
2.11e-01
|
0.3460
|
0.041500
|
0.164000
|
-0.021400
|
2.47e-01
|
1.72e-01
|
7.09e-01
|
1.40e-01
|
8.47e-01
|
2.64e-02
|
1.22e-01
|
SIGNALLING TO ERKS
|
31
|
2.02e-02
|
5.04e-02
|
0.3460
|
-0.019200
|
-0.234000
|
-0.052500
|
-4.42e-02
|
2.44e-01
|
8.53e-01
|
2.43e-02
|
6.13e-01
|
6.70e-01
|
1.85e-02
|
PROTEIN FOLDING
|
87
|
2.50e-06
|
2.15e-05
|
0.3450
|
-0.192000
|
-0.079200
|
0.082000
|
2.38e-01
|
-1.14e-01
|
2.03e-03
|
2.02e-01
|
1.87e-01
|
1.26e-04
|
6.66e-02
|
IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL
|
43
|
1.13e-02
|
3.21e-02
|
0.3450
|
-0.069500
|
0.057100
|
-0.200000
|
3.53e-02
|
-2.64e-01
|
4.31e-01
|
5.17e-01
|
2.36e-02
|
6.89e-01
|
2.77e-03
|
PHASE 2 PLATEAU PHASE
|
11
|
3.37e-01
|
4.34e-01
|
0.3430
|
0.147000
|
0.154000
|
0.085300
|
-2.10e-01
|
-1.45e-01
|
3.98e-01
|
3.77e-01
|
6.24e-01
|
2.29e-01
|
4.05e-01
|
GABA B RECEPTOR ACTIVATION
|
39
|
1.30e-02
|
3.60e-02
|
0.3430
|
-0.164000
|
-0.183000
|
0.040200
|
-2.34e-01
|
2.80e-02
|
7.56e-02
|
4.82e-02
|
6.64e-01
|
1.16e-02
|
7.62e-01
|
ION CHANNEL TRANSPORT
|
136
|
2.72e-06
|
2.32e-05
|
0.3430
|
0.226000
|
0.015100
|
0.095700
|
-6.46e-02
|
2.30e-01
|
5.37e-06
|
7.61e-01
|
5.42e-02
|
1.94e-01
|
3.87e-06
|
METALLOPROTEASE DUBS
|
26
|
1.76e-01
|
2.66e-01
|
0.3420
|
-0.235000
|
0.060100
|
-0.143000
|
1.86e-01
|
-5.03e-02
|
3.79e-02
|
5.96e-01
|
2.06e-01
|
9.99e-02
|
6.57e-01
|
MICRORNA MIRNA BIOGENESIS
|
24
|
1.20e-01
|
2.03e-01
|
0.3420
|
-0.065400
|
-0.142000
|
-0.008690
|
1.65e-01
|
-2.55e-01
|
5.79e-01
|
2.28e-01
|
9.41e-01
|
1.62e-01
|
3.08e-02
|
SIGNALING BY BRAF AND RAF FUSIONS
|
60
|
4.03e-03
|
1.38e-02
|
0.3410
|
0.062500
|
-0.231000
|
0.041800
|
-2.17e-01
|
9.80e-02
|
4.02e-01
|
1.94e-03
|
5.75e-01
|
3.64e-03
|
1.89e-01
|
CTLA4 INHIBITORY SIGNALING
|
20
|
1.68e-01
|
2.58e-01
|
0.3400
|
-0.142000
|
-0.201000
|
-0.031900
|
-1.39e-01
|
1.86e-01
|
2.72e-01
|
1.19e-01
|
8.05e-01
|
2.83e-01
|
1.49e-01
|
AMINO ACID TRANSPORT ACROSS THE PLASMA MEMBRANE
|
24
|
2.54e-01
|
3.53e-01
|
0.3400
|
0.161000
|
-0.004330
|
0.087600
|
-1.74e-01
|
2.27e-01
|
1.72e-01
|
9.71e-01
|
4.58e-01
|
1.40e-01
|
5.38e-02
|
PROTEIN UBIQUITINATION
|
67
|
2.25e-03
|
8.69e-03
|
0.3400
|
-0.268000
|
-0.047600
|
-0.146000
|
1.21e-01
|
-7.42e-02
|
1.48e-04
|
5.00e-01
|
3.89e-02
|
8.79e-02
|
2.94e-01
|
INTRA GOLGI TRAFFIC
|
43
|
1.79e-02
|
4.58e-02
|
0.3400
|
0.077800
|
-0.023800
|
0.143000
|
-4.35e-02
|
2.94e-01
|
3.77e-01
|
7.87e-01
|
1.04e-01
|
6.21e-01
|
8.59e-04
|
FCERI MEDIATED CA 2 MOBILIZATION
|
25
|
1.24e-01
|
2.07e-01
|
0.3390
|
-0.083100
|
-0.155000
|
-0.230000
|
-7.07e-02
|
1.61e-01
|
4.72e-01
|
1.80e-01
|
4.64e-02
|
5.40e-01
|
1.64e-01
|
DOWNSTREAM SIGNAL TRANSDUCTION
|
29
|
1.20e-01
|
2.03e-01
|
0.3390
|
0.090300
|
-0.195000
|
-0.015000
|
-1.69e-01
|
1.99e-01
|
4.00e-01
|
6.99e-02
|
8.89e-01
|
1.15e-01
|
6.33e-02
|
DCC MEDIATED ATTRACTIVE SIGNALING
|
14
|
2.81e-01
|
3.76e-01
|
0.3380
|
-0.186000
|
-0.137000
|
0.090800
|
-2.20e-01
|
6.69e-02
|
2.28e-01
|
3.76e-01
|
5.56e-01
|
1.54e-01
|
6.65e-01
|
REGULATION OF TP53 ACTIVITY THROUGH ASSOCIATION WITH CO FACTORS
|
12
|
5.95e-01
|
6.66e-01
|
0.3380
|
0.113000
|
-0.241000
|
-0.071900
|
-1.55e-01
|
1.20e-01
|
4.99e-01
|
1.49e-01
|
6.66e-01
|
3.53e-01
|
4.73e-01
|
ACTIVATED NOTCH1 TRANSMITS SIGNAL TO THE NUCLEUS
|
32
|
9.40e-02
|
1.68e-01
|
0.3370
|
-0.167000
|
-0.105000
|
-0.029300
|
-2.05e-01
|
-1.78e-01
|
1.02e-01
|
3.03e-01
|
7.74e-01
|
4.49e-02
|
8.15e-02
|
FORMATION OF RNA POL II ELONGATION COMPLEX
|
57
|
2.27e-03
|
8.72e-03
|
0.3370
|
-0.082800
|
0.043600
|
0.165000
|
1.98e-01
|
-1.95e-01
|
2.80e-01
|
5.69e-01
|
3.12e-02
|
9.76e-03
|
1.08e-02
|
CLEC7A DECTIN 1 SIGNALING
|
93
|
5.02e-06
|
3.93e-05
|
0.3370
|
-0.188000
|
0.009090
|
-0.065800
|
2.71e-01
|
-2.16e-03
|
1.70e-03
|
8.80e-01
|
2.73e-01
|
6.44e-06
|
9.71e-01
|
MITOTIC G1 PHASE AND G1 S TRANSITION
|
139
|
5.59e-09
|
8.16e-08
|
0.3360
|
-0.202000
|
0.041000
|
-0.012500
|
2.65e-01
|
2.33e-03
|
3.91e-05
|
4.05e-01
|
7.99e-01
|
6.87e-08
|
9.62e-01
|
RNA POLYMERASE I TRANSCRIPTION
|
65
|
2.68e-03
|
1.00e-02
|
0.3360
|
-0.158000
|
0.074300
|
0.024000
|
2.30e-01
|
-1.70e-01
|
2.79e-02
|
3.00e-01
|
7.38e-01
|
1.33e-03
|
1.81e-02
|
CS DS DEGRADATION
|
14
|
2.56e-01
|
3.54e-01
|
0.3350
|
0.165000
|
0.132000
|
0.120000
|
-1.83e-01
|
-1.41e-01
|
2.85e-01
|
3.94e-01
|
4.38e-01
|
2.35e-01
|
3.60e-01
|
IRS MEDIATED SIGNALLING
|
35
|
5.75e-02
|
1.16e-01
|
0.3350
|
0.092000
|
-0.178000
|
-0.107000
|
-1.61e-01
|
1.87e-01
|
3.46e-01
|
6.90e-02
|
2.74e-01
|
9.97e-02
|
5.53e-02
|
SENESCENCE ASSOCIATED SECRETORY PHENOTYPE SASP
|
59
|
7.78e-03
|
2.38e-02
|
0.3350
|
-0.207000
|
0.106000
|
-0.084900
|
1.96e-01
|
-1.12e-01
|
5.98e-03
|
1.58e-01
|
2.60e-01
|
9.19e-03
|
1.38e-01
|
DISEASES ASSOCIATED WITH N GLYCOSYLATION OF PROTEINS
|
17
|
1.34e-01
|
2.19e-01
|
0.3350
|
-0.078000
|
-0.131000
|
0.147000
|
1.97e-01
|
1.69e-01
|
5.78e-01
|
3.49e-01
|
2.93e-01
|
1.61e-01
|
2.28e-01
|
NR1H2 AND NR1H3 MEDIATED SIGNALING
|
38
|
2.60e-02
|
6.15e-02
|
0.3340
|
0.175000
|
-0.024500
|
-0.099600
|
-2.55e-01
|
7.55e-02
|
6.22e-02
|
7.94e-01
|
2.88e-01
|
6.60e-03
|
4.21e-01
|
NOTCH4 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
|
20
|
1.71e-01
|
2.62e-01
|
0.3330
|
0.155000
|
0.119000
|
-0.082300
|
-2.31e-01
|
1.13e-01
|
2.30e-01
|
3.58e-01
|
5.24e-01
|
7.33e-02
|
3.82e-01
|
HOST INTERACTIONS OF HIV FACTORS
|
122
|
2.34e-08
|
3.03e-07
|
0.3330
|
-0.203000
|
-0.051200
|
0.032900
|
2.50e-01
|
-5.80e-02
|
1.10e-04
|
3.30e-01
|
5.30e-01
|
1.81e-06
|
2.69e-01
|
BIOLOGICAL OXIDATIONS
|
120
|
8.55e-06
|
6.44e-05
|
0.3330
|
-0.065800
|
0.227000
|
0.006760
|
2.29e-01
|
5.27e-02
|
2.14e-01
|
1.81e-05
|
8.98e-01
|
1.54e-05
|
3.19e-01
|
INSULIN RECEPTOR SIGNALLING CASCADE
|
40
|
4.19e-02
|
9.01e-02
|
0.3330
|
0.145000
|
-0.130000
|
-0.061300
|
-1.71e-01
|
1.99e-01
|
1.12e-01
|
1.55e-01
|
5.03e-01
|
6.09e-02
|
2.96e-02
|
L1CAM INTERACTIONS
|
107
|
2.50e-06
|
2.15e-05
|
0.3330
|
0.085800
|
-0.078000
|
0.176000
|
-2.26e-01
|
1.23e-01
|
1.25e-01
|
1.64e-01
|
1.62e-03
|
5.58e-05
|
2.84e-02
|
CELLULAR RESPONSE TO HEAT STRESS
|
94
|
7.43e-04
|
3.44e-03
|
0.3320
|
-0.145000
|
-0.204000
|
-0.075200
|
-1.86e-01
|
-8.87e-02
|
1.55e-02
|
6.37e-04
|
2.08e-01
|
1.89e-03
|
1.38e-01
|
GLUCAGON SIGNALING IN METABOLIC REGULATION
|
29
|
8.03e-02
|
1.49e-01
|
0.3320
|
-0.168000
|
-0.172000
|
0.063900
|
-2.03e-01
|
-8.56e-02
|
1.18e-01
|
1.10e-01
|
5.52e-01
|
5.82e-02
|
4.25e-01
|
REGULATION OF FOXO TRANSCRIPTIONAL ACTIVITY BY ACETYLATION
|
10
|
5.07e-01
|
5.94e-01
|
0.3320
|
0.054700
|
-0.241000
|
-0.142000
|
6.64e-03
|
1.70e-01
|
7.65e-01
|
1.87e-01
|
4.36e-01
|
9.71e-01
|
3.51e-01
|
RHOA GTPASE CYCLE
|
142
|
2.34e-07
|
2.54e-06
|
0.3320
|
0.075300
|
-0.109000
|
-0.069300
|
-2.47e-01
|
1.64e-01
|
1.22e-01
|
2.53e-02
|
1.55e-01
|
4.02e-07
|
7.55e-04
|
ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING
|
28
|
5.20e-02
|
1.07e-01
|
0.3320
|
-0.070600
|
-0.186000
|
0.176000
|
8.45e-02
|
-1.79e-01
|
5.18e-01
|
8.78e-02
|
1.07e-01
|
4.39e-01
|
1.01e-01
|
GLUCAGON TYPE LIGAND RECEPTORS
|
23
|
2.15e-01
|
3.10e-01
|
0.3320
|
-0.134000
|
-0.047700
|
0.051300
|
1.87e-01
|
-2.28e-01
|
2.65e-01
|
6.92e-01
|
6.71e-01
|
1.20e-01
|
5.84e-02
|
COBALAMIN CBL VITAMIN B12 TRANSPORT AND METABOLISM
|
13
|
2.55e-01
|
3.53e-01
|
0.3310
|
0.045000
|
-0.064700
|
-0.268000
|
1.75e-01
|
3.82e-02
|
7.79e-01
|
6.87e-01
|
9.46e-02
|
2.76e-01
|
8.11e-01
|
TRNA MODIFICATION IN THE NUCLEUS AND CYTOSOL
|
43
|
3.39e-02
|
7.62e-02
|
0.3310
|
0.108000
|
0.092200
|
0.143000
|
2.52e-01
|
-7.32e-02
|
2.20e-01
|
2.96e-01
|
1.05e-01
|
4.26e-03
|
4.07e-01
|
TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD3 SMAD4 HETEROTRIMER
|
43
|
3.93e-02
|
8.64e-02
|
0.3300
|
-0.068700
|
-0.156000
|
-0.022500
|
-2.79e-01
|
-3.89e-02
|
4.36e-01
|
7.60e-02
|
7.99e-01
|
1.55e-03
|
6.59e-01
|
TRANSMISSION ACROSS CHEMICAL SYNAPSES
|
235
|
6.80e-12
|
1.67e-10
|
0.3300
|
0.151000
|
-0.122000
|
0.138000
|
-1.76e-01
|
1.46e-01
|
6.89e-05
|
1.32e-03
|
2.79e-04
|
3.49e-06
|
1.17e-04
|
SIGNALING BY FLT3 ITD AND TKD MUTANTS
|
15
|
5.32e-01
|
6.14e-01
|
0.3300
|
0.108000
|
0.118000
|
0.011300
|
9.48e-02
|
2.72e-01
|
4.69e-01
|
4.27e-01
|
9.40e-01
|
5.25e-01
|
6.80e-02
|
TP53 REGULATES TRANSCRIPTION OF ADDITIONAL CELL CYCLE GENES WHOSE EXACT ROLE IN THE P53 PATHWAY REMAIN UNCERTAIN
|
20
|
4.14e-01
|
5.12e-01
|
0.3290
|
-0.062400
|
-0.233000
|
-0.003240
|
-2.18e-01
|
-5.09e-02
|
6.29e-01
|
7.13e-02
|
9.80e-01
|
9.12e-02
|
6.94e-01
|
CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE
|
19
|
2.79e-01
|
3.75e-01
|
0.3290
|
-0.142000
|
0.101000
|
0.083000
|
2.48e-01
|
9.91e-02
|
2.84e-01
|
4.46e-01
|
5.31e-01
|
6.17e-02
|
4.55e-01
|
CELL EXTRACELLULAR MATRIX INTERACTIONS
|
18
|
3.85e-01
|
4.82e-01
|
0.3290
|
-0.106000
|
0.000619
|
-0.293000
|
-1.04e-01
|
1.74e-02
|
4.38e-01
|
9.96e-01
|
3.15e-02
|
4.45e-01
|
8.98e-01
|
EXPORT OF VIRAL RIBONUCLEOPROTEINS FROM NUCLEUS
|
31
|
1.12e-01
|
1.93e-01
|
0.3280
|
0.065100
|
-0.234000
|
0.087000
|
-1.74e-01
|
1.01e-01
|
5.30e-01
|
2.39e-02
|
4.02e-01
|
9.34e-02
|
3.29e-01
|
REGULATION OF GENE EXPRESSION IN LATE STAGE BRANCHING MORPHOGENESIS PANCREATIC BUD PRECURSOR CELLS
|
13
|
4.39e-01
|
5.29e-01
|
0.3270
|
0.112000
|
0.041300
|
-0.159000
|
-2.56e-01
|
4.51e-02
|
4.83e-01
|
7.97e-01
|
3.20e-01
|
1.10e-01
|
7.78e-01
|
TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY DREAM COMPLEX
|
18
|
2.20e-01
|
3.14e-01
|
0.3270
|
-0.153000
|
0.053500
|
-0.152000
|
7.90e-02
|
2.27e-01
|
2.60e-01
|
6.94e-01
|
2.64e-01
|
5.62e-01
|
9.58e-02
|
DOWNSTREAM SIGNALING OF ACTIVATED FGFR2
|
21
|
2.83e-01
|
3.79e-01
|
0.3270
|
0.016800
|
-0.197000
|
-0.228000
|
-1.12e-01
|
5.88e-02
|
8.94e-01
|
1.17e-01
|
7.04e-02
|
3.76e-01
|
6.41e-01
|
INTERLEUKIN 1 SIGNALING
|
93
|
1.12e-05
|
8.10e-05
|
0.3270
|
-0.127000
|
0.018500
|
-0.017800
|
3.00e-01
|
-2.33e-02
|
3.50e-02
|
7.59e-01
|
7.67e-01
|
5.98e-07
|
6.98e-01
|
COLLAGEN BIOSYNTHESIS AND MODIFYING ENZYMES
|
58
|
2.18e-03
|
8.53e-03
|
0.3260
|
-0.113000
|
-0.067300
|
0.004040
|
-2.20e-01
|
-2.02e-01
|
1.38e-01
|
3.76e-01
|
9.58e-01
|
3.81e-03
|
7.68e-03
|
CELL JUNCTION ORGANIZATION
|
70
|
2.30e-04
|
1.21e-03
|
0.3260
|
-0.149000
|
-0.024500
|
-0.113000
|
-2.42e-01
|
1.10e-01
|
3.06e-02
|
7.23e-01
|
1.04e-01
|
4.77e-04
|
1.13e-01
|
TRANSCRIPTION OF THE HIV GENOME
|
67
|
2.07e-03
|
8.18e-03
|
0.3250
|
-0.149000
|
0.045200
|
0.068300
|
2.29e-01
|
-1.56e-01
|
3.51e-02
|
5.22e-01
|
3.34e-01
|
1.18e-03
|
2.68e-02
|
TRANSCRIPTIONAL REGULATION BY RUNX2
|
105
|
1.98e-05
|
1.33e-04
|
0.3250
|
-0.230000
|
-0.102000
|
-0.018800
|
1.36e-01
|
-1.54e-01
|
4.71e-05
|
6.98e-02
|
7.39e-01
|
1.64e-02
|
6.56e-03
|
AGGREPHAGY
|
34
|
6.54e-02
|
1.27e-01
|
0.3250
|
-0.084100
|
0.010700
|
0.119000
|
2.41e-01
|
-1.63e-01
|
3.96e-01
|
9.14e-01
|
2.31e-01
|
1.51e-02
|
1.01e-01
|
FORMATION OF THE BETA CATENIN TCF TRANSACTIVATING COMPLEX
|
44
|
4.73e-02
|
9.94e-02
|
0.3250
|
-0.158000
|
-0.036900
|
-0.130000
|
-1.83e-01
|
-1.70e-01
|
6.95e-02
|
6.72e-01
|
1.35e-01
|
3.62e-02
|
5.06e-02
|
NUCLEAR EVENTS KINASE AND TRANSCRIPTION FACTOR ACTIVATION
|
58
|
1.02e-02
|
2.99e-02
|
0.3250
|
0.131000
|
-0.172000
|
0.099500
|
-1.98e-01
|
9.74e-02
|
8.38e-02
|
2.33e-02
|
1.90e-01
|
9.06e-03
|
2.00e-01
|
SIGNALING BY NODAL
|
15
|
5.60e-01
|
6.38e-01
|
0.3240
|
0.191000
|
-0.117000
|
-0.012000
|
-1.82e-01
|
1.47e-01
|
2.00e-01
|
4.35e-01
|
9.36e-01
|
2.22e-01
|
3.23e-01
|
RHOC GTPASE CYCLE
|
73
|
8.33e-04
|
3.76e-03
|
0.3230
|
0.039900
|
-0.049700
|
-0.133000
|
-2.48e-01
|
1.46e-01
|
5.56e-01
|
4.63e-01
|
4.95e-02
|
2.54e-04
|
3.08e-02
|
REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEIN
|
29
|
1.66e-01
|
2.56e-01
|
0.3230
|
0.130000
|
-0.176000
|
0.134000
|
-1.37e-01
|
1.39e-01
|
2.25e-01
|
1.01e-01
|
2.11e-01
|
2.01e-01
|
1.94e-01
|
INTERLEUKIN 37 SIGNALING
|
17
|
2.98e-01
|
3.94e-01
|
0.3230
|
0.118000
|
-0.102000
|
-0.250000
|
-1.30e-01
|
8.81e-03
|
4.00e-01
|
4.65e-01
|
7.40e-02
|
3.53e-01
|
9.50e-01
|
RND2 GTPASE CYCLE
|
38
|
1.60e-02
|
4.24e-02
|
0.3230
|
0.051500
|
0.005430
|
-0.031600
|
-3.11e-01
|
-6.24e-02
|
5.83e-01
|
9.54e-01
|
7.36e-01
|
9.21e-04
|
5.06e-01
|
METAL ION SLC TRANSPORTERS
|
23
|
2.89e-01
|
3.84e-01
|
0.3230
|
0.251000
|
-0.020000
|
0.028300
|
-1.65e-01
|
1.12e-01
|
3.73e-02
|
8.68e-01
|
8.15e-01
|
1.71e-01
|
3.52e-01
|
ERCC6 CSB AND EHMT2 G9A POSITIVELY REGULATE RRNA EXPRESSION
|
30
|
2.20e-01
|
3.14e-01
|
0.3220
|
-0.181000
|
0.046900
|
-0.137000
|
1.48e-01
|
-1.68e-01
|
8.58e-02
|
6.56e-01
|
1.93e-01
|
1.62e-01
|
1.11e-01
|
SIGNALING BY VEGF
|
100
|
4.80e-05
|
2.99e-04
|
0.3220
|
0.001420
|
-0.173000
|
-0.032400
|
-2.06e-01
|
1.75e-01
|
9.80e-01
|
2.85e-03
|
5.76e-01
|
3.83e-04
|
2.52e-03
|
ACTIVATED NTRK2 SIGNALS THROUGH FRS2 AND FRS3
|
10
|
8.20e-01
|
8.54e-01
|
0.3220
|
-0.136000
|
-0.204000
|
-0.153000
|
-1.41e-01
|
1.60e-02
|
4.58e-01
|
2.64e-01
|
4.01e-01
|
4.39e-01
|
9.30e-01
|
NEUROTRANSMITTER RECEPTORS AND POSTSYNAPTIC SIGNAL TRANSMISSION
|
176
|
2.52e-09
|
3.92e-08
|
0.3220
|
0.083000
|
-0.155000
|
0.143000
|
-1.98e-01
|
1.15e-01
|
5.79e-02
|
3.89e-04
|
1.09e-03
|
6.20e-06
|
8.86e-03
|
SIGNALING BY NOTCH3
|
48
|
1.67e-02
|
4.36e-02
|
0.3210
|
-0.109000
|
-0.091300
|
0.002830
|
-1.80e-01
|
-2.25e-01
|
1.90e-01
|
2.74e-01
|
9.73e-01
|
3.11e-02
|
6.98e-03
|
G BETA GAMMA SIGNALLING THROUGH PI3KGAMMA
|
23
|
1.22e-01
|
2.05e-01
|
0.3210
|
-0.158000
|
-0.214000
|
-0.012900
|
1.66e-01
|
-6.70e-02
|
1.90e-01
|
7.50e-02
|
9.15e-01
|
1.68e-01
|
5.78e-01
|
SMOOTH MUSCLE CONTRACTION
|
32
|
2.12e-02
|
5.24e-02
|
0.3210
|
0.217000
|
0.175000
|
-0.068600
|
1.15e-01
|
-8.57e-02
|
3.34e-02
|
8.67e-02
|
5.02e-01
|
2.60e-01
|
4.01e-01
|
SHC1 EVENTS IN ERBB2 SIGNALING
|
20
|
4.25e-01
|
5.20e-01
|
0.3210
|
0.004470
|
-0.126000
|
-0.182000
|
-2.21e-01
|
7.13e-02
|
9.72e-01
|
3.30e-01
|
1.59e-01
|
8.76e-02
|
5.81e-01
|
METABOLISM OF FOLATE AND PTERINES
|
15
|
5.38e-01
|
6.19e-01
|
0.3200
|
-0.075100
|
0.094800
|
0.034500
|
2.94e-01
|
-1.49e-02
|
6.15e-01
|
5.25e-01
|
8.17e-01
|
4.86e-02
|
9.20e-01
|
RHO GTPASES ACTIVATE PKNS
|
45
|
5.36e-02
|
1.08e-01
|
0.3200
|
-0.175000
|
0.093700
|
-0.142000
|
1.70e-01
|
-1.18e-01
|
4.21e-02
|
2.77e-01
|
1.00e-01
|
4.79e-02
|
1.70e-01
|
RHOQ GTPASE CYCLE
|
57
|
2.01e-02
|
5.04e-02
|
0.3200
|
0.061400
|
-0.164000
|
-0.095000
|
-2.46e-01
|
4.45e-02
|
4.23e-01
|
3.20e-02
|
2.15e-01
|
1.33e-03
|
5.61e-01
|
SIGNALING BY NOTCH1
|
75
|
3.06e-03
|
1.11e-02
|
0.3190
|
-0.076400
|
-0.158000
|
-0.035200
|
-2.46e-01
|
-9.87e-02
|
2.53e-01
|
1.82e-02
|
5.98e-01
|
2.37e-04
|
1.40e-01
|
NF KB IS ACTIVATED AND SIGNALS SURVIVAL
|
12
|
6.60e-01
|
7.14e-01
|
0.3190
|
-0.070600
|
0.099500
|
-0.082100
|
2.12e-01
|
-1.88e-01
|
6.72e-01
|
5.50e-01
|
6.22e-01
|
2.04e-01
|
2.60e-01
|
REGULATION OF INSULIN LIKE GROWTH FACTOR IGF TRANSPORT AND UPTAKE BY INSULIN LIKE GROWTH FACTOR BINDING PROTEINS IGFBPS
|
85
|
1.21e-05
|
8.69e-05
|
0.3180
|
0.168000
|
0.234000
|
-0.109000
|
7.06e-02
|
4.12e-02
|
7.59e-03
|
1.98e-04
|
8.28e-02
|
2.61e-01
|
5.12e-01
|
FGFR1 MUTANT RECEPTOR ACTIVATION
|
25
|
2.84e-01
|
3.79e-01
|
0.3180
|
0.051600
|
-0.109000
|
-0.121000
|
-2.62e-01
|
5.57e-02
|
6.55e-01
|
3.47e-01
|
2.94e-01
|
2.33e-02
|
6.30e-01
|
PHASE 4 RESTING MEMBRANE POTENTIAL
|
13
|
3.28e-01
|
4.25e-01
|
0.3180
|
-0.092600
|
0.049100
|
0.195000
|
-1.17e-01
|
1.95e-01
|
5.63e-01
|
7.59e-01
|
2.23e-01
|
4.64e-01
|
2.24e-01
|
SIGNALING BY NTRK3 TRKC
|
16
|
5.17e-01
|
6.03e-01
|
0.3170
|
0.009240
|
-0.208000
|
0.064000
|
-2.03e-01
|
-1.10e-01
|
9.49e-01
|
1.50e-01
|
6.58e-01
|
1.60e-01
|
4.46e-01
|
SIGNALING BY FGFR2 IN DISEASE
|
34
|
7.29e-02
|
1.38e-01
|
0.3170
|
-0.124000
|
-0.110000
|
-0.051900
|
1.96e-01
|
-1.80e-01
|
2.12e-01
|
2.67e-01
|
6.00e-01
|
4.82e-02
|
7.00e-02
|
SEMAPHORIN INTERACTIONS
|
64
|
1.14e-02
|
3.23e-02
|
0.3170
|
-0.003280
|
-0.197000
|
-0.020200
|
-2.23e-01
|
-1.09e-01
|
9.64e-01
|
6.53e-03
|
7.80e-01
|
2.09e-03
|
1.32e-01
|
HYALURONAN METABOLISM
|
15
|
3.61e-01
|
4.58e-01
|
0.3170
|
0.178000
|
0.165000
|
0.099400
|
-1.77e-01
|
-5.83e-03
|
2.31e-01
|
2.68e-01
|
5.05e-01
|
2.36e-01
|
9.69e-01
|
SIGNAL REGULATORY PROTEIN FAMILY INTERACTIONS
|
11
|
6.11e-01
|
6.78e-01
|
0.3170
|
0.120000
|
-0.237000
|
0.058900
|
-6.90e-02
|
-1.47e-01
|
4.91e-01
|
1.74e-01
|
7.35e-01
|
6.92e-01
|
3.99e-01
|
INTERLEUKIN 17 SIGNALING
|
66
|
7.12e-03
|
2.22e-02
|
0.3170
|
0.167000
|
-0.128000
|
0.032600
|
-1.61e-01
|
1.70e-01
|
1.87e-02
|
7.30e-02
|
6.47e-01
|
2.41e-02
|
1.67e-02
|
TRANSLESION SYNTHESIS BY Y FAMILY DNA POLYMERASES BYPASSES LESIONS ON DNA TEMPLATE
|
38
|
8.72e-02
|
1.59e-01
|
0.3160
|
-0.115000
|
0.095700
|
0.066200
|
2.54e-01
|
-9.14e-02
|
2.18e-01
|
3.08e-01
|
4.80e-01
|
6.72e-03
|
3.30e-01
|
METABOLISM OF PORPHYRINS
|
19
|
4.48e-01
|
5.39e-01
|
0.3160
|
0.082800
|
0.047000
|
0.153000
|
2.10e-01
|
1.52e-01
|
5.32e-01
|
7.23e-01
|
2.47e-01
|
1.13e-01
|
2.52e-01
|
CHROMOSOME MAINTENANCE
|
97
|
9.24e-05
|
5.38e-04
|
0.3160
|
-0.078100
|
0.068200
|
-0.056400
|
2.52e-01
|
-1.49e-01
|
1.84e-01
|
2.46e-01
|
3.37e-01
|
1.82e-05
|
1.13e-02
|
ROLE OF PHOSPHOLIPIDS IN PHAGOCYTOSIS
|
22
|
3.65e-01
|
4.61e-01
|
0.3150
|
0.166000
|
-0.095900
|
-0.026900
|
-1.85e-01
|
1.67e-01
|
1.79e-01
|
4.36e-01
|
8.27e-01
|
1.33e-01
|
1.75e-01
|
GLYCOSAMINOGLYCAN METABOLISM
|
113
|
1.02e-05
|
7.55e-05
|
0.3140
|
0.107000
|
0.159000
|
0.176000
|
-1.06e-01
|
1.41e-01
|
5.01e-02
|
3.61e-03
|
1.25e-03
|
5.20e-02
|
9.51e-03
|
FORMATION OF SENESCENCE ASSOCIATED HETEROCHROMATIN FOCI SAHF
|
14
|
3.48e-01
|
4.45e-01
|
0.3140
|
0.200000
|
0.219000
|
-0.077400
|
-6.77e-02
|
-2.68e-05
|
1.94e-01
|
1.56e-01
|
6.16e-01
|
6.61e-01
|
1.00e+00
|
INTERLEUKIN 4 AND INTERLEUKIN 13 SIGNALING
|
75
|
2.46e-03
|
9.38e-03
|
0.3130
|
-0.092300
|
-0.086700
|
-0.273000
|
-8.25e-02
|
2.73e-02
|
1.67e-01
|
1.95e-01
|
4.47e-05
|
2.17e-01
|
6.83e-01
|
INTERFERON SIGNALING
|
163
|
3.65e-06
|
3.00e-05
|
0.3130
|
-0.065300
|
-0.211000
|
-0.153000
|
-8.33e-02
|
-1.36e-01
|
1.51e-01
|
3.46e-06
|
7.37e-04
|
6.68e-02
|
2.76e-03
|
NEGATIVE REGULATION OF THE PI3K AKT NETWORK
|
88
|
4.84e-04
|
2.38e-03
|
0.3120
|
0.107000
|
-0.131000
|
-0.064700
|
-1.71e-01
|
1.88e-01
|
8.20e-02
|
3.43e-02
|
2.94e-01
|
5.48e-03
|
2.30e-03
|
TP53 REGULATES TRANSCRIPTION OF CELL DEATH GENES
|
37
|
1.07e-01
|
1.87e-01
|
0.3120
|
0.069900
|
0.149000
|
0.005200
|
2.37e-01
|
1.18e-01
|
4.62e-01
|
1.16e-01
|
9.56e-01
|
1.27e-02
|
2.13e-01
|
ACTIVATION OF AMPK DOWNSTREAM OF NMDARS
|
20
|
1.87e-01
|
2.77e-01
|
0.3120
|
-0.051000
|
-0.066400
|
0.198000
|
1.96e-01
|
1.12e-01
|
6.93e-01
|
6.07e-01
|
1.25e-01
|
1.28e-01
|
3.87e-01
|
HS GAG DEGRADATION
|
20
|
4.38e-01
|
5.29e-01
|
0.3120
|
0.156000
|
0.104000
|
0.206000
|
-9.99e-02
|
9.70e-02
|
2.28e-01
|
4.19e-01
|
1.10e-01
|
4.39e-01
|
4.53e-01
|
RET SIGNALING
|
35
|
1.22e-01
|
2.05e-01
|
0.3120
|
0.102000
|
-0.117000
|
0.093300
|
-2.36e-01
|
9.17e-02
|
2.96e-01
|
2.29e-01
|
3.40e-01
|
1.57e-02
|
3.48e-01
|
SIALIC ACID METABOLISM
|
32
|
1.73e-01
|
2.63e-01
|
0.3110
|
0.096600
|
0.174000
|
0.037200
|
-1.79e-02
|
2.36e-01
|
3.45e-01
|
8.87e-02
|
7.16e-01
|
8.61e-01
|
2.10e-02
|
SIGNALING BY MODERATE KINASE ACTIVITY BRAF MUTANTS
|
41
|
3.45e-02
|
7.76e-02
|
0.3110
|
0.013400
|
-0.239000
|
0.082800
|
-1.32e-01
|
1.24e-01
|
8.82e-01
|
8.12e-03
|
3.59e-01
|
1.44e-01
|
1.71e-01
|
NONHOMOLOGOUS END JOINING NHEJ
|
41
|
1.68e-01
|
2.58e-01
|
0.3110
|
-0.147000
|
-0.082200
|
-0.201000
|
-7.96e-03
|
-1.67e-01
|
1.03e-01
|
3.62e-01
|
2.57e-02
|
9.30e-01
|
6.50e-02
|
REGULATED PROTEOLYSIS OF P75NTR
|
12
|
5.96e-01
|
6.66e-01
|
0.3100
|
-0.030900
|
-0.075100
|
-0.299000
|
-1.38e-02
|
1.48e-02
|
8.53e-01
|
6.53e-01
|
7.30e-02
|
9.34e-01
|
9.29e-01
|
ABC FAMILY PROTEINS MEDIATED TRANSPORT
|
92
|
2.60e-05
|
1.71e-04
|
0.3100
|
-0.190000
|
-0.012300
|
0.043600
|
2.39e-01
|
-2.33e-02
|
1.62e-03
|
8.39e-01
|
4.70e-01
|
7.49e-05
|
7.00e-01
|
A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED FOR GAG SYNTHESIS
|
26
|
2.71e-01
|
3.69e-01
|
0.3100
|
0.153000
|
0.192000
|
0.147000
|
-6.76e-02
|
9.64e-02
|
1.78e-01
|
8.98e-02
|
1.94e-01
|
5.51e-01
|
3.95e-01
|
LDL CLEARANCE
|
15
|
4.54e-01
|
5.42e-01
|
0.3100
|
-0.148000
|
-0.134000
|
-0.014500
|
-2.04e-01
|
1.20e-01
|
3.22e-01
|
3.68e-01
|
9.23e-01
|
1.72e-01
|
4.22e-01
|
SIGNALING BY NOTCH1 PEST DOMAIN MUTANTS IN CANCER
|
59
|
1.67e-02
|
4.36e-02
|
0.3090
|
-0.069600
|
-0.121000
|
-0.041300
|
-2.06e-01
|
-1.79e-01
|
3.56e-01
|
1.09e-01
|
5.84e-01
|
6.34e-03
|
1.75e-02
|
TP53 REGULATES TRANSCRIPTION OF CASPASE ACTIVATORS AND CASPASES
|
11
|
5.00e-01
|
5.88e-01
|
0.3090
|
0.175000
|
-0.169000
|
-0.183000
|
-4.35e-02
|
-2.68e-02
|
3.15e-01
|
3.33e-01
|
2.92e-01
|
8.03e-01
|
8.78e-01
|
CELLULAR RESPONSES TO EXTERNAL STIMULI
|
593
|
8.78e-29
|
5.32e-27
|
0.3080
|
-0.175000
|
-0.020600
|
-0.040500
|
2.05e-01
|
-1.42e-01
|
4.24e-13
|
3.93e-01
|
9.40e-02
|
1.98e-17
|
4.00e-09
|
SHC1 EVENTS IN ERBB4 SIGNALING
|
12
|
6.54e-01
|
7.10e-01
|
0.3080
|
-0.070800
|
-0.032200
|
-0.238000
|
-1.27e-01
|
1.27e-01
|
6.71e-01
|
8.47e-01
|
1.54e-01
|
4.48e-01
|
4.45e-01
|
REGULATION OF TP53 ACTIVITY THROUGH ACETYLATION
|
30
|
1.56e-01
|
2.45e-01
|
0.3080
|
0.185000
|
-0.158000
|
0.172000
|
-2.03e-02
|
7.39e-02
|
7.97e-02
|
1.34e-01
|
1.03e-01
|
8.48e-01
|
4.84e-01
|
IRE1ALPHA ACTIVATES CHAPERONES
|
49
|
2.72e-02
|
6.36e-02
|
0.3070
|
-0.062000
|
-0.269000
|
0.010700
|
-1.33e-01
|
2.68e-02
|
4.53e-01
|
1.15e-03
|
8.97e-01
|
1.07e-01
|
7.45e-01
|
POSTMITOTIC NUCLEAR PORE COMPLEX NPC REFORMATION
|
26
|
1.80e-01
|
2.71e-01
|
0.3070
|
0.028600
|
-0.198000
|
0.046000
|
-1.08e-01
|
2.01e-01
|
8.01e-01
|
8.00e-02
|
6.85e-01
|
3.40e-01
|
7.64e-02
|
SIGNALING BY TGFB FAMILY MEMBERS
|
97
|
1.10e-03
|
4.71e-03
|
0.3070
|
-0.143000
|
-0.134000
|
-0.105000
|
-2.11e-01
|
-2.09e-02
|
1.51e-02
|
2.24e-02
|
7.46e-02
|
3.36e-04
|
7.22e-01
|
APOPTOTIC EXECUTION PHASE
|
43
|
1.04e-02
|
3.05e-02
|
0.3070
|
-0.063100
|
0.114000
|
-0.128000
|
-1.76e-01
|
1.73e-01
|
4.74e-01
|
1.95e-01
|
1.47e-01
|
4.58e-02
|
4.99e-02
|
SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R
|
40
|
5.77e-02
|
1.16e-01
|
0.3070
|
0.130000
|
-0.119000
|
-0.139000
|
-1.60e-01
|
1.34e-01
|
1.56e-01
|
1.93e-01
|
1.29e-01
|
7.92e-02
|
1.41e-01
|
FRS MEDIATED FGFR2 SIGNALING
|
16
|
3.39e-01
|
4.35e-01
|
0.3070
|
0.041400
|
-0.139000
|
-0.228000
|
-6.86e-03
|
1.45e-01
|
7.75e-01
|
3.35e-01
|
1.15e-01
|
9.62e-01
|
3.14e-01
|
NEF MEDIATES DOWN MODULATION OF CELL SURFACE RECEPTORS BY RECRUITING THEM TO CLATHRIN ADAPTERS
|
18
|
2.31e-01
|
3.27e-01
|
0.3070
|
-0.129000
|
-0.172000
|
0.180000
|
1.02e-01
|
-6.93e-02
|
3.42e-01
|
2.06e-01
|
1.86e-01
|
4.54e-01
|
6.11e-01
|
NEGATIVE REGULATION OF FGFR1 SIGNALING
|
25
|
3.79e-01
|
4.76e-01
|
0.3060
|
0.182000
|
-0.030900
|
0.210000
|
5.11e-02
|
1.14e-01
|
1.16e-01
|
7.89e-01
|
6.90e-02
|
6.58e-01
|
3.22e-01
|
PEROXISOMAL PROTEIN IMPORT
|
58
|
5.42e-03
|
1.77e-02
|
0.3060
|
-0.047500
|
0.110000
|
-0.094800
|
2.53e-01
|
7.78e-02
|
5.31e-01
|
1.47e-01
|
2.12e-01
|
8.44e-04
|
3.05e-01
|
G ALPHA 12 13 SIGNALLING EVENTS
|
74
|
2.52e-03
|
9.59e-03
|
0.3060
|
0.062100
|
-0.131000
|
0.036700
|
-1.73e-01
|
2.02e-01
|
3.56e-01
|
5.10e-02
|
5.85e-01
|
9.91e-03
|
2.63e-03
|
N GLYCAN ANTENNAE ELONGATION
|
15
|
6.09e-01
|
6.77e-01
|
0.3050
|
-0.046100
|
-0.060700
|
-0.152000
|
-2.53e-01
|
1.60e-02
|
7.57e-01
|
6.84e-01
|
3.09e-01
|
8.93e-02
|
9.15e-01
|
DEREGULATED CDK5 TRIGGERS MULTIPLE NEURODEGENERATIVE PATHWAYS IN ALZHEIMER S DISEASE MODELS
|
19
|
5.46e-01
|
6.27e-01
|
0.3050
|
0.247000
|
0.063800
|
0.163000
|
-4.07e-03
|
3.77e-02
|
6.19e-02
|
6.30e-01
|
2.20e-01
|
9.75e-01
|
7.76e-01
|
OPIOID SIGNALLING
|
85
|
3.06e-04
|
1.57e-03
|
0.3050
|
0.037000
|
-0.157000
|
0.137000
|
-1.70e-01
|
1.38e-01
|
5.55e-01
|
1.25e-02
|
2.89e-02
|
6.72e-03
|
2.77e-02
|
VLDLR INTERNALISATION AND DEGRADATION
|
11
|
8.33e-01
|
8.63e-01
|
0.3040
|
0.143000
|
0.138000
|
0.170000
|
-2.62e-02
|
1.53e-01
|
4.12e-01
|
4.29e-01
|
3.30e-01
|
8.80e-01
|
3.79e-01
|
NUCLEAR ENVELOPE BREAKDOWN
|
48
|
6.18e-02
|
1.22e-01
|
0.3040
|
0.168000
|
-0.106000
|
0.152000
|
-9.15e-02
|
1.46e-01
|
4.43e-02
|
2.02e-01
|
6.88e-02
|
2.73e-01
|
8.03e-02
|
SIGNALING BY CSF3 G CSF
|
29
|
1.70e-01
|
2.60e-01
|
0.3030
|
-0.192000
|
-0.094000
|
-0.190000
|
9.79e-02
|
2.33e-02
|
7.35e-02
|
3.81e-01
|
7.62e-02
|
3.62e-01
|
8.28e-01
|
REGULATION OF FZD BY UBIQUITINATION
|
19
|
2.88e-01
|
3.83e-01
|
0.3030
|
-0.132000
|
0.096400
|
-0.172000
|
-1.42e-01
|
1.24e-01
|
3.18e-01
|
4.67e-01
|
1.95e-01
|
2.82e-01
|
3.50e-01
|
RECYCLING PATHWAY OF L1
|
40
|
8.78e-02
|
1.60e-01
|
0.3030
|
0.085500
|
0.030000
|
0.215000
|
-6.90e-02
|
1.80e-01
|
3.49e-01
|
7.43e-01
|
1.85e-02
|
4.51e-01
|
4.84e-02
|
ACTIVATION OF IRF3 IRF7 MEDIATED BY TBK1 IKK EPSILON
|
15
|
6.30e-01
|
6.94e-01
|
0.3020
|
-0.111000
|
-0.173000
|
-0.187000
|
4.84e-02
|
-1.07e-01
|
4.57e-01
|
2.45e-01
|
2.09e-01
|
7.45e-01
|
4.75e-01
|
PI3K AKT SIGNALING IN CANCER
|
83
|
1.25e-03
|
5.20e-03
|
0.3020
|
0.150000
|
-0.097600
|
-0.078700
|
-1.72e-01
|
1.53e-01
|
1.83e-02
|
1.25e-01
|
2.15e-01
|
6.89e-03
|
1.59e-02
|
VASOPRESSIN REGULATES RENAL WATER HOMEOSTASIS VIA AQUAPORINS
|
35
|
6.45e-02
|
1.27e-01
|
0.3020
|
-0.165000
|
-0.185000
|
0.070400
|
-1.54e-01
|
-2.97e-02
|
9.09e-02
|
5.84e-02
|
4.71e-01
|
1.15e-01
|
7.61e-01
|
NUCLEAR IMPORT OF REV PROTEIN
|
32
|
1.61e-01
|
2.50e-01
|
0.3010
|
0.117000
|
-0.189000
|
0.090500
|
-1.07e-01
|
1.47e-01
|
2.51e-01
|
6.41e-02
|
3.75e-01
|
2.95e-01
|
1.50e-01
|
P75NTR SIGNALS VIA NF KB
|
15
|
5.69e-01
|
6.45e-01
|
0.3010
|
-0.062300
|
0.027100
|
-0.129000
|
1.49e-01
|
-2.18e-01
|
6.76e-01
|
8.56e-01
|
3.88e-01
|
3.18e-01
|
1.44e-01
|
PROCESSING OF INTRONLESS PRE MRNAS
|
19
|
2.99e-01
|
3.95e-01
|
0.3010
|
0.018600
|
-0.132000
|
0.224000
|
-6.47e-02
|
-1.36e-01
|
8.88e-01
|
3.18e-01
|
9.15e-02
|
6.25e-01
|
3.03e-01
|
PRE NOTCH PROCESSING IN GOLGI
|
17
|
5.47e-01
|
6.28e-01
|
0.3010
|
0.081800
|
0.085500
|
0.041900
|
-5.33e-02
|
2.68e-01
|
5.59e-01
|
5.42e-01
|
7.65e-01
|
7.04e-01
|
5.55e-02
|
SUMOYLATION OF UBIQUITINYLATION PROTEINS
|
37
|
1.04e-01
|
1.82e-01
|
0.3000
|
0.079000
|
-0.189000
|
0.092200
|
-1.36e-01
|
1.46e-01
|
4.06e-01
|
4.66e-02
|
3.32e-01
|
1.53e-01
|
1.26e-01
|
PARASITE INFECTION
|
54
|
1.48e-02
|
3.96e-02
|
0.3000
|
0.042200
|
-0.141000
|
0.096900
|
-1.44e-01
|
1.96e-01
|
5.92e-01
|
7.40e-02
|
2.18e-01
|
6.67e-02
|
1.29e-02
|
NRIF SIGNALS CELL DEATH FROM THE NUCLEUS
|
16
|
5.96e-01
|
6.66e-01
|
0.3000
|
-0.143000
|
0.053000
|
-0.047300
|
2.33e-01
|
-1.01e-01
|
3.20e-01
|
7.14e-01
|
7.43e-01
|
1.07e-01
|
4.84e-01
|
SIGNALING BY ERBB4
|
56
|
6.65e-02
|
1.28e-01
|
0.3000
|
-0.150000
|
-0.045400
|
-0.208000
|
-1.15e-01
|
-9.45e-02
|
5.25e-02
|
5.57e-01
|
7.05e-03
|
1.38e-01
|
2.22e-01
|
BILE ACID AND BILE SALT METABOLISM
|
25
|
2.49e-01
|
3.47e-01
|
0.3000
|
0.120000
|
0.127000
|
-0.082700
|
-4.29e-02
|
2.25e-01
|
2.97e-01
|
2.71e-01
|
4.74e-01
|
7.11e-01
|
5.20e-02
|
ABERRANT REGULATION OF MITOTIC EXIT IN CANCER DUE TO RB1 DEFECTS
|
19
|
3.00e-01
|
3.95e-01
|
0.3000
|
-0.239000
|
0.131000
|
0.075200
|
9.76e-02
|
-2.17e-02
|
7.14e-02
|
3.25e-01
|
5.71e-01
|
4.62e-01
|
8.70e-01
|
SLC TRANSPORTER DISORDERS
|
64
|
1.49e-02
|
3.98e-02
|
0.3000
|
0.180000
|
-0.091500
|
0.038300
|
-9.39e-02
|
1.97e-01
|
1.30e-02
|
2.06e-01
|
5.96e-01
|
1.94e-01
|
6.46e-03
|
ARACHIDONIC ACID METABOLISM
|
37
|
6.75e-02
|
1.30e-01
|
0.2990
|
0.059400
|
0.140000
|
-0.087100
|
2.36e-01
|
5.53e-02
|
5.32e-01
|
1.40e-01
|
3.60e-01
|
1.31e-02
|
5.61e-01
|
POLYMERASE SWITCHING ON THE C STRAND OF THE TELOMERE
|
25
|
2.69e-01
|
3.68e-01
|
0.2990
|
0.047500
|
0.060100
|
0.079300
|
2.54e-01
|
-1.11e-01
|
6.81e-01
|
6.03e-01
|
4.93e-01
|
2.77e-02
|
3.36e-01
|
TCR SIGNALING
|
98
|
3.55e-04
|
1.80e-03
|
0.2980
|
-0.162000
|
0.009010
|
-0.053800
|
2.21e-01
|
-1.05e-01
|
5.52e-03
|
8.78e-01
|
3.58e-01
|
1.61e-04
|
7.33e-02
|
DNA DAMAGE TELOMERE STRESS INDUCED SENESCENCE
|
41
|
6.10e-02
|
1.21e-01
|
0.2980
|
-0.100000
|
0.157000
|
-0.201000
|
1.09e-01
|
-4.44e-02
|
2.66e-01
|
8.20e-02
|
2.60e-02
|
2.28e-01
|
6.23e-01
|
APOPTOTIC CLEAVAGE OF CELLULAR PROTEINS
|
32
|
6.04e-02
|
1.20e-01
|
0.2970
|
-0.097100
|
0.047300
|
-0.073200
|
-2.24e-01
|
1.45e-01
|
3.42e-01
|
6.43e-01
|
4.74e-01
|
2.81e-02
|
1.56e-01
|
CARDIAC CONDUCTION
|
102
|
1.48e-03
|
5.99e-03
|
0.2970
|
0.180000
|
-0.022800
|
0.125000
|
-1.26e-01
|
1.53e-01
|
1.69e-03
|
6.90e-01
|
2.90e-02
|
2.85e-02
|
7.46e-03
|
RHOD GTPASE CYCLE
|
49
|
1.77e-02
|
4.53e-02
|
0.2970
|
0.070800
|
-0.020400
|
0.061500
|
-2.77e-01
|
4.37e-02
|
3.91e-01
|
8.05e-01
|
4.57e-01
|
7.94e-04
|
5.97e-01
|
SIGNALING BY THE B CELL RECEPTOR BCR
|
103
|
1.08e-05
|
7.85e-05
|
0.2960
|
-0.190000
|
-0.088200
|
-0.026600
|
2.06e-01
|
-2.78e-02
|
8.89e-04
|
1.22e-01
|
6.41e-01
|
3.09e-04
|
6.27e-01
|
TRANSCRIPTIONAL REGULATION BY E2F6
|
34
|
2.64e-01
|
3.62e-01
|
0.2950
|
-0.128000
|
-0.219000
|
-0.079700
|
-1.27e-01
|
-2.33e-02
|
1.96e-01
|
2.75e-02
|
4.21e-01
|
2.01e-01
|
8.14e-01
|
TRANSPORT OF BILE SALTS AND ORGANIC ACIDS METAL IONS AND AMINE COMPOUNDS
|
58
|
5.66e-03
|
1.84e-02
|
0.2950
|
0.201000
|
0.135000
|
-0.046000
|
-1.22e-01
|
1.05e-01
|
8.00e-03
|
7.44e-02
|
5.45e-01
|
1.09e-01
|
1.66e-01
|
ESTROGEN DEPENDENT GENE EXPRESSION
|
99
|
5.85e-03
|
1.89e-02
|
0.2950
|
-0.156000
|
-0.079100
|
-0.140000
|
-1.02e-01
|
-1.62e-01
|
7.41e-03
|
1.74e-01
|
1.59e-02
|
7.90e-02
|
5.50e-03
|
SLC MEDIATED TRANSMEMBRANE TRANSPORT
|
172
|
8.51e-07
|
8.24e-06
|
0.2950
|
0.165000
|
0.042000
|
0.014300
|
-1.26e-01
|
2.05e-01
|
1.98e-04
|
3.43e-01
|
7.47e-01
|
4.53e-03
|
3.72e-06
|
FOXO MEDIATED TRANSCRIPTION OF CELL CYCLE GENES
|
15
|
5.55e-01
|
6.35e-01
|
0.2940
|
0.087400
|
-0.144000
|
-0.037300
|
-7.41e-02
|
2.26e-01
|
5.58e-01
|
3.33e-01
|
8.03e-01
|
6.19e-01
|
1.29e-01
|
FANCONI ANEMIA PATHWAY
|
36
|
1.84e-01
|
2.74e-01
|
0.2940
|
0.180000
|
0.157000
|
0.057400
|
1.59e-01
|
2.78e-02
|
6.18e-02
|
1.03e-01
|
5.51e-01
|
9.84e-02
|
7.73e-01
|
DOWNSTREAM SIGNALING OF ACTIVATED FGFR1
|
24
|
4.03e-01
|
5.01e-01
|
0.2940
|
0.046100
|
-0.201000
|
-0.140000
|
-1.52e-01
|
3.34e-02
|
6.96e-01
|
8.81e-02
|
2.35e-01
|
1.99e-01
|
7.77e-01
|
CYTOSOLIC SULFONATION OF SMALL MOLECULES
|
15
|
6.98e-01
|
7.47e-01
|
0.2930
|
0.004630
|
0.144000
|
0.204000
|
1.38e-01
|
6.62e-02
|
9.75e-01
|
3.35e-01
|
1.72e-01
|
3.53e-01
|
6.57e-01
|
DEFECTS IN VITAMIN AND COFACTOR METABOLISM
|
20
|
4.36e-01
|
5.28e-01
|
0.2920
|
0.030600
|
0.199000
|
-0.088100
|
1.41e-01
|
1.32e-01
|
8.13e-01
|
1.24e-01
|
4.95e-01
|
2.75e-01
|
3.08e-01
|
LISTERIA MONOCYTOGENES ENTRY INTO HOST CELLS
|
19
|
4.40e-01
|
5.29e-01
|
0.2920
|
-0.165000
|
-0.142000
|
0.040000
|
-1.65e-01
|
-9.68e-02
|
2.13e-01
|
2.83e-01
|
7.63e-01
|
2.14e-01
|
4.65e-01
|
SPHINGOLIPID METABOLISM
|
78
|
2.68e-04
|
1.40e-03
|
0.2920
|
-0.024200
|
-0.011300
|
-0.090500
|
-8.32e-03
|
2.77e-01
|
7.12e-01
|
8.63e-01
|
1.67e-01
|
8.99e-01
|
2.44e-05
|
PEXOPHAGY
|
11
|
8.29e-01
|
8.61e-01
|
0.2920
|
0.032800
|
0.158000
|
0.103000
|
2.08e-01
|
-7.48e-02
|
8.51e-01
|
3.63e-01
|
5.56e-01
|
2.33e-01
|
6.67e-01
|
RND1 GTPASE CYCLE
|
37
|
1.24e-01
|
2.07e-01
|
0.2920
|
0.042000
|
-0.050800
|
-0.127000
|
-2.52e-01
|
3.42e-02
|
6.58e-01
|
5.93e-01
|
1.80e-01
|
8.04e-03
|
7.19e-01
|
NOTCH2 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
|
23
|
2.85e-01
|
3.79e-01
|
0.2920
|
-0.144000
|
-0.005840
|
0.020700
|
-1.12e-01
|
-2.27e-01
|
2.31e-01
|
9.61e-01
|
8.63e-01
|
3.54e-01
|
6.00e-02
|
INFLAMMASOMES
|
19
|
4.51e-01
|
5.40e-01
|
0.2910
|
-0.062200
|
0.043200
|
-0.248000
|
-7.66e-02
|
-1.08e-01
|
6.39e-01
|
7.44e-01
|
6.17e-02
|
5.63e-01
|
4.15e-01
|
HIV INFECTION
|
218
|
1.24e-10
|
2.20e-09
|
0.2900
|
-0.161000
|
-0.003830
|
0.057800
|
2.23e-01
|
-7.34e-02
|
4.37e-05
|
9.22e-01
|
1.42e-01
|
1.49e-08
|
6.24e-02
|
CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE
|
72
|
9.02e-03
|
2.71e-02
|
0.2900
|
0.094500
|
-0.050400
|
0.043900
|
-1.72e-01
|
2.02e-01
|
1.66e-01
|
4.60e-01
|
5.20e-01
|
1.16e-02
|
3.05e-03
|
ONCOGENE INDUCED SENESCENCE
|
32
|
2.67e-01
|
3.65e-01
|
0.2890
|
-0.032900
|
-0.165000
|
-0.044800
|
-1.02e-01
|
-2.07e-01
|
7.48e-01
|
1.07e-01
|
6.61e-01
|
3.16e-01
|
4.24e-02
|
TP53 REGULATES TRANSCRIPTION OF SEVERAL ADDITIONAL CELL DEATH GENES WHOSE SPECIFIC ROLES IN P53 DEPENDENT APOPTOSIS REMAIN UNCERTAIN
|
12
|
7.95e-01
|
8.33e-01
|
0.2890
|
0.162000
|
0.081700
|
0.057400
|
1.53e-01
|
1.54e-01
|
3.31e-01
|
6.24e-01
|
7.31e-01
|
3.59e-01
|
3.55e-01
|
BUTYRATE RESPONSE FACTOR 1 BRF1 BINDS AND DESTABILIZES MRNA
|
16
|
4.21e-01
|
5.17e-01
|
0.2890
|
-0.154000
|
0.037200
|
0.171000
|
1.64e-01
|
4.51e-02
|
2.88e-01
|
7.97e-01
|
2.35e-01
|
2.56e-01
|
7.55e-01
|
SYNTHESIS OF BILE ACIDS AND BILE SALTS
|
22
|
4.79e-01
|
5.66e-01
|
0.2870
|
0.121000
|
0.097400
|
0.002570
|
-1.28e-02
|
2.41e-01
|
3.28e-01
|
4.29e-01
|
9.83e-01
|
9.17e-01
|
5.02e-02
|
DEPOLYMERISATION OF THE NUCLEAR LAMINA
|
13
|
8.13e-01
|
8.47e-01
|
0.2860
|
0.194000
|
-0.009890
|
0.133000
|
-9.06e-02
|
1.36e-01
|
2.26e-01
|
9.51e-01
|
4.08e-01
|
5.72e-01
|
3.97e-01
|
GLUTATHIONE SYNTHESIS AND RECYCLING
|
11
|
8.03e-01
|
8.39e-01
|
0.2860
|
-0.015800
|
0.146000
|
-0.011100
|
2.22e-01
|
1.04e-01
|
9.28e-01
|
4.01e-01
|
9.49e-01
|
2.02e-01
|
5.50e-01
|
COLLAGEN CHAIN TRIMERIZATION
|
36
|
6.04e-02
|
1.20e-01
|
0.2860
|
-0.000401
|
-0.031000
|
0.042100
|
-2.29e-01
|
-1.63e-01
|
9.97e-01
|
7.47e-01
|
6.62e-01
|
1.74e-02
|
8.98e-02
|
SMAD2 SMAD3 SMAD4 HETEROTRIMER REGULATES TRANSCRIPTION
|
31
|
3.53e-01
|
4.50e-01
|
0.2860
|
-0.141000
|
-0.108000
|
-0.062400
|
-1.50e-01
|
-1.54e-01
|
1.73e-01
|
2.96e-01
|
5.48e-01
|
1.49e-01
|
1.38e-01
|
RAC2 GTPASE CYCLE
|
86
|
8.88e-04
|
3.95e-03
|
0.2850
|
0.061800
|
0.016900
|
-0.087500
|
-2.00e-01
|
1.72e-01
|
3.22e-01
|
7.87e-01
|
1.61e-01
|
1.34e-03
|
5.81e-03
|
REGULATION OF LOCALIZATION OF FOXO TRANSCRIPTION FACTORS
|
12
|
6.47e-01
|
7.07e-01
|
0.2850
|
0.124000
|
-0.219000
|
0.033900
|
-1.99e-02
|
1.29e-01
|
4.58e-01
|
1.89e-01
|
8.39e-01
|
9.05e-01
|
4.39e-01
|
KERATAN SULFATE BIOSYNTHESIS
|
24
|
4.94e-01
|
5.81e-01
|
0.2850
|
0.056600
|
0.152000
|
0.071000
|
8.73e-02
|
2.06e-01
|
6.32e-01
|
1.97e-01
|
5.47e-01
|
4.59e-01
|
8.08e-02
|
BIOSYNTHESIS OF SPECIALIZED PRORESOLVING MEDIATORS SPMS
|
11
|
6.14e-01
|
6.80e-01
|
0.2850
|
0.054200
|
-0.000370
|
-0.063000
|
2.66e-01
|
-5.95e-02
|
7.56e-01
|
9.98e-01
|
7.18e-01
|
1.26e-01
|
7.32e-01
|
SPHINGOLIPID DE NOVO BIOSYNTHESIS
|
41
|
5.15e-02
|
1.06e-01
|
0.2850
|
-0.058300
|
-0.066700
|
-0.202000
|
-3.97e-02
|
1.75e-01
|
5.19e-01
|
4.60e-01
|
2.52e-02
|
6.60e-01
|
5.19e-02
|
CLASS B 2 SECRETIN FAMILY RECEPTORS
|
63
|
5.73e-03
|
1.85e-02
|
0.2840
|
-0.242000
|
0.107000
|
-0.004110
|
2.23e-02
|
-1.02e-01
|
9.07e-04
|
1.44e-01
|
9.55e-01
|
7.60e-01
|
1.63e-01
|
PHOSPHOLIPID METABOLISM
|
184
|
2.78e-07
|
3.00e-06
|
0.2840
|
0.132000
|
-0.107000
|
0.032900
|
-7.96e-02
|
2.10e-01
|
1.99e-03
|
1.21e-02
|
4.42e-01
|
6.30e-02
|
9.62e-07
|
GLUCOSE METABOLISM
|
79
|
2.23e-03
|
8.69e-03
|
0.2830
|
0.028200
|
0.008260
|
0.174000
|
4.29e-02
|
2.17e-01
|
6.65e-01
|
8.99e-01
|
7.45e-03
|
5.10e-01
|
8.37e-04
|
LAMININ INTERACTIONS
|
27
|
1.92e-01
|
2.82e-01
|
0.2830
|
0.088300
|
0.019200
|
-0.105000
|
-2.47e-01
|
-3.90e-03
|
4.27e-01
|
8.63e-01
|
3.44e-01
|
2.64e-02
|
9.72e-01
|
NR1H3 NR1H2 REGULATE GENE EXPRESSION LINKED TO CHOLESTEROL TRANSPORT AND EFFLUX
|
32
|
1.60e-01
|
2.50e-01
|
0.2830
|
0.182000
|
-0.052600
|
-0.071600
|
-1.97e-01
|
1.93e-02
|
7.55e-02
|
6.07e-01
|
4.84e-01
|
5.35e-02
|
8.50e-01
|
TP53 REGULATES METABOLIC GENES
|
85
|
8.50e-04
|
3.81e-03
|
0.2830
|
-0.171000
|
-0.022100
|
-0.033700
|
2.19e-01
|
-3.48e-02
|
6.50e-03
|
7.25e-01
|
5.91e-01
|
4.79e-04
|
5.79e-01
|
NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION
|
48
|
1.21e-01
|
2.05e-01
|
0.2830
|
-0.052300
|
-0.143000
|
-0.042100
|
-2.16e-01
|
-9.13e-02
|
5.31e-01
|
8.62e-02
|
6.14e-01
|
9.74e-03
|
2.74e-01
|
PROCESSING AND ACTIVATION OF SUMO
|
10
|
8.21e-01
|
8.54e-01
|
0.2830
|
-0.116000
|
0.097200
|
0.025600
|
2.35e-01
|
3.48e-02
|
5.26e-01
|
5.94e-01
|
8.89e-01
|
1.99e-01
|
8.49e-01
|
TRISTETRAPROLIN TTP ZFP36 BINDS AND DESTABILIZES MRNA
|
16
|
4.71e-01
|
5.58e-01
|
0.2820
|
-0.136000
|
0.017300
|
0.123000
|
2.05e-01
|
6.29e-02
|
3.47e-01
|
9.05e-01
|
3.94e-01
|
1.56e-01
|
6.63e-01
|
SIGNALING BY NTRKS
|
126
|
1.34e-04
|
7.50e-04
|
0.2820
|
0.096600
|
-0.131000
|
0.098300
|
-1.67e-01
|
1.25e-01
|
6.15e-02
|
1.13e-02
|
5.70e-02
|
1.26e-03
|
1.54e-02
|
CONSTITUTIVE SIGNALING BY ABERRANT PI3K IN CANCER
|
56
|
2.40e-02
|
5.79e-02
|
0.2820
|
0.118000
|
-0.037200
|
-0.128000
|
-1.81e-01
|
1.22e-01
|
1.27e-01
|
6.30e-01
|
9.68e-02
|
1.91e-02
|
1.15e-01
|
TOLL LIKE RECEPTOR 9 TLR9 CASCADE
|
89
|
3.38e-03
|
1.20e-02
|
0.2810
|
0.137000
|
-0.124000
|
-0.011400
|
-1.41e-01
|
1.59e-01
|
2.61e-02
|
4.38e-02
|
8.52e-01
|
2.18e-02
|
9.54e-03
|
POSITIVE EPIGENETIC REGULATION OF RRNA EXPRESSION
|
60
|
3.34e-02
|
7.56e-02
|
0.2810
|
-0.120000
|
-0.015800
|
-0.010100
|
1.53e-01
|
-2.02e-01
|
1.08e-01
|
8.32e-01
|
8.93e-01
|
4.09e-02
|
6.72e-03
|
FATTY ACYL COA BIOSYNTHESIS
|
32
|
1.42e-01
|
2.28e-01
|
0.2810
|
-0.011800
|
0.106000
|
-0.084600
|
1.52e-02
|
2.45e-01
|
9.08e-01
|
2.98e-01
|
4.08e-01
|
8.81e-01
|
1.65e-02
|
SEPARATION OF SISTER CHROMATIDS
|
165
|
3.73e-08
|
4.52e-07
|
0.2800
|
-0.191000
|
-0.024900
|
0.018200
|
2.03e-01
|
-1.13e-02
|
2.39e-05
|
5.82e-01
|
6.87e-01
|
7.34e-06
|
8.02e-01
|
SELECTIVE AUTOPHAGY
|
71
|
2.25e-03
|
8.69e-03
|
0.2790
|
-0.060200
|
-0.025500
|
0.086500
|
2.56e-01
|
-2.22e-02
|
3.81e-01
|
7.10e-01
|
2.08e-01
|
1.92e-04
|
7.46e-01
|
PROLACTIN RECEPTOR SIGNALING
|
11
|
6.53e-01
|
7.10e-01
|
0.2790
|
-0.030700
|
0.116000
|
-0.031900
|
-1.82e-01
|
1.71e-01
|
8.60e-01
|
5.06e-01
|
8.55e-01
|
2.96e-01
|
3.26e-01
|
INTRAFLAGELLAR TRANSPORT
|
49
|
2.49e-02
|
5.94e-02
|
0.2780
|
-0.127000
|
0.168000
|
0.152000
|
8.60e-02
|
-4.73e-02
|
1.23e-01
|
4.16e-02
|
6.49e-02
|
2.98e-01
|
5.67e-01
|
PI 3K CASCADE FGFR1
|
14
|
6.43e-01
|
7.03e-01
|
0.2780
|
0.199000
|
-0.102000
|
-0.059500
|
-7.65e-02
|
1.35e-01
|
1.98e-01
|
5.08e-01
|
7.00e-01
|
6.20e-01
|
3.83e-01
|
C TYPE LECTIN RECEPTORS CLRS
|
110
|
5.00e-05
|
3.08e-04
|
0.2780
|
-0.171000
|
-0.042200
|
-0.079900
|
1.99e-01
|
-3.39e-03
|
1.91e-03
|
4.44e-01
|
1.48e-01
|
3.08e-04
|
9.51e-01
|
O LINKED GLYCOSYLATION OF MUCINS
|
40
|
9.00e-02
|
1.63e-01
|
0.2780
|
0.025300
|
0.067800
|
0.047800
|
-1.10e-01
|
2.40e-01
|
7.82e-01
|
4.58e-01
|
6.01e-01
|
2.30e-01
|
8.65e-03
|
CD28 CO STIMULATION
|
30
|
2.09e-01
|
3.02e-01
|
0.2780
|
0.022200
|
-0.198000
|
0.004880
|
-9.27e-02
|
1.69e-01
|
8.33e-01
|
6.04e-02
|
9.63e-01
|
3.80e-01
|
1.08e-01
|
NEGATIVE REGULATION OF MAPK PATHWAY
|
41
|
2.01e-02
|
5.04e-02
|
0.2780
|
-0.048900
|
-0.199000
|
0.120000
|
1.08e-02
|
1.43e-01
|
5.88e-01
|
2.73e-02
|
1.82e-01
|
9.05e-01
|
1.14e-01
|
METABOLISM OF NITRIC OXIDE NOS3 ACTIVATION AND REGULATION
|
15
|
6.06e-01
|
6.74e-01
|
0.2770
|
-0.113000
|
0.078300
|
-0.224000
|
5.05e-02
|
7.28e-02
|
4.49e-01
|
6.00e-01
|
1.33e-01
|
7.35e-01
|
6.26e-01
|
PECAM1 INTERACTIONS
|
12
|
7.90e-01
|
8.30e-01
|
0.2770
|
0.109000
|
-0.084000
|
-0.027000
|
-2.37e-01
|
3.14e-02
|
5.13e-01
|
6.15e-01
|
8.71e-01
|
1.55e-01
|
8.50e-01
|
RIPK1 MEDIATED REGULATED NECROSIS
|
25
|
5.32e-01
|
6.14e-01
|
0.2770
|
-0.175000
|
-0.020900
|
-0.172000
|
7.58e-02
|
-1.02e-01
|
1.29e-01
|
8.57e-01
|
1.37e-01
|
5.12e-01
|
3.79e-01
|
SUMOYLATION OF CHROMATIN ORGANIZATION PROTEINS
|
55
|
4.47e-02
|
9.48e-02
|
0.2770
|
0.067700
|
-0.218000
|
0.075700
|
-1.34e-01
|
2.97e-02
|
3.86e-01
|
5.17e-03
|
3.32e-01
|
8.66e-02
|
7.03e-01
|
RHOJ GTPASE CYCLE
|
54
|
5.19e-02
|
1.07e-01
|
0.2760
|
0.112000
|
-0.060300
|
-0.076500
|
-2.15e-01
|
9.05e-02
|
1.56e-01
|
4.44e-01
|
3.31e-01
|
6.26e-03
|
2.50e-01
|
PLATELET AGGREGATION PLUG FORMATION
|
31
|
2.33e-01
|
3.29e-01
|
0.2760
|
0.005310
|
-0.059400
|
-0.021000
|
-1.96e-01
|
1.84e-01
|
9.59e-01
|
5.67e-01
|
8.40e-01
|
5.91e-02
|
7.67e-02
|
GAP JUNCTION TRAFFICKING AND REGULATION
|
32
|
2.79e-01
|
3.75e-01
|
0.2760
|
-0.084900
|
0.210000
|
0.054700
|
1.40e-01
|
4.65e-02
|
4.06e-01
|
4.00e-02
|
5.92e-01
|
1.71e-01
|
6.49e-01
|
SYNTHESIS OF PA
|
28
|
2.99e-01
|
3.95e-01
|
0.2760
|
-0.054900
|
-0.176000
|
-0.031300
|
-1.49e-01
|
1.36e-01
|
6.15e-01
|
1.07e-01
|
7.75e-01
|
1.71e-01
|
2.12e-01
|
MRNA DECAY BY 5 TO 3 EXORIBONUCLEASE
|
15
|
5.88e-01
|
6.61e-01
|
0.2750
|
0.119000
|
0.081800
|
0.047800
|
1.79e-01
|
-1.44e-01
|
4.25e-01
|
5.83e-01
|
7.49e-01
|
2.31e-01
|
3.34e-01
|
ER TO GOLGI ANTEROGRADE TRANSPORT
|
138
|
1.55e-05
|
1.09e-04
|
0.2750
|
0.024200
|
0.019500
|
0.165000
|
9.48e-02
|
1.96e-01
|
6.23e-01
|
6.93e-01
|
8.28e-04
|
5.48e-02
|
7.02e-05
|
SYNTHESIS OF GLYCOSYLPHOSPHATIDYLINOSITOL GPI
|
18
|
3.26e-01
|
4.24e-01
|
0.2750
|
0.109000
|
-0.208000
|
0.075000
|
1.03e-01
|
-6.63e-02
|
4.24e-01
|
1.27e-01
|
5.82e-01
|
4.50e-01
|
6.26e-01
|
FCGAMMA RECEPTOR FCGR DEPENDENT PHAGOCYTOSIS
|
81
|
6.95e-03
|
2.17e-02
|
0.2750
|
0.076800
|
-0.141000
|
0.067100
|
-1.41e-01
|
1.59e-01
|
2.33e-01
|
2.85e-02
|
2.96e-01
|
2.84e-02
|
1.33e-02
|
ACTIVATION OF THE PRE REPLICATIVE COMPLEX
|
28
|
2.75e-01
|
3.73e-01
|
0.2750
|
-0.009110
|
0.089700
|
-0.013700
|
1.97e-01
|
1.68e-01
|
9.33e-01
|
4.11e-01
|
9.00e-01
|
7.09e-02
|
1.24e-01
|
CARNITINE METABOLISM
|
14
|
6.58e-01
|
7.13e-01
|
0.2740
|
0.140000
|
0.114000
|
-0.093900
|
-4.03e-04
|
1.84e-01
|
3.64e-01
|
4.62e-01
|
5.43e-01
|
9.98e-01
|
2.33e-01
|
SIGNAL TRANSDUCTION BY L1
|
21
|
3.85e-01
|
4.82e-01
|
0.2740
|
0.011300
|
-0.093400
|
0.141000
|
-2.16e-01
|
8.32e-03
|
9.29e-01
|
4.59e-01
|
2.64e-01
|
8.71e-02
|
9.47e-01
|
INTERLEUKIN 15 SIGNALING
|
13
|
6.34e-01
|
6.95e-01
|
0.2740
|
0.059400
|
0.049500
|
-0.006000
|
-2.54e-01
|
6.83e-02
|
7.11e-01
|
7.57e-01
|
9.70e-01
|
1.13e-01
|
6.70e-01
|
CARBOXYTERMINAL POST TRANSLATIONAL MODIFICATIONS OF TUBULIN
|
34
|
2.37e-01
|
3.35e-01
|
0.2730
|
-0.045800
|
0.162000
|
0.110000
|
1.16e-01
|
1.44e-01
|
6.44e-01
|
1.03e-01
|
2.68e-01
|
2.41e-01
|
1.46e-01
|
TBC RABGAPS
|
41
|
7.75e-02
|
1.45e-01
|
0.2720
|
0.015000
|
-0.037100
|
0.161000
|
-1.76e-02
|
2.15e-01
|
8.68e-01
|
6.81e-01
|
7.47e-02
|
8.46e-01
|
1.71e-02
|
NUCLEAR RECEPTOR TRANSCRIPTION PATHWAY
|
40
|
1.78e-01
|
2.69e-01
|
0.2720
|
-0.000768
|
-0.100000
|
-0.032200
|
-2.41e-01
|
6.96e-02
|
9.93e-01
|
2.73e-01
|
7.25e-01
|
8.32e-03
|
4.47e-01
|
SUMOYLATION OF TRANSCRIPTION COFACTORS
|
42
|
1.32e-01
|
2.15e-01
|
0.2710
|
-0.029400
|
-0.144000
|
0.049900
|
-2.02e-01
|
-9.22e-02
|
7.41e-01
|
1.06e-01
|
5.76e-01
|
2.32e-02
|
3.02e-01
|
COLLAGEN DEGRADATION
|
47
|
8.34e-03
|
2.52e-02
|
0.2710
|
0.008080
|
0.099700
|
-0.015700
|
-2.02e-01
|
-1.50e-01
|
9.24e-01
|
2.37e-01
|
8.52e-01
|
1.67e-02
|
7.47e-02
|
TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY P107 RBL1 AND P130 RBL2 IN COMPLEX WITH HDAC1
|
15
|
5.59e-01
|
6.38e-01
|
0.2710
|
-0.174000
|
-0.023100
|
-0.129000
|
-8.99e-03
|
1.61e-01
|
2.43e-01
|
8.77e-01
|
3.86e-01
|
9.52e-01
|
2.80e-01
|
GRB2 EVENTS IN ERBB2 SIGNALING
|
14
|
7.63e-01
|
8.08e-01
|
0.2710
|
-0.091900
|
-0.039400
|
-0.200000
|
-1.47e-01
|
4.21e-02
|
5.52e-01
|
7.98e-01
|
1.95e-01
|
3.41e-01
|
7.85e-01
|
HDACS DEACETYLATE HISTONES
|
44
|
1.81e-01
|
2.72e-01
|
0.2710
|
-0.094500
|
-0.075600
|
-0.127000
|
5.73e-02
|
-1.99e-01
|
2.78e-01
|
3.86e-01
|
1.47e-01
|
5.11e-01
|
2.28e-02
|
TELOMERE C STRAND SYNTHESIS INITIATION
|
13
|
6.39e-01
|
7.00e-01
|
0.2700
|
0.138000
|
0.021200
|
0.028200
|
2.29e-01
|
-2.01e-02
|
3.90e-01
|
8.95e-01
|
8.60e-01
|
1.53e-01
|
9.00e-01
|
PURINE RIBONUCLEOSIDE MONOPHOSPHATE BIOSYNTHESIS
|
12
|
6.30e-01
|
6.94e-01
|
0.2690
|
-0.131000
|
0.027800
|
-0.015200
|
9.97e-02
|
2.11e-01
|
4.33e-01
|
8.68e-01
|
9.28e-01
|
5.50e-01
|
2.06e-01
|
INWARDLY RECTIFYING K CHANNELS
|
31
|
7.02e-02
|
1.34e-01
|
0.2690
|
-0.187000
|
-0.152000
|
0.104000
|
1.56e-03
|
6.00e-02
|
7.21e-02
|
1.43e-01
|
3.15e-01
|
9.88e-01
|
5.63e-01
|
SHC MEDIATED CASCADE FGFR1
|
14
|
5.24e-01
|
6.07e-01
|
0.2690
|
0.064800
|
-0.117000
|
-0.096100
|
5.95e-02
|
2.04e-01
|
6.75e-01
|
4.50e-01
|
5.34e-01
|
7.00e-01
|
1.86e-01
|
UPTAKE AND ACTIONS OF BACTERIAL TOXINS
|
27
|
2.52e-01
|
3.51e-01
|
0.2690
|
0.115000
|
-0.194000
|
-0.008460
|
-2.96e-02
|
1.42e-01
|
3.00e-01
|
8.09e-02
|
9.39e-01
|
7.90e-01
|
2.01e-01
|
NOD1 2 SIGNALING PATHWAY
|
34
|
5.31e-02
|
1.08e-01
|
0.2690
|
0.131000
|
-0.194000
|
-0.124000
|
2.68e-02
|
2.99e-02
|
1.86e-01
|
4.98e-02
|
2.09e-01
|
7.87e-01
|
7.63e-01
|
GAP JUNCTION DEGRADATION
|
11
|
6.67e-01
|
7.20e-01
|
0.2680
|
-0.053700
|
0.187000
|
0.081300
|
-8.17e-02
|
1.44e-01
|
7.58e-01
|
2.82e-01
|
6.41e-01
|
6.39e-01
|
4.08e-01
|
AUTOPHAGY
|
137
|
4.61e-06
|
3.69e-05
|
0.2680
|
-0.024200
|
-0.000777
|
0.112000
|
2.26e-01
|
8.78e-02
|
6.25e-01
|
9.87e-01
|
2.37e-02
|
4.94e-06
|
7.64e-02
|
RMTS METHYLATE HISTONE ARGININES
|
42
|
1.08e-01
|
1.88e-01
|
0.2680
|
-0.111000
|
-0.088400
|
-0.031200
|
1.75e-01
|
-1.42e-01
|
2.15e-01
|
3.22e-01
|
7.26e-01
|
4.95e-02
|
1.10e-01
|
CELL CELL COMMUNICATION
|
101
|
8.15e-04
|
3.71e-03
|
0.2680
|
-0.022100
|
-0.053800
|
-0.041500
|
-2.41e-01
|
9.22e-02
|
7.01e-01
|
3.51e-01
|
4.72e-01
|
2.84e-05
|
1.10e-01
|
PROCESSING OF DNA DOUBLE STRAND BREAK ENDS
|
67
|
7.00e-02
|
1.34e-01
|
0.2680
|
-0.168000
|
-0.049800
|
-0.116000
|
8.76e-02
|
-1.40e-01
|
1.73e-02
|
4.81e-01
|
9.98e-02
|
2.15e-01
|
4.74e-02
|
GPVI MEDIATED ACTIVATION CASCADE
|
31
|
1.61e-01
|
2.50e-01
|
0.2680
|
-0.060400
|
-0.030600
|
-0.139000
|
-1.84e-02
|
2.18e-01
|
5.61e-01
|
7.68e-01
|
1.81e-01
|
8.59e-01
|
3.58e-02
|
ACYL CHAIN REMODELLING OF PS
|
14
|
6.24e-01
|
6.90e-01
|
0.2670
|
0.059700
|
-0.027400
|
0.234000
|
-7.27e-02
|
-8.52e-02
|
6.99e-01
|
8.59e-01
|
1.30e-01
|
6.38e-01
|
5.81e-01
|
TRANSCRIPTIONAL REGULATION BY RUNX3
|
93
|
7.96e-03
|
2.43e-02
|
0.2670
|
-0.185000
|
0.023100
|
-0.059200
|
1.46e-01
|
-1.09e-01
|
2.10e-03
|
7.00e-01
|
3.24e-01
|
1.53e-02
|
7.03e-02
|
REGULATION OF IFNG SIGNALING
|
13
|
4.59e-01
|
5.46e-01
|
0.2670
|
0.100000
|
-0.086100
|
-0.167000
|
1.37e-01
|
8.36e-02
|
5.31e-01
|
5.91e-01
|
2.96e-01
|
3.94e-01
|
6.02e-01
|
COPI INDEPENDENT GOLGI TO ER RETROGRADE TRAFFIC
|
44
|
1.52e-02
|
4.05e-02
|
0.2670
|
-0.138000
|
-0.024300
|
0.109000
|
8.51e-02
|
1.80e-01
|
1.13e-01
|
7.80e-01
|
2.12e-01
|
3.29e-01
|
3.93e-02
|
PROCESSIVE SYNTHESIS ON THE LAGGING STRAND
|
15
|
5.90e-01
|
6.62e-01
|
0.2660
|
-0.064700
|
0.039400
|
-0.153000
|
1.97e-01
|
5.64e-02
|
6.64e-01
|
7.92e-01
|
3.05e-01
|
1.87e-01
|
7.05e-01
|
RHO GTPASES ACTIVATE CIT
|
18
|
3.79e-01
|
4.76e-01
|
0.2660
|
0.120000
|
0.054700
|
0.007380
|
1.57e-02
|
-2.30e-01
|
3.78e-01
|
6.88e-01
|
9.57e-01
|
9.08e-01
|
9.10e-02
|
HEDGEHOG OFF STATE
|
106
|
2.04e-04
|
1.10e-03
|
0.2660
|
-0.236000
|
-0.030800
|
0.025600
|
9.84e-02
|
-5.74e-02
|
2.62e-05
|
5.84e-01
|
6.49e-01
|
8.03e-02
|
3.08e-01
|
SIGNALING BY TGF BETA RECEPTOR COMPLEX
|
72
|
3.53e-02
|
7.88e-02
|
0.2650
|
-0.146000
|
-0.132000
|
-0.065700
|
-1.64e-01
|
-1.15e-02
|
3.19e-02
|
5.26e-02
|
3.36e-01
|
1.61e-02
|
8.67e-01
|
NGF STIMULATED TRANSCRIPTION
|
36
|
2.61e-01
|
3.59e-01
|
0.2650
|
0.092200
|
-0.138000
|
0.011300
|
-2.00e-01
|
-5.00e-02
|
3.38e-01
|
1.52e-01
|
9.07e-01
|
3.83e-02
|
6.04e-01
|
G PROTEIN BETA GAMMA SIGNALLING
|
30
|
1.29e-01
|
2.12e-01
|
0.2640
|
-0.130000
|
-0.163000
|
0.005310
|
1.62e-01
|
-9.60e-03
|
2.18e-01
|
1.22e-01
|
9.60e-01
|
1.24e-01
|
9.28e-01
|
RNA POLYMERASE I TRANSCRIPTION INITIATION
|
47
|
6.03e-02
|
1.20e-01
|
0.2640
|
-0.054800
|
-0.019900
|
0.167000
|
1.34e-01
|
-1.43e-01
|
5.16e-01
|
8.13e-01
|
4.72e-02
|
1.11e-01
|
9.06e-02
|
SENSORY PROCESSING OF SOUND BY OUTER HAIR CELLS OF THE COCHLEA
|
39
|
8.38e-02
|
1.55e-01
|
0.2640
|
0.097600
|
0.157000
|
-0.020700
|
-1.55e-01
|
1.06e-01
|
2.92e-01
|
9.06e-02
|
8.23e-01
|
9.40e-02
|
2.53e-01
|
TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM
|
79
|
2.88e-03
|
1.07e-02
|
0.2640
|
-0.097200
|
-0.115000
|
0.120000
|
3.65e-02
|
-1.77e-01
|
1.36e-01
|
7.86e-02
|
6.48e-02
|
5.76e-01
|
6.64e-03
|
SIGNALING BY SCF KIT
|
41
|
2.38e-01
|
3.35e-01
|
0.2630
|
0.003780
|
-0.177000
|
-0.101000
|
-1.45e-01
|
7.93e-02
|
9.67e-01
|
4.95e-02
|
2.65e-01
|
1.08e-01
|
3.80e-01
|
ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA
|
15
|
6.58e-01
|
7.13e-01
|
0.2620
|
-0.112000
|
0.048500
|
0.077700
|
2.11e-01
|
5.65e-02
|
4.51e-01
|
7.45e-01
|
6.02e-01
|
1.57e-01
|
7.05e-01
|
AQUAPORIN MEDIATED TRANSPORT
|
37
|
1.34e-01
|
2.18e-01
|
0.2610
|
-0.137000
|
-0.163000
|
0.062700
|
-1.37e-01
|
-3.93e-03
|
1.48e-01
|
8.60e-02
|
5.09e-01
|
1.48e-01
|
9.67e-01
|
DISEASES OF PROGRAMMED CELL DEATH
|
51
|
4.71e-02
|
9.94e-02
|
0.2610
|
-0.003050
|
0.101000
|
-0.124000
|
1.99e-01
|
-5.43e-02
|
9.70e-01
|
2.13e-01
|
1.25e-01
|
1.40e-02
|
5.02e-01
|
GROWTH HORMONE RECEPTOR SIGNALING
|
20
|
6.43e-01
|
7.03e-01
|
0.2600
|
0.086700
|
-0.121000
|
-0.039900
|
-2.09e-01
|
-1.30e-02
|
5.02e-01
|
3.49e-01
|
7.57e-01
|
1.05e-01
|
9.20e-01
|
SYNTHESIS OF SUBSTRATES IN N GLYCAN BIOSYTHESIS
|
62
|
6.51e-02
|
1.27e-01
|
0.2600
|
0.062800
|
0.029800
|
0.148000
|
1.25e-01
|
1.59e-01
|
3.92e-01
|
6.85e-01
|
4.46e-02
|
8.92e-02
|
3.06e-02
|
DOWNREGULATION OF ERBB2 SIGNALING
|
27
|
6.24e-01
|
6.90e-01
|
0.2600
|
-0.140000
|
-0.093300
|
-0.143000
|
9.83e-03
|
-1.36e-01
|
2.07e-01
|
4.01e-01
|
1.99e-01
|
9.30e-01
|
2.21e-01
|
RHO GTPASES ACTIVATE WASPS AND WAVES
|
36
|
2.00e-01
|
2.93e-01
|
0.2590
|
0.064400
|
-0.089300
|
0.200000
|
-2.91e-02
|
1.20e-01
|
5.04e-01
|
3.54e-01
|
3.81e-02
|
7.63e-01
|
2.14e-01
|
ELEVATION OF CYTOSOLIC CA2 LEVELS
|
14
|
7.83e-01
|
8.25e-01
|
0.2590
|
0.122000
|
0.127000
|
-0.023500
|
-1.55e-02
|
1.87e-01
|
4.29e-01
|
4.09e-01
|
8.79e-01
|
9.20e-01
|
2.25e-01
|
NEDDYLATION
|
214
|
2.77e-09
|
4.25e-08
|
0.2590
|
-0.080100
|
0.031600
|
0.101000
|
1.86e-01
|
1.21e-01
|
4.39e-02
|
4.26e-01
|
1.13e-02
|
2.73e-06
|
2.23e-03
|
TRANSCRIPTIONAL REGULATION BY VENTX
|
35
|
2.67e-01
|
3.65e-01
|
0.2580
|
-0.081800
|
-0.075000
|
-0.023500
|
-2.02e-01
|
-1.14e-01
|
4.02e-01
|
4.43e-01
|
8.10e-01
|
3.84e-02
|
2.45e-01
|
TRANSPORT OF MATURE MRNAS DERIVED FROM INTRONLESS TRANSCRIPTS
|
41
|
1.67e-01
|
2.57e-01
|
0.2580
|
0.089200
|
-0.125000
|
0.175000
|
-6.33e-02
|
9.32e-02
|
3.23e-01
|
1.67e-01
|
5.31e-02
|
4.83e-01
|
3.02e-01
|
MISMATCH REPAIR
|
14
|
7.01e-01
|
7.49e-01
|
0.2580
|
-0.208000
|
0.057100
|
-0.019100
|
1.37e-01
|
3.11e-02
|
1.78e-01
|
7.12e-01
|
9.01e-01
|
3.74e-01
|
8.40e-01
|
INTEGRATION OF ENERGY METABOLISM
|
96
|
3.25e-03
|
1.17e-02
|
0.2570
|
0.053000
|
-0.116000
|
0.125000
|
-1.60e-01
|
9.15e-02
|
3.70e-01
|
5.05e-02
|
3.44e-02
|
6.66e-03
|
1.22e-01
|
TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES
|
30
|
4.39e-01
|
5.29e-01
|
0.2570
|
0.065300
|
0.125000
|
0.010100
|
9.58e-02
|
1.91e-01
|
5.36e-01
|
2.35e-01
|
9.24e-01
|
3.64e-01
|
6.96e-02
|
G0 AND EARLY G1
|
24
|
3.51e-01
|
4.48e-01
|
0.2560
|
-0.122000
|
0.056000
|
-0.137000
|
3.90e-02
|
1.66e-01
|
3.03e-01
|
6.35e-01
|
2.45e-01
|
7.41e-01
|
1.60e-01
|
SENSORY PROCESSING OF SOUND
|
59
|
7.67e-02
|
1.44e-01
|
0.2560
|
0.142000
|
0.043400
|
0.116000
|
-1.45e-01
|
9.55e-02
|
5.99e-02
|
5.64e-01
|
1.24e-01
|
5.38e-02
|
2.05e-01
|
TNFR1 INDUCED PROAPOPTOTIC SIGNALING
|
12
|
8.47e-01
|
8.73e-01
|
0.2560
|
0.150000
|
-0.123000
|
-0.004520
|
-1.24e-01
|
1.11e-01
|
3.67e-01
|
4.59e-01
|
9.78e-01
|
4.58e-01
|
5.04e-01
|
CYCLIN D ASSOCIATED EVENTS IN G1
|
45
|
8.77e-02
|
1.60e-01
|
0.2560
|
-0.228000
|
0.078100
|
-0.055000
|
6.33e-02
|
2.63e-02
|
8.29e-03
|
3.65e-01
|
5.23e-01
|
4.63e-01
|
7.60e-01
|
CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM
|
48
|
1.16e-01
|
1.97e-01
|
0.2560
|
0.137000
|
0.140000
|
0.119000
|
-9.40e-02
|
6.14e-02
|
1.00e-01
|
9.26e-02
|
1.53e-01
|
2.60e-01
|
4.62e-01
|
RNA POLYMERASE III TRANSCRIPTION
|
41
|
1.18e-01
|
2.01e-01
|
0.2550
|
0.021000
|
-0.001380
|
0.066700
|
2.45e-01
|
-5.09e-03
|
8.16e-01
|
9.88e-01
|
4.60e-01
|
6.58e-03
|
9.55e-01
|
ADRENALINE NORADRENALINE INHIBITS INSULIN SECRETION
|
26
|
3.16e-01
|
4.12e-01
|
0.2540
|
-0.094800
|
-0.091000
|
0.120000
|
-9.35e-02
|
-1.55e-01
|
4.03e-01
|
4.22e-01
|
2.89e-01
|
4.09e-01
|
1.70e-01
|
ACYL CHAIN REMODELLING OF PG
|
10
|
7.46e-01
|
7.93e-01
|
0.2540
|
-0.100000
|
-0.117000
|
0.177000
|
-9.26e-02
|
-3.29e-02
|
5.84e-01
|
5.22e-01
|
3.34e-01
|
6.12e-01
|
8.57e-01
|
ROS AND RNS PRODUCTION IN PHAGOCYTES
|
29
|
2.64e-01
|
3.62e-01
|
0.2540
|
-0.042000
|
0.046000
|
-0.082700
|
2.16e-01
|
8.42e-02
|
6.95e-01
|
6.69e-01
|
4.41e-01
|
4.42e-02
|
4.33e-01
|
UNFOLDED PROTEIN RESPONSE UPR
|
84
|
4.42e-03
|
1.48e-02
|
0.2540
|
-0.120000
|
-0.222000
|
-0.011500
|
-2.39e-02
|
4.22e-03
|
5.78e-02
|
4.36e-04
|
8.56e-01
|
7.05e-01
|
9.47e-01
|
DOWNREGULATION OF ERBB2 ERBB3 SIGNALING
|
13
|
8.33e-01
|
8.63e-01
|
0.2540
|
-0.169000
|
-0.092000
|
-0.034900
|
9.77e-02
|
-1.28e-01
|
2.90e-01
|
5.66e-01
|
8.27e-01
|
5.42e-01
|
4.23e-01
|
HYALURONAN UPTAKE AND DEGRADATION
|
11
|
7.79e-01
|
8.22e-01
|
0.2540
|
0.136000
|
0.164000
|
0.051600
|
-1.23e-01
|
3.59e-02
|
4.35e-01
|
3.47e-01
|
7.67e-01
|
4.81e-01
|
8.37e-01
|
COPII MEDIATED VESICLE TRANSPORT
|
63
|
6.64e-02
|
1.28e-01
|
0.2530
|
0.075800
|
0.039700
|
0.063500
|
7.63e-02
|
2.17e-01
|
2.99e-01
|
5.86e-01
|
3.84e-01
|
2.95e-01
|
2.93e-03
|
ESR MEDIATED SIGNALING
|
160
|
2.07e-03
|
8.18e-03
|
0.2530
|
-0.150000
|
-0.113000
|
-0.108000
|
-9.31e-02
|
-9.29e-02
|
1.11e-03
|
1.37e-02
|
1.84e-02
|
4.23e-02
|
4.29e-02
|
PHASE I FUNCTIONALIZATION OF COMPOUNDS
|
57
|
1.28e-01
|
2.11e-01
|
0.2530
|
-0.011200
|
0.201000
|
0.011800
|
1.34e-01
|
7.30e-02
|
8.83e-01
|
8.67e-03
|
8.78e-01
|
7.94e-02
|
3.41e-01
|
TCF DEPENDENT SIGNALING IN RESPONSE TO WNT
|
173
|
4.58e-05
|
2.88e-04
|
0.2530
|
-0.227000
|
-0.039400
|
-0.092100
|
-2.64e-02
|
-4.23e-02
|
2.69e-07
|
3.72e-01
|
3.69e-02
|
5.50e-01
|
3.37e-01
|
CA2 PATHWAY
|
55
|
1.13e-01
|
1.94e-01
|
0.2530
|
0.006530
|
-0.083900
|
-0.051700
|
-2.29e-01
|
3.98e-02
|
9.33e-01
|
2.82e-01
|
5.07e-01
|
3.30e-03
|
6.10e-01
|
G2 M DNA DAMAGE CHECKPOINT
|
63
|
1.46e-01
|
2.32e-01
|
0.2530
|
-0.169000
|
-0.032600
|
-0.126000
|
6.24e-02
|
-1.20e-01
|
2.04e-02
|
6.55e-01
|
8.35e-02
|
3.92e-01
|
9.95e-02
|
INTERLEUKIN 1 FAMILY SIGNALING
|
118
|
1.15e-04
|
6.56e-04
|
0.2530
|
-0.082300
|
-0.003210
|
-0.053300
|
2.33e-01
|
3.08e-03
|
1.23e-01
|
9.52e-01
|
3.18e-01
|
1.28e-05
|
9.54e-01
|
E2F MEDIATED REGULATION OF DNA REPLICATION
|
19
|
5.04e-01
|
5.92e-01
|
0.2520
|
-0.196000
|
-0.026700
|
-0.097300
|
-1.20e-02
|
1.22e-01
|
1.39e-01
|
8.40e-01
|
4.63e-01
|
9.28e-01
|
3.59e-01
|
TRNA AMINOACYLATION
|
42
|
1.04e-01
|
1.82e-01
|
0.2520
|
-0.124000
|
0.063600
|
0.071600
|
1.65e-01
|
1.07e-01
|
1.63e-01
|
4.76e-01
|
4.22e-01
|
6.42e-02
|
2.30e-01
|
RNA POLYMERASE II TRANSCRIBES SNRNA GENES
|
74
|
1.25e-02
|
3.47e-02
|
0.2510
|
-0.070200
|
-0.159000
|
0.032700
|
7.40e-02
|
-1.63e-01
|
2.97e-01
|
1.84e-02
|
6.27e-01
|
2.72e-01
|
1.54e-02
|
ABERRANT REGULATION OF MITOTIC G1 S TRANSITION IN CANCER DUE TO RB1 DEFECTS
|
17
|
5.77e-01
|
6.52e-01
|
0.2510
|
-0.231000
|
0.019400
|
0.030000
|
-2.16e-02
|
-8.92e-02
|
9.89e-02
|
8.90e-01
|
8.30e-01
|
8.78e-01
|
5.24e-01
|
SIGNALING BY FGFR1
|
42
|
2.78e-01
|
3.75e-01
|
0.2510
|
-0.006710
|
-0.195000
|
-0.006330
|
-1.56e-01
|
2.80e-02
|
9.40e-01
|
2.91e-02
|
9.43e-01
|
8.05e-02
|
7.54e-01
|
COLLAGEN FORMATION
|
74
|
1.12e-02
|
3.21e-02
|
0.2510
|
-0.083100
|
-0.047500
|
0.012800
|
-1.82e-01
|
-1.43e-01
|
2.17e-01
|
4.80e-01
|
8.49e-01
|
6.89e-03
|
3.30e-02
|
INTEGRIN CELL SURFACE INTERACTIONS
|
66
|
1.08e-02
|
3.13e-02
|
0.2510
|
0.017900
|
0.033400
|
-0.141000
|
-1.57e-01
|
-1.30e-01
|
8.01e-01
|
6.39e-01
|
4.80e-02
|
2.72e-02
|
6.87e-02
|
FRS MEDIATED FGFR1 SIGNALING
|
16
|
5.78e-01
|
6.52e-01
|
0.2510
|
0.133000
|
-0.055400
|
-0.076500
|
5.21e-02
|
1.83e-01
|
3.57e-01
|
7.01e-01
|
5.96e-01
|
7.18e-01
|
2.05e-01
|
POST TRANSLATIONAL MODIFICATION SYNTHESIS OF GPI ANCHORED PROTEINS
|
56
|
6.06e-02
|
1.20e-01
|
0.2500
|
0.132000
|
0.060600
|
0.189000
|
-6.06e-02
|
-4.81e-02
|
8.74e-02
|
4.33e-01
|
1.46e-02
|
4.33e-01
|
5.33e-01
|
RHO GTPASE CYCLE
|
421
|
1.27e-12
|
3.32e-11
|
0.2500
|
0.029800
|
-0.083600
|
-0.046500
|
-2.22e-01
|
5.89e-02
|
2.97e-01
|
3.35e-03
|
1.03e-01
|
7.58e-15
|
3.90e-02
|
MEIOSIS
|
61
|
5.81e-02
|
1.16e-01
|
0.2490
|
-0.113000
|
0.173000
|
-0.087400
|
7.29e-02
|
-8.01e-02
|
1.27e-01
|
1.94e-02
|
2.38e-01
|
3.25e-01
|
2.79e-01
|
REGULATION OF TP53 ACTIVITY THROUGH METHYLATION
|
18
|
7.88e-01
|
8.29e-01
|
0.2490
|
-0.096800
|
-0.087800
|
-0.125000
|
2.48e-02
|
-1.70e-01
|
4.77e-01
|
5.19e-01
|
3.60e-01
|
8.56e-01
|
2.12e-01
|
EPHA MEDIATED GROWTH CONE COLLAPSE
|
27
|
2.71e-01
|
3.69e-01
|
0.2490
|
0.108000
|
-0.019700
|
-0.014800
|
-1.58e-01
|
-1.58e-01
|
3.33e-01
|
8.59e-01
|
8.94e-01
|
1.57e-01
|
1.56e-01
|
TRANSPORT OF THE SLBP DEPENDANT MATURE MRNA
|
34
|
2.81e-01
|
3.76e-01
|
0.2490
|
0.069100
|
-0.166000
|
0.123000
|
-7.35e-02
|
9.39e-02
|
4.86e-01
|
9.40e-02
|
2.13e-01
|
4.59e-01
|
3.44e-01
|
INTERACTIONS OF REV WITH HOST CELLULAR PROTEINS
|
35
|
3.08e-01
|
4.03e-01
|
0.2490
|
0.068300
|
-0.173000
|
0.067400
|
-1.05e-01
|
1.08e-01
|
4.84e-01
|
7.69e-02
|
4.91e-01
|
2.83e-01
|
2.69e-01
|
MITOTIC METAPHASE AND ANAPHASE
|
205
|
2.51e-08
|
3.21e-07
|
0.2470
|
-0.166000
|
-0.021200
|
0.045300
|
1.76e-01
|
5.00e-03
|
4.49e-05
|
6.01e-01
|
2.65e-01
|
1.46e-05
|
9.02e-01
|
CARGO CONCENTRATION IN THE ER
|
29
|
4.05e-01
|
5.02e-01
|
0.2470
|
0.029100
|
-0.037200
|
-0.064000
|
-1.34e-01
|
1.91e-01
|
7.86e-01
|
7.29e-01
|
5.51e-01
|
2.13e-01
|
7.45e-02
|
RHO GTPASES ACTIVATE PAKS
|
21
|
4.19e-01
|
5.16e-01
|
0.2440
|
0.132000
|
-0.018300
|
0.052900
|
-5.56e-02
|
-1.90e-01
|
2.94e-01
|
8.85e-01
|
6.75e-01
|
6.59e-01
|
1.33e-01
|
NUCLEOBASE BIOSYNTHESIS
|
15
|
6.20e-01
|
6.86e-01
|
0.2440
|
-0.175000
|
0.061900
|
-0.019200
|
6.72e-02
|
1.43e-01
|
2.41e-01
|
6.78e-01
|
8.98e-01
|
6.52e-01
|
3.39e-01
|
MYD88 INDEPENDENT TLR4 CASCADE
|
91
|
1.06e-02
|
3.10e-02
|
0.2440
|
0.086300
|
-0.130000
|
-0.070500
|
-1.08e-01
|
1.36e-01
|
1.55e-01
|
3.28e-02
|
2.46e-01
|
7.45e-02
|
2.52e-02
|
ECM PROTEOGLYCANS
|
62
|
2.79e-02
|
6.48e-02
|
0.2430
|
0.210000
|
0.046700
|
0.006660
|
-1.12e-01
|
4.25e-05
|
4.22e-03
|
5.25e-01
|
9.28e-01
|
1.27e-01
|
1.00e+00
|
MEIOTIC SYNAPSIS
|
38
|
3.11e-01
|
4.06e-01
|
0.2430
|
-0.092300
|
0.140000
|
-0.083100
|
9.24e-02
|
-1.24e-01
|
3.25e-01
|
1.36e-01
|
3.75e-01
|
3.24e-01
|
1.87e-01
|
DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TYPE
|
20
|
6.33e-01
|
6.95e-01
|
0.2430
|
0.096200
|
0.177000
|
0.096600
|
-6.20e-02
|
7.22e-02
|
4.56e-01
|
1.72e-01
|
4.54e-01
|
6.31e-01
|
5.76e-01
|
METABOLISM OF WATER SOLUBLE VITAMINS AND COFACTORS
|
100
|
1.88e-02
|
4.77e-02
|
0.2420
|
0.028300
|
0.134000
|
0.031500
|
1.39e-01
|
1.41e-01
|
6.25e-01
|
2.09e-02
|
5.86e-01
|
1.64e-02
|
1.51e-02
|
KERATAN SULFATE KERATIN METABOLISM
|
30
|
5.34e-01
|
6.15e-01
|
0.2420
|
0.021900
|
0.133000
|
0.086800
|
7.92e-02
|
1.64e-01
|
8.35e-01
|
2.07e-01
|
4.11e-01
|
4.53e-01
|
1.21e-01
|
SIGNALING BY INSULIN RECEPTOR
|
59
|
4.25e-02
|
9.09e-02
|
0.2420
|
0.067800
|
-0.112000
|
0.011800
|
-8.26e-03
|
2.04e-01
|
3.68e-01
|
1.39e-01
|
8.75e-01
|
9.13e-01
|
6.78e-03
|
DEFECTIVE EXT2 CAUSES EXOSTOSES 2
|
14
|
8.52e-01
|
8.77e-01
|
0.2420
|
0.082300
|
0.062500
|
0.174000
|
-3.88e-02
|
1.28e-01
|
5.94e-01
|
6.86e-01
|
2.61e-01
|
8.01e-01
|
4.06e-01
|
SUPPRESSION OF PHAGOSOMAL MATURATION
|
13
|
8.43e-01
|
8.71e-01
|
0.2420
|
-0.163000
|
-0.067900
|
-0.115000
|
1.11e-01
|
-4.29e-02
|
3.10e-01
|
6.72e-01
|
4.71e-01
|
4.87e-01
|
7.89e-01
|
TRANSCRIPTIONAL REGULATION BY RUNX1
|
174
|
4.39e-04
|
2.20e-03
|
0.2410
|
-0.143000
|
-0.103000
|
-0.037900
|
2.83e-02
|
-1.58e-01
|
1.13e-03
|
1.94e-02
|
3.89e-01
|
5.20e-01
|
3.34e-04
|
RHOG GTPASE CYCLE
|
73
|
2.21e-02
|
5.42e-02
|
0.2410
|
0.034000
|
0.017500
|
-0.097300
|
-1.00e-01
|
1.93e-01
|
6.16e-01
|
7.97e-01
|
1.51e-01
|
1.39e-01
|
4.40e-03
|
SIGNALING BY HEDGEHOG
|
141
|
1.54e-04
|
8.51e-04
|
0.2410
|
-0.221000
|
-0.082400
|
-0.010800
|
-1.72e-02
|
-4.70e-02
|
6.22e-06
|
9.14e-02
|
8.24e-01
|
7.24e-01
|
3.36e-01
|
TRNA PROCESSING
|
105
|
2.30e-03
|
8.80e-03
|
0.2400
|
0.028300
|
-0.018800
|
0.150000
|
1.82e-01
|
-2.07e-02
|
6.17e-01
|
7.40e-01
|
7.78e-03
|
1.26e-03
|
7.14e-01
|
G ALPHA Z SIGNALLING EVENTS
|
44
|
2.06e-01
|
3.01e-01
|
0.2390
|
-0.054900
|
-0.155000
|
0.062700
|
-1.56e-01
|
-4.34e-02
|
5.29e-01
|
7.47e-02
|
4.72e-01
|
7.32e-02
|
6.18e-01
|
TP53 REGULATES TRANSCRIPTION OF DNA REPAIR GENES
|
61
|
6.74e-02
|
1.30e-01
|
0.2380
|
-0.064600
|
0.002010
|
0.108000
|
1.37e-01
|
-1.50e-01
|
3.83e-01
|
9.78e-01
|
1.46e-01
|
6.52e-02
|
4.31e-02
|
REGULATION OF TP53 EXPRESSION AND DEGRADATION
|
33
|
1.73e-01
|
2.63e-01
|
0.2380
|
0.059800
|
-0.175000
|
-0.074500
|
2.39e-02
|
1.28e-01
|
5.53e-01
|
8.13e-02
|
4.59e-01
|
8.12e-01
|
2.03e-01
|
SIGNALING BY ERBB2
|
47
|
3.82e-01
|
4.79e-01
|
0.2370
|
-0.105000
|
-0.167000
|
-0.095700
|
-7.80e-02
|
-4.61e-02
|
2.13e-01
|
4.73e-02
|
2.56e-01
|
3.55e-01
|
5.84e-01
|
GLYCOLYSIS
|
65
|
5.24e-02
|
1.07e-01
|
0.2370
|
0.047200
|
-0.058200
|
0.158000
|
-2.17e-02
|
1.59e-01
|
5.11e-01
|
4.17e-01
|
2.79e-02
|
7.63e-01
|
2.64e-02
|
SIGNALING BY EGFR
|
46
|
3.29e-01
|
4.27e-01
|
0.2360
|
-0.105000
|
-0.118000
|
-0.050700
|
-1.63e-01
|
-4.31e-02
|
2.19e-01
|
1.67e-01
|
5.52e-01
|
5.60e-02
|
6.13e-01
|
REGULATION OF BETA CELL DEVELOPMENT
|
24
|
6.26e-01
|
6.91e-01
|
0.2360
|
0.088600
|
-0.058700
|
-0.033500
|
-1.99e-01
|
6.15e-02
|
4.53e-01
|
6.19e-01
|
7.76e-01
|
9.14e-02
|
6.02e-01
|
EGR2 AND SOX10 MEDIATED INITIATION OF SCHWANN CELL MYELINATION
|
26
|
4.59e-01
|
5.47e-01
|
0.2360
|
0.008660
|
-0.014500
|
-0.037100
|
-2.32e-01
|
-8.59e-03
|
9.39e-01
|
8.98e-01
|
7.44e-01
|
4.05e-02
|
9.40e-01
|
KILLING MECHANISMS
|
10
|
8.81e-01
|
9.01e-01
|
0.2360
|
-0.009600
|
-0.087600
|
0.077400
|
-2.04e-01
|
4.81e-03
|
9.58e-01
|
6.32e-01
|
6.72e-01
|
2.63e-01
|
9.79e-01
|
TRAF6 MEDIATED IRF7 ACTIVATION IN TLR7 8 OR 9 SIGNALING
|
13
|
8.40e-01
|
8.68e-01
|
0.2350
|
-0.062500
|
0.003410
|
-0.131000
|
1.34e-01
|
-1.28e-01
|
6.97e-01
|
9.83e-01
|
4.15e-01
|
4.03e-01
|
4.24e-01
|
CELL CYCLE CHECKPOINTS
|
235
|
9.81e-08
|
1.15e-06
|
0.2350
|
-0.165000
|
-0.034600
|
-0.025800
|
1.61e-01
|
-1.73e-02
|
1.42e-05
|
3.62e-01
|
4.97e-01
|
2.20e-05
|
6.49e-01
|
REPRODUCTION
|
70
|
8.48e-02
|
1.56e-01
|
0.2350
|
-0.145000
|
0.110000
|
-0.094000
|
6.37e-02
|
-9.49e-02
|
3.56e-02
|
1.12e-01
|
1.74e-01
|
3.57e-01
|
1.70e-01
|
CASPASE ACTIVATION VIA EXTRINSIC APOPTOTIC SIGNALLING PATHWAY
|
22
|
4.60e-01
|
5.47e-01
|
0.2340
|
0.081400
|
-0.021900
|
-0.205000
|
-5.70e-02
|
5.11e-02
|
5.09e-01
|
8.59e-01
|
9.64e-02
|
6.44e-01
|
6.78e-01
|
MITOCHONDRIAL BIOGENESIS
|
92
|
3.04e-04
|
1.56e-03
|
0.2340
|
0.024700
|
-0.168000
|
0.035000
|
1.54e-01
|
-2.98e-02
|
6.83e-01
|
5.25e-03
|
5.62e-01
|
1.08e-02
|
6.21e-01
|
REGULATION OF INSULIN SECRETION
|
70
|
3.37e-02
|
7.60e-02
|
0.2340
|
0.025500
|
-0.101000
|
0.137000
|
-1.57e-01
|
2.07e-02
|
7.12e-01
|
1.43e-01
|
4.77e-02
|
2.32e-02
|
7.64e-01
|
METABOLISM OF CARBOHYDRATES
|
255
|
1.13e-06
|
1.05e-05
|
0.2340
|
0.032000
|
0.105000
|
0.115000
|
-7.27e-04
|
1.71e-01
|
3.80e-01
|
4.07e-03
|
1.56e-03
|
9.84e-01
|
2.60e-06
|
REGULATION OF KIT SIGNALING
|
16
|
8.09e-01
|
8.44e-01
|
0.2330
|
-0.054200
|
-0.175000
|
-0.027500
|
-1.26e-01
|
6.57e-02
|
7.07e-01
|
2.26e-01
|
8.49e-01
|
3.83e-01
|
6.49e-01
|
RHO GTPASES ACTIVATE ROCKS
|
19
|
5.07e-01
|
5.94e-01
|
0.2330
|
0.105000
|
0.032000
|
-0.007100
|
4.67e-02
|
-2.00e-01
|
4.27e-01
|
8.09e-01
|
9.57e-01
|
7.24e-01
|
1.31e-01
|
SIGNALING BY NOTCH
|
186
|
4.02e-04
|
2.02e-03
|
0.2320
|
-0.171000
|
-0.083500
|
-0.039400
|
3.48e-02
|
-1.22e-01
|
6.01e-05
|
4.98e-02
|
3.54e-01
|
4.14e-01
|
4.11e-03
|
PROGRAMMED CELL DEATH
|
182
|
2.49e-05
|
1.65e-04
|
0.2320
|
-0.131000
|
0.020600
|
-0.014500
|
1.89e-01
|
-1.04e-02
|
2.28e-03
|
6.33e-01
|
7.37e-01
|
1.14e-05
|
8.09e-01
|
INLB MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CELL
|
15
|
8.31e-01
|
8.62e-01
|
0.2310
|
-0.121000
|
-0.074900
|
0.026800
|
-1.72e-02
|
-1.79e-01
|
4.15e-01
|
6.15e-01
|
8.58e-01
|
9.08e-01
|
2.29e-01
|
DNA DAMAGE BYPASS
|
46
|
2.57e-01
|
3.54e-01
|
0.2310
|
-0.067700
|
0.066100
|
0.084600
|
1.93e-01
|
-1.02e-02
|
4.27e-01
|
4.38e-01
|
3.21e-01
|
2.38e-02
|
9.05e-01
|
INFECTIOUS DISEASE
|
711
|
1.29e-18
|
6.17e-17
|
0.2310
|
-0.153000
|
-0.035000
|
-0.016500
|
1.24e-01
|
-1.14e-01
|
5.29e-12
|
1.14e-01
|
4.55e-01
|
1.95e-08
|
2.93e-07
|
NON INTEGRIN MEMBRANE ECM INTERACTIONS
|
55
|
7.16e-02
|
1.36e-01
|
0.2300
|
0.119000
|
-0.005590
|
-0.046400
|
-1.87e-01
|
-4.22e-02
|
1.28e-01
|
9.43e-01
|
5.52e-01
|
1.68e-02
|
5.88e-01
|
PYRIMIDINE SALVAGE
|
10
|
8.70e-01
|
8.91e-01
|
0.2300
|
-0.127000
|
0.078400
|
0.087200
|
1.25e-01
|
8.43e-02
|
4.86e-01
|
6.68e-01
|
6.33e-01
|
4.93e-01
|
6.44e-01
|
RAB GEFS EXCHANGE GTP FOR GDP ON RABS
|
86
|
7.31e-03
|
2.26e-02
|
0.2290
|
-0.033200
|
-0.040100
|
0.005270
|
-7.61e-02
|
2.10e-01
|
5.95e-01
|
5.20e-01
|
9.33e-01
|
2.23e-01
|
7.65e-04
|
RAC3 GTPASE CYCLE
|
88
|
1.74e-02
|
4.48e-02
|
0.2290
|
0.060600
|
0.027900
|
0.002210
|
-1.72e-01
|
1.36e-01
|
3.26e-01
|
6.51e-01
|
9.71e-01
|
5.28e-03
|
2.74e-02
|
BIOSYNTHESIS OF THE N GLYCAN PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND TRANSFER TO A NASCENT PROTEIN
|
76
|
4.40e-02
|
9.34e-02
|
0.2290
|
0.038600
|
0.005120
|
0.114000
|
1.33e-01
|
1.41e-01
|
5.61e-01
|
9.39e-01
|
8.46e-02
|
4.46e-02
|
3.39e-02
|
SUMOYLATION OF SUMOYLATION PROTEINS
|
33
|
4.30e-01
|
5.24e-01
|
0.2280
|
0.055200
|
-0.151000
|
0.094900
|
-9.69e-02
|
8.95e-02
|
5.83e-01
|
1.35e-01
|
3.45e-01
|
3.35e-01
|
3.74e-01
|
CARGO TRAFFICKING TO THE PERICILIARY MEMBRANE
|
49
|
4.00e-01
|
4.99e-01
|
0.2280
|
-0.137000
|
-0.140000
|
-0.075600
|
-6.09e-02
|
-6.57e-02
|
9.73e-02
|
9.05e-02
|
3.60e-01
|
4.61e-01
|
4.26e-01
|
SUMOYLATION OF RNA BINDING PROTEINS
|
45
|
2.43e-01
|
3.41e-01
|
0.2280
|
0.038300
|
-0.168000
|
0.098800
|
-1.08e-01
|
2.52e-02
|
6.57e-01
|
5.08e-02
|
2.52e-01
|
2.12e-01
|
7.70e-01
|
NUCLEAR SIGNALING BY ERBB4
|
30
|
3.91e-01
|
4.88e-01
|
0.2270
|
-0.085900
|
0.133000
|
-0.120000
|
-3.16e-02
|
-1.07e-01
|
4.16e-01
|
2.08e-01
|
2.57e-01
|
7.65e-01
|
3.11e-01
|
RUNX1 REGULATES GENES INVOLVED IN MEGAKARYOCYTE DIFFERENTIATION AND PLATELET FUNCTION
|
48
|
2.73e-01
|
3.71e-01
|
0.2270
|
-0.012100
|
-0.079800
|
-0.095500
|
-8.70e-02
|
-1.69e-01
|
8.85e-01
|
3.39e-01
|
2.53e-01
|
2.97e-01
|
4.34e-02
|
DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN METABOLISM
|
39
|
5.19e-01
|
6.03e-01
|
0.2270
|
0.110000
|
0.162000
|
0.055700
|
5.34e-02
|
8.51e-02
|
2.33e-01
|
8.03e-02
|
5.47e-01
|
5.64e-01
|
3.58e-01
|
PTEN REGULATION
|
132
|
8.06e-04
|
3.68e-03
|
0.2260
|
-0.140000
|
-0.109000
|
0.033400
|
9.04e-02
|
-1.01e-01
|
5.61e-03
|
3.03e-02
|
5.08e-01
|
7.31e-02
|
4.43e-02
|
DEADENYLATION OF MRNA
|
25
|
5.44e-01
|
6.25e-01
|
0.2260
|
0.054500
|
-0.108000
|
0.176000
|
-7.34e-02
|
2.39e-03
|
6.37e-01
|
3.48e-01
|
1.28e-01
|
5.26e-01
|
9.83e-01
|
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G2 CELL CYCLE ARREST
|
15
|
6.28e-01
|
6.93e-01
|
0.2250
|
-0.134000
|
-0.042600
|
0.027800
|
2.76e-02
|
1.72e-01
|
3.69e-01
|
7.75e-01
|
8.52e-01
|
8.53e-01
|
2.50e-01
|
G1 S SPECIFIC TRANSCRIPTION
|
25
|
4.54e-01
|
5.42e-01
|
0.2250
|
-0.045100
|
0.016000
|
-0.014600
|
1.02e-01
|
1.94e-01
|
6.96e-01
|
8.90e-01
|
8.99e-01
|
3.80e-01
|
9.30e-02
|
ALPHA PROTEIN KINASE 1 SIGNALING PATHWAY
|
11
|
7.62e-01
|
8.08e-01
|
0.2250
|
0.067200
|
-0.104000
|
-0.039700
|
1.54e-01
|
-9.95e-02
|
7.00e-01
|
5.52e-01
|
8.20e-01
|
3.76e-01
|
5.68e-01
|
TRANSCRIPTIONAL REGULATION BY THE AP 2 TFAP2 FAMILY OF TRANSCRIPTION FACTORS
|
28
|
3.31e-01
|
4.28e-01
|
0.2240
|
-0.064200
|
0.116000
|
-0.018000
|
-8.20e-02
|
-1.60e-01
|
5.57e-01
|
2.89e-01
|
8.69e-01
|
4.53e-01
|
1.43e-01
|
APOPTOSIS
|
161
|
2.18e-04
|
1.16e-03
|
0.2230
|
-0.138000
|
0.014000
|
-0.030300
|
1.72e-01
|
-2.72e-03
|
2.63e-03
|
7.60e-01
|
5.08e-01
|
1.64e-04
|
9.53e-01
|
DISEASES OF CARBOHYDRATE METABOLISM
|
29
|
4.15e-01
|
5.13e-01
|
0.2230
|
-0.080600
|
0.171000
|
0.095100
|
3.84e-02
|
5.93e-02
|
4.53e-01
|
1.11e-01
|
3.76e-01
|
7.21e-01
|
5.80e-01
|
INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS
|
34
|
4.73e-01
|
5.60e-01
|
0.2230
|
0.101000
|
-0.099300
|
0.072000
|
-4.26e-02
|
1.50e-01
|
3.07e-01
|
3.16e-01
|
4.68e-01
|
6.68e-01
|
1.30e-01
|
IRON UPTAKE AND TRANSPORT
|
52
|
1.38e-01
|
2.23e-01
|
0.2230
|
-0.080300
|
0.055600
|
-0.052200
|
1.72e-01
|
8.80e-02
|
3.17e-01
|
4.88e-01
|
5.15e-01
|
3.18e-02
|
2.72e-01
|
SIGNALING BY FGFR2
|
60
|
1.26e-01
|
2.09e-01
|
0.2230
|
-0.069100
|
-0.079500
|
0.019900
|
9.33e-02
|
-1.72e-01
|
3.55e-01
|
2.87e-01
|
7.90e-01
|
2.12e-01
|
2.16e-02
|
CYTOCHROME P450 ARRANGED BY SUBSTRATE TYPE
|
31
|
5.66e-01
|
6.43e-01
|
0.2230
|
0.162000
|
0.127000
|
0.020300
|
5.25e-02
|
6.38e-02
|
1.19e-01
|
2.20e-01
|
8.45e-01
|
6.13e-01
|
5.39e-01
|
PEPTIDE LIGAND BINDING RECEPTORS
|
84
|
5.31e-03
|
1.74e-02
|
0.2230
|
-0.095200
|
0.096000
|
-0.005220
|
-9.07e-02
|
-1.52e-01
|
1.32e-01
|
1.29e-01
|
9.34e-01
|
1.51e-01
|
1.63e-02
|
RESOLUTION OF D LOOP STRUCTURES THROUGH SYNTHESIS DEPENDENT STRAND ANNEALING SDSA
|
24
|
4.89e-01
|
5.77e-01
|
0.2230
|
0.048200
|
0.022800
|
-0.154000
|
-1.28e-01
|
-8.09e-02
|
6.83e-01
|
8.47e-01
|
1.91e-01
|
2.78e-01
|
4.93e-01
|
MUSCLE CONTRACTION
|
150
|
3.06e-03
|
1.11e-02
|
0.2230
|
0.191000
|
0.006950
|
0.091400
|
-5.32e-02
|
4.19e-02
|
5.39e-05
|
8.83e-01
|
5.36e-02
|
2.61e-01
|
3.76e-01
|
DISEASES OF MITOTIC CELL CYCLE
|
37
|
2.81e-01
|
3.76e-01
|
0.2230
|
-0.186000
|
0.043800
|
0.054400
|
3.60e-02
|
-9.32e-02
|
5.00e-02
|
6.45e-01
|
5.67e-01
|
7.05e-01
|
3.27e-01
|
RAB REGULATION OF TRAFFICKING
|
115
|
1.33e-03
|
5.47e-03
|
0.2220
|
-0.016400
|
-0.038000
|
0.060800
|
-5.37e-02
|
2.03e-01
|
7.62e-01
|
4.82e-01
|
2.60e-01
|
3.20e-01
|
1.73e-04
|
INITIATION OF NUCLEAR ENVELOPE NE REFORMATION
|
16
|
7.65e-01
|
8.09e-01
|
0.2220
|
-0.103000
|
0.114000
|
0.125000
|
9.88e-02
|
2.29e-02
|
4.75e-01
|
4.32e-01
|
3.88e-01
|
4.94e-01
|
8.74e-01
|
THE ROLE OF NEF IN HIV 1 REPLICATION AND DISEASE PATHOGENESIS
|
24
|
3.56e-01
|
4.54e-01
|
0.2220
|
-0.151000
|
-0.120000
|
0.088200
|
2.30e-02
|
6.25e-02
|
2.02e-01
|
3.10e-01
|
4.54e-01
|
8.46e-01
|
5.96e-01
|
ACYL CHAIN REMODELLING OF PC
|
16
|
6.93e-01
|
7.43e-01
|
0.2220
|
-0.120000
|
-0.091900
|
0.113000
|
-8.67e-02
|
-7.70e-02
|
4.06e-01
|
5.25e-01
|
4.34e-01
|
5.48e-01
|
5.94e-01
|
FC EPSILON RECEPTOR FCERI SIGNALING
|
122
|
1.07e-03
|
4.64e-03
|
0.2210
|
-0.157000
|
-0.083500
|
-0.045900
|
1.23e-01
|
7.69e-04
|
2.74e-03
|
1.12e-01
|
3.82e-01
|
1.90e-02
|
9.88e-01
|
MITOTIC G2 G2 M PHASES
|
182
|
4.64e-05
|
2.91e-04
|
0.2210
|
-0.125000
|
0.012400
|
0.059300
|
1.69e-01
|
-3.14e-02
|
3.67e-03
|
7.74e-01
|
1.68e-01
|
8.50e-05
|
4.66e-01
|
RETROGRADE TRANSPORT AT THE TRANS GOLGI NETWORK
|
48
|
1.88e-01
|
2.77e-01
|
0.2210
|
0.011100
|
-0.011200
|
0.121000
|
2.86e-02
|
1.82e-01
|
8.95e-01
|
8.94e-01
|
1.46e-01
|
7.32e-01
|
2.93e-02
|
TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATION
|
166
|
1.32e-04
|
7.41e-04
|
0.2210
|
0.006790
|
0.009890
|
0.114000
|
2.83e-02
|
1.87e-01
|
8.80e-01
|
8.26e-01
|
1.17e-02
|
5.30e-01
|
3.28e-05
|
DOWNREGULATION OF TGF BETA RECEPTOR SIGNALING
|
26
|
6.81e-01
|
7.33e-01
|
0.2200
|
-0.195000
|
-0.040100
|
-0.072000
|
-3.84e-02
|
-4.94e-02
|
8.60e-02
|
7.23e-01
|
5.25e-01
|
7.34e-01
|
6.63e-01
|
ANTIVIRAL MECHANISM BY IFN STIMULATED GENES
|
74
|
4.38e-02
|
9.33e-02
|
0.2200
|
-0.049600
|
-0.201000
|
0.037300
|
-6.10e-02
|
2.15e-02
|
4.61e-01
|
2.80e-03
|
5.80e-01
|
3.65e-01
|
7.49e-01
|
WNT LIGAND BIOGENESIS AND TRAFFICKING
|
18
|
6.52e-01
|
7.10e-01
|
0.2200
|
-0.163000
|
-0.125000
|
-0.029600
|
1.32e-02
|
7.18e-02
|
2.31e-01
|
3.60e-01
|
8.28e-01
|
9.23e-01
|
5.98e-01
|
VIRAL MESSENGER RNA SYNTHESIS
|
42
|
1.73e-01
|
2.63e-01
|
0.2200
|
0.030800
|
-0.110000
|
0.148000
|
1.12e-01
|
-2.93e-02
|
7.30e-01
|
2.17e-01
|
9.77e-02
|
2.10e-01
|
7.43e-01
|
CHROMATIN MODIFYING ENZYMES
|
216
|
7.62e-05
|
4.50e-04
|
0.2190
|
0.058100
|
-0.167000
|
0.025500
|
-1.19e-01
|
-4.21e-02
|
1.42e-01
|
2.38e-05
|
5.19e-01
|
2.59e-03
|
2.87e-01
|
P75 NTR RECEPTOR MEDIATED SIGNALLING
|
93
|
5.08e-02
|
1.05e-01
|
0.2190
|
0.079300
|
-0.068200
|
0.033700
|
-1.16e-01
|
1.50e-01
|
1.87e-01
|
2.56e-01
|
5.74e-01
|
5.42e-02
|
1.27e-02
|
OXIDATIVE STRESS INDUCED SENESCENCE
|
76
|
1.68e-01
|
2.58e-01
|
0.2190
|
-0.104000
|
-0.131000
|
-0.046800
|
-9.80e-03
|
-1.33e-01
|
1.16e-01
|
4.93e-02
|
4.81e-01
|
8.83e-01
|
4.58e-02
|
TNF RECEPTOR SUPERFAMILY TNFSF MEMBERS MEDIATING NON CANONICAL NF KB PATHWAY
|
11
|
9.29e-01
|
9.39e-01
|
0.2180
|
-0.168000
|
-0.105000
|
-0.081200
|
2.89e-02
|
-2.41e-02
|
3.34e-01
|
5.46e-01
|
6.41e-01
|
8.68e-01
|
8.90e-01
|
NEUTROPHIL DEGRANULATION
|
378
|
7.04e-11
|
1.31e-09
|
0.2180
|
-0.104000
|
-0.006310
|
-0.135000
|
1.33e-01
|
2.21e-02
|
5.52e-04
|
8.34e-01
|
6.56e-06
|
9.62e-06
|
4.61e-01
|
TRIGLYCERIDE METABOLISM
|
22
|
5.53e-01
|
6.33e-01
|
0.2160
|
-0.105000
|
-0.018900
|
-0.076000
|
1.39e-01
|
1.01e-01
|
3.93e-01
|
8.78e-01
|
5.37e-01
|
2.58e-01
|
4.11e-01
|
TOLL LIKE RECEPTOR TLR1 TLR2 CASCADE
|
90
|
4.72e-02
|
9.94e-02
|
0.2160
|
0.079700
|
-0.083100
|
-0.018400
|
-9.16e-02
|
1.58e-01
|
1.92e-01
|
1.73e-01
|
7.63e-01
|
1.33e-01
|
9.81e-03
|
CLASS A 1 RHODOPSIN LIKE RECEPTORS
|
150
|
1.08e-05
|
7.85e-05
|
0.2160
|
-0.046800
|
0.049200
|
0.017400
|
-1.91e-01
|
-7.44e-02
|
3.23e-01
|
2.99e-01
|
7.14e-01
|
5.73e-05
|
1.16e-01
|
IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLEX
|
10
|
9.29e-01
|
9.39e-01
|
0.2160
|
0.026700
|
0.101000
|
-0.018800
|
1.65e-01
|
-9.10e-02
|
8.84e-01
|
5.81e-01
|
9.18e-01
|
3.67e-01
|
6.18e-01
|
OTHER INTERLEUKIN SIGNALING
|
19
|
6.77e-01
|
7.29e-01
|
0.2160
|
0.086700
|
-0.190000
|
0.028800
|
-1.25e-02
|
4.57e-02
|
5.13e-01
|
1.52e-01
|
8.28e-01
|
9.25e-01
|
7.30e-01
|
BASIGIN INTERACTIONS
|
22
|
6.33e-01
|
6.95e-01
|
0.2150
|
-0.136000
|
0.135000
|
-0.095900
|
-1.21e-02
|
8.71e-04
|
2.69e-01
|
2.72e-01
|
4.36e-01
|
9.22e-01
|
9.94e-01
|
MAP2K AND MAPK ACTIVATION
|
36
|
3.64e-01
|
4.61e-01
|
0.2150
|
-0.104000
|
-0.177000
|
0.001510
|
-5.02e-02
|
3.90e-02
|
2.81e-01
|
6.60e-02
|
9.88e-01
|
6.02e-01
|
6.86e-01
|
EPH EPHRIN MEDIATED REPULSION OF CELLS
|
49
|
1.40e-01
|
2.25e-01
|
0.2140
|
-0.012100
|
-0.045300
|
0.114000
|
-1.73e-01
|
2.48e-02
|
8.83e-01
|
5.83e-01
|
1.69e-01
|
3.62e-02
|
7.64e-01
|
ACTIVATION OF ATR IN RESPONSE TO REPLICATION STRESS
|
32
|
4.03e-01
|
5.01e-01
|
0.2130
|
-0.048500
|
0.037700
|
-0.124000
|
1.51e-01
|
5.82e-02
|
6.35e-01
|
7.12e-01
|
2.23e-01
|
1.39e-01
|
5.69e-01
|
MATURATION OF SARS COV 2 SPIKE PROTEIN
|
29
|
5.18e-01
|
6.03e-01
|
0.2130
|
-0.071100
|
-0.157000
|
-0.013500
|
-7.98e-02
|
9.59e-02
|
5.08e-01
|
1.44e-01
|
9.00e-01
|
4.57e-01
|
3.71e-01
|
G ALPHA S SIGNALLING EVENTS
|
94
|
1.88e-02
|
4.77e-02
|
0.2120
|
0.071700
|
-0.020600
|
0.117000
|
-1.61e-01
|
2.65e-03
|
2.30e-01
|
7.30e-01
|
5.04e-02
|
7.12e-03
|
9.65e-01
|
TELOMERE C STRAND LAGGING STRAND SYNTHESIS
|
33
|
5.16e-01
|
6.02e-01
|
0.2110
|
0.040100
|
0.062900
|
0.018000
|
1.92e-01
|
-4.38e-02
|
6.90e-01
|
5.32e-01
|
8.58e-01
|
5.70e-02
|
6.63e-01
|
SIGNALING BY NOTCH2
|
33
|
3.17e-01
|
4.13e-01
|
0.2110
|
-0.075500
|
0.040800
|
0.003380
|
-1.48e-01
|
-1.23e-01
|
4.53e-01
|
6.85e-01
|
9.73e-01
|
1.42e-01
|
2.21e-01
|
SNRNP ASSEMBLY
|
51
|
1.50e-01
|
2.38e-01
|
0.2100
|
-0.066800
|
-0.055600
|
0.123000
|
1.34e-01
|
-5.95e-02
|
4.09e-01
|
4.92e-01
|
1.29e-01
|
9.79e-02
|
4.63e-01
|
THE PHOTOTRANSDUCTION CASCADE
|
18
|
7.86e-01
|
8.28e-01
|
0.2100
|
0.123000
|
-0.030300
|
0.149000
|
1.83e-02
|
-7.41e-02
|
3.65e-01
|
8.24e-01
|
2.75e-01
|
8.93e-01
|
5.86e-01
|
PLATELET HOMEOSTASIS
|
77
|
1.57e-01
|
2.46e-01
|
0.2100
|
0.114000
|
-0.071500
|
0.091700
|
-1.06e-01
|
7.87e-02
|
8.32e-02
|
2.79e-01
|
1.65e-01
|
1.09e-01
|
2.33e-01
|
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN G1 CELL CYCLE ARREST
|
12
|
7.98e-01
|
8.35e-01
|
0.2090
|
-0.119000
|
-0.005810
|
0.041100
|
3.71e-02
|
1.63e-01
|
4.76e-01
|
9.72e-01
|
8.05e-01
|
8.24e-01
|
3.28e-01
|
TRANSLOCATION OF SLC2A4 GLUT4 TO THE PLASMA MEMBRANE
|
63
|
2.95e-02
|
6.81e-02
|
0.2080
|
-0.041400
|
-0.121000
|
0.085600
|
7.32e-02
|
1.20e-01
|
5.70e-01
|
9.71e-02
|
2.40e-01
|
3.16e-01
|
9.90e-02
|
NEGATIVE REGULATION OF FGFR2 SIGNALING
|
25
|
7.05e-01
|
7.52e-01
|
0.2080
|
0.123000
|
-0.084500
|
0.113000
|
1.33e-02
|
9.05e-02
|
2.88e-01
|
4.65e-01
|
3.26e-01
|
9.08e-01
|
4.34e-01
|
SUMOYLATION OF DNA REPLICATION PROTEINS
|
43
|
2.43e-01
|
3.41e-01
|
0.2080
|
-0.021800
|
-0.142000
|
0.082400
|
-6.32e-02
|
1.09e-01
|
8.05e-01
|
1.07e-01
|
3.50e-01
|
4.73e-01
|
2.16e-01
|
RAB GERANYLGERANYLATION
|
57
|
1.20e-01
|
2.03e-01
|
0.2080
|
-0.090000
|
0.026300
|
0.019000
|
1.55e-01
|
1.00e-01
|
2.40e-01
|
7.32e-01
|
8.04e-01
|
4.26e-02
|
1.92e-01
|
METABOLISM OF VITAMINS AND COFACTORS
|
147
|
1.10e-02
|
3.15e-02
|
0.2080
|
0.016500
|
0.132000
|
-0.002480
|
1.40e-01
|
7.60e-02
|
7.31e-01
|
5.70e-03
|
9.59e-01
|
3.43e-03
|
1.12e-01
|
DEGRADATION OF THE EXTRACELLULAR MATRIX
|
101
|
4.78e-03
|
1.59e-02
|
0.2080
|
0.107000
|
0.090900
|
0.031500
|
-1.50e-01
|
-4.98e-03
|
6.32e-02
|
1.15e-01
|
5.85e-01
|
9.43e-03
|
9.31e-01
|
FOXO MEDIATED TRANSCRIPTION OF OXIDATIVE STRESS METABOLIC AND NEURONAL GENES
|
23
|
7.01e-01
|
7.49e-01
|
0.2070
|
0.105000
|
-0.076000
|
-0.038700
|
-1.46e-01
|
-5.72e-02
|
3.85e-01
|
5.28e-01
|
7.48e-01
|
2.24e-01
|
6.35e-01
|
MET ACTIVATES PTK2 SIGNALING
|
28
|
4.31e-01
|
5.24e-01
|
0.2070
|
0.127000
|
0.025400
|
-0.003080
|
-1.35e-01
|
-8.91e-02
|
2.46e-01
|
8.16e-01
|
9.78e-01
|
2.16e-01
|
4.14e-01
|
EPIGENETIC REGULATION OF GENE EXPRESSION
|
100
|
3.23e-02
|
7.36e-02
|
0.2070
|
-0.047000
|
-0.052900
|
0.010800
|
6.55e-02
|
-1.83e-01
|
4.17e-01
|
3.61e-01
|
8.52e-01
|
2.58e-01
|
1.60e-03
|
TRANSLATION OF SARS COV 2 STRUCTURAL PROTEINS
|
44
|
4.02e-01
|
5.01e-01
|
0.2060
|
-0.160000
|
-0.105000
|
-0.008940
|
-5.54e-02
|
-5.33e-02
|
6.68e-02
|
2.27e-01
|
9.18e-01
|
5.25e-01
|
5.41e-01
|
TP53 REGULATES TRANSCRIPTION OF CELL CYCLE GENES
|
44
|
2.09e-01
|
3.02e-01
|
0.2040
|
-0.101000
|
-0.097500
|
0.036700
|
-9.87e-02
|
1.05e-01
|
2.48e-01
|
2.63e-01
|
6.74e-01
|
2.57e-01
|
2.30e-01
|
NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR NLR SIGNALING PATHWAYS
|
52
|
1.56e-01
|
2.45e-01
|
0.2040
|
0.053500
|
-0.114000
|
-0.159000
|
-2.02e-02
|
-7.37e-03
|
5.04e-01
|
1.55e-01
|
4.76e-02
|
8.01e-01
|
9.27e-01
|
SIGNALING BY FGFR
|
70
|
1.92e-01
|
2.82e-01
|
0.2040
|
-0.071700
|
-0.111000
|
0.001370
|
7.68e-03
|
-1.55e-01
|
3.00e-01
|
1.10e-01
|
9.84e-01
|
9.12e-01
|
2.48e-02
|
ASSOCIATION OF TRIC CCT WITH TARGET PROTEINS DURING BIOSYNTHESIS
|
37
|
2.20e-01
|
3.14e-01
|
0.2030
|
-0.031200
|
-0.109000
|
0.054700
|
1.51e-01
|
5.10e-02
|
7.43e-01
|
2.52e-01
|
5.65e-01
|
1.11e-01
|
5.92e-01
|
SIGNALING BY GPCR
|
437
|
8.34e-10
|
1.33e-08
|
0.2030
|
0.040800
|
-0.046200
|
0.062600
|
-1.74e-01
|
5.64e-02
|
1.45e-01
|
9.87e-02
|
2.53e-02
|
5.67e-10
|
4.42e-02
|
NEGATIVE REGULATION OF FGFR3 SIGNALING
|
23
|
8.33e-01
|
8.63e-01
|
0.2020
|
0.131000
|
0.014900
|
0.065300
|
5.17e-02
|
1.28e-01
|
2.75e-01
|
9.01e-01
|
5.88e-01
|
6.68e-01
|
2.87e-01
|
METABOLIC DISORDERS OF BIOLOGICAL OXIDATION ENZYMES
|
20
|
7.78e-01
|
8.22e-01
|
0.2010
|
-0.008610
|
0.108000
|
-0.099900
|
1.35e-01
|
-2.30e-02
|
9.47e-01
|
4.02e-01
|
4.39e-01
|
2.96e-01
|
8.59e-01
|
DEATH RECEPTOR SIGNALLING
|
132
|
2.45e-02
|
5.86e-02
|
0.2010
|
0.075200
|
-0.089300
|
0.024200
|
-1.22e-01
|
1.07e-01
|
1.36e-01
|
7.67e-02
|
6.32e-01
|
1.59e-02
|
3.43e-02
|
MHC CLASS II ANTIGEN PRESENTATION
|
101
|
1.22e-01
|
2.05e-01
|
0.2010
|
0.065600
|
0.060500
|
0.082700
|
8.30e-02
|
1.37e-01
|
2.55e-01
|
2.94e-01
|
1.51e-01
|
1.50e-01
|
1.78e-02
|
SUMOYLATION
|
157
|
1.64e-02
|
4.32e-02
|
0.2010
|
-0.003700
|
-0.139000
|
-0.016400
|
-1.42e-01
|
-2.39e-02
|
9.36e-01
|
2.69e-03
|
7.23e-01
|
2.18e-03
|
6.06e-01
|
NEGATIVE REGULATION OF FLT3
|
14
|
8.69e-01
|
8.91e-01
|
0.2010
|
0.086400
|
-0.006480
|
0.089600
|
1.35e-01
|
-8.00e-02
|
5.76e-01
|
9.67e-01
|
5.62e-01
|
3.80e-01
|
6.04e-01
|
TOLL LIKE RECEPTOR CASCADES
|
134
|
5.65e-03
|
1.84e-02
|
0.2000
|
0.041700
|
-0.047400
|
-0.099600
|
-7.10e-02
|
1.45e-01
|
4.05e-01
|
3.44e-01
|
4.66e-02
|
1.56e-01
|
3.71e-03
|
EXTRACELLULAR MATRIX ORGANIZATION
|
232
|
8.73e-07
|
8.38e-06
|
0.2000
|
0.092200
|
0.054500
|
-0.044400
|
-1.62e-01
|
-1.84e-02
|
1.58e-02
|
1.53e-01
|
2.45e-01
|
2.31e-05
|
6.29e-01
|
GPCR LIGAND BINDING
|
224
|
1.32e-07
|
1.50e-06
|
0.2000
|
-0.095900
|
0.058300
|
0.022600
|
-1.44e-01
|
-7.74e-02
|
1.36e-02
|
1.34e-01
|
5.61e-01
|
2.06e-04
|
4.65e-02
|
NUCLEAR ENVELOPE NE REASSEMBLY
|
63
|
9.44e-02
|
1.69e-01
|
0.2000
|
-0.061200
|
-0.004340
|
0.147000
|
1.05e-01
|
5.72e-02
|
4.01e-01
|
9.52e-01
|
4.32e-02
|
1.49e-01
|
4.33e-01
|
RESOLUTION OF D LOOP STRUCTURES
|
30
|
3.73e-01
|
4.70e-01
|
0.1990
|
0.167000
|
0.063200
|
-0.068600
|
-4.78e-02
|
-3.19e-02
|
1.14e-01
|
5.49e-01
|
5.16e-01
|
6.50e-01
|
7.63e-01
|
PLASMA LIPOPROTEIN ASSEMBLY REMODELING AND CLEARANCE
|
46
|
4.51e-01
|
5.40e-01
|
0.1990
|
0.030100
|
0.118000
|
0.046500
|
4.08e-03
|
1.51e-01
|
7.24e-01
|
1.66e-01
|
5.85e-01
|
9.62e-01
|
7.69e-02
|
UB SPECIFIC PROCESSING PROTEASES
|
163
|
5.08e-04
|
2.48e-03
|
0.1990
|
-0.117000
|
-0.126000
|
-0.056100
|
8.42e-02
|
-8.80e-03
|
1.02e-02
|
5.75e-03
|
2.17e-01
|
6.40e-02
|
8.47e-01
|
TRNA PROCESSING IN THE NUCLEUS
|
56
|
1.13e-01
|
1.94e-01
|
0.1980
|
-0.006390
|
-0.114000
|
0.125000
|
1.00e-01
|
-2.34e-02
|
9.34e-01
|
1.39e-01
|
1.05e-01
|
1.96e-01
|
7.62e-01
|
SUMOYLATION OF INTRACELLULAR RECEPTORS
|
24
|
5.99e-01
|
6.67e-01
|
0.1980
|
-0.014000
|
0.051500
|
-0.023200
|
-1.78e-01
|
6.39e-02
|
9.05e-01
|
6.62e-01
|
8.44e-01
|
1.30e-01
|
5.88e-01
|
DISEASES ASSOCIATED WITH O GLYCOSYLATION OF PROTEINS
|
48
|
2.80e-01
|
3.76e-01
|
0.1980
|
0.079400
|
0.056900
|
-0.033800
|
-1.52e-01
|
7.45e-02
|
3.41e-01
|
4.95e-01
|
6.86e-01
|
6.92e-02
|
3.72e-01
|
EPH EPHRIN SIGNALING
|
90
|
5.10e-02
|
1.05e-01
|
0.1980
|
-0.006840
|
-0.111000
|
0.094500
|
-1.26e-01
|
-4.49e-02
|
9.11e-01
|
6.80e-02
|
1.21e-01
|
3.94e-02
|
4.62e-01
|
O GLYCOSYLATION OF TSR DOMAIN CONTAINING PROTEINS
|
33
|
3.73e-01
|
4.70e-01
|
0.1980
|
0.108000
|
0.036700
|
-0.080900
|
-1.31e-01
|
-4.99e-02
|
2.83e-01
|
7.16e-01
|
4.21e-01
|
1.94e-01
|
6.20e-01
|
HIV LIFE CYCLE
|
142
|
5.89e-03
|
1.89e-02
|
0.1980
|
-0.089100
|
0.006920
|
0.074300
|
1.41e-01
|
-7.57e-02
|
6.70e-02
|
8.87e-01
|
1.27e-01
|
3.78e-03
|
1.20e-01
|
GOLGI ASSOCIATED VESICLE BIOGENESIS
|
54
|
1.74e-01
|
2.64e-01
|
0.1970
|
-0.044100
|
-0.002730
|
-0.017500
|
-3.99e-02
|
1.87e-01
|
5.75e-01
|
9.72e-01
|
8.24e-01
|
6.13e-01
|
1.73e-02
|
O LINKED GLYCOSYLATION
|
82
|
1.26e-01
|
2.09e-01
|
0.1970
|
0.083700
|
0.053000
|
0.030100
|
-1.11e-01
|
1.26e-01
|
1.90e-01
|
4.07e-01
|
6.38e-01
|
8.28e-02
|
4.84e-02
|
DNA REPAIR
|
287
|
3.23e-05
|
2.10e-04
|
0.1970
|
-0.009010
|
0.052800
|
0.065600
|
1.74e-01
|
-3.75e-02
|
7.93e-01
|
1.25e-01
|
5.65e-02
|
4.03e-07
|
2.76e-01
|
SARS COV 1 INFECTION
|
48
|
2.20e-01
|
3.14e-01
|
0.1970
|
-0.070500
|
0.016700
|
0.162000
|
8.11e-02
|
2.80e-02
|
3.98e-01
|
8.41e-01
|
5.28e-02
|
3.31e-01
|
7.37e-01
|
BETA CATENIN INDEPENDENT WNT SIGNALING
|
136
|
4.72e-03
|
1.57e-02
|
0.1960
|
-0.162000
|
-0.027700
|
0.014800
|
1.02e-01
|
-3.30e-02
|
1.16e-03
|
5.78e-01
|
7.67e-01
|
4.03e-02
|
5.08e-01
|
SYNDECAN INTERACTIONS
|
26
|
4.58e-01
|
5.46e-01
|
0.1950
|
0.131000
|
0.086700
|
-0.088600
|
-5.72e-02
|
-4.92e-02
|
2.48e-01
|
4.44e-01
|
4.34e-01
|
6.14e-01
|
6.64e-01
|
TIE2 SIGNALING
|
17
|
9.10e-01
|
9.24e-01
|
0.1940
|
0.000365
|
-0.147000
|
-0.079500
|
-9.30e-02
|
3.04e-02
|
9.98e-01
|
2.93e-01
|
5.70e-01
|
5.07e-01
|
8.28e-01
|
IRAK1 RECRUITS IKK COMPLEX
|
14
|
9.48e-01
|
9.56e-01
|
0.1930
|
-0.065600
|
-0.025900
|
-0.124000
|
-6.47e-02
|
-1.14e-01
|
6.71e-01
|
8.67e-01
|
4.23e-01
|
6.75e-01
|
4.60e-01
|
DEADENYLATION DEPENDENT MRNA DECAY
|
55
|
2.28e-01
|
3.23e-01
|
0.1930
|
-0.006500
|
-0.039800
|
0.142000
|
1.10e-01
|
-5.78e-02
|
9.34e-01
|
6.10e-01
|
6.94e-02
|
1.59e-01
|
4.59e-01
|
ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION
|
282
|
9.99e-09
|
1.39e-07
|
0.1930
|
-0.077400
|
-0.038600
|
0.092400
|
6.60e-02
|
1.29e-01
|
2.57e-02
|
2.66e-01
|
7.75e-03
|
5.70e-02
|
1.95e-04
|
SIGNALING BY PDGF
|
53
|
4.25e-01
|
5.20e-01
|
0.1910
|
0.079300
|
-0.120000
|
-0.006770
|
-9.76e-02
|
7.86e-02
|
3.18e-01
|
1.30e-01
|
9.32e-01
|
2.19e-01
|
3.23e-01
|
SUMOYLATION OF IMMUNE RESPONSE PROTEINS
|
11
|
9.54e-01
|
9.61e-01
|
0.1910
|
-0.064300
|
0.093400
|
-0.045100
|
6.06e-02
|
-1.34e-01
|
7.12e-01
|
5.92e-01
|
7.95e-01
|
7.28e-01
|
4.42e-01
|
TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN CYTOCHROME C RELEASE
|
19
|
8.93e-01
|
9.10e-01
|
0.1900
|
0.029800
|
0.137000
|
-0.009190
|
1.28e-01
|
5.08e-03
|
8.22e-01
|
3.02e-01
|
9.45e-01
|
3.36e-01
|
9.69e-01
|
SIGNALING BY WNT
|
260
|
2.02e-04
|
1.09e-03
|
0.1900
|
-0.158000
|
-0.082800
|
-0.059500
|
-2.29e-02
|
-8.03e-03
|
1.21e-05
|
2.18e-02
|
9.96e-02
|
5.26e-01
|
8.24e-01
|
GLYCEROPHOSPHOLIPID BIOSYNTHESIS
|
106
|
2.81e-02
|
6.51e-02
|
0.1890
|
0.080000
|
-0.073900
|
0.001810
|
1.35e-02
|
1.54e-01
|
1.55e-01
|
1.89e-01
|
9.74e-01
|
8.11e-01
|
6.09e-03
|
DISEASES OF GLYCOSYLATION
|
121
|
1.38e-01
|
2.23e-01
|
0.1890
|
0.074400
|
0.086700
|
0.083600
|
3.08e-02
|
1.21e-01
|
1.58e-01
|
1.00e-01
|
1.13e-01
|
5.58e-01
|
2.14e-02
|
NICOTINATE METABOLISM
|
24
|
6.98e-01
|
7.47e-01
|
0.1890
|
-0.152000
|
0.090700
|
0.034600
|
5.22e-02
|
-1.65e-02
|
1.97e-01
|
4.42e-01
|
7.70e-01
|
6.58e-01
|
8.89e-01
|
MITOCHONDRIAL TRNA AMINOACYLATION
|
21
|
7.12e-01
|
7.59e-01
|
0.1880
|
-0.125000
|
0.051100
|
0.100000
|
7.87e-02
|
2.95e-02
|
3.20e-01
|
6.85e-01
|
4.26e-01
|
5.32e-01
|
8.15e-01
|
CLATHRIN MEDIATED ENDOCYTOSIS
|
128
|
4.31e-02
|
9.20e-02
|
0.1880
|
0.064400
|
-0.035800
|
0.081100
|
-9.55e-02
|
1.19e-01
|
2.09e-01
|
4.84e-01
|
1.14e-01
|
6.24e-02
|
2.00e-02
|
ENDOGENOUS STEROLS
|
20
|
7.15e-01
|
7.62e-01
|
0.1870
|
0.082400
|
-0.009480
|
-0.007610
|
2.49e-02
|
-1.66e-01
|
5.24e-01
|
9.42e-01
|
9.53e-01
|
8.47e-01
|
2.00e-01
|
PROCESSIVE SYNTHESIS ON THE C STRAND OF THE TELOMERE
|
19
|
8.17e-01
|
8.51e-01
|
0.1860
|
-0.116000
|
0.051200
|
-0.043600
|
9.91e-02
|
8.26e-02
|
3.81e-01
|
6.99e-01
|
7.42e-01
|
4.55e-01
|
5.33e-01
|
INTRINSIC PATHWAY FOR APOPTOSIS
|
52
|
3.26e-01
|
4.24e-01
|
0.1850
|
-0.039200
|
0.007170
|
0.030700
|
1.77e-01
|
1.90e-02
|
6.25e-01
|
9.29e-01
|
7.02e-01
|
2.76e-02
|
8.13e-01
|
POLO LIKE KINASE MEDIATED EVENTS
|
13
|
9.18e-01
|
9.30e-01
|
0.1840
|
0.016100
|
-0.090900
|
0.051600
|
4.04e-03
|
-1.51e-01
|
9.20e-01
|
5.70e-01
|
7.47e-01
|
9.80e-01
|
3.47e-01
|
MEMBRANE TRAFFICKING
|
567
|
7.79e-12
|
1.87e-10
|
0.1840
|
0.004150
|
-0.026000
|
0.061200
|
-3.87e-02
|
1.67e-01
|
8.67e-01
|
2.92e-01
|
1.32e-02
|
1.17e-01
|
1.34e-11
|
ASSEMBLY OF COLLAGEN FIBRILS AND OTHER MULTIMERIC STRUCTURES
|
48
|
3.53e-01
|
4.50e-01
|
0.1830
|
0.039400
|
-0.034300
|
0.083200
|
-1.45e-01
|
-5.39e-02
|
6.37e-01
|
6.82e-01
|
3.19e-01
|
8.33e-02
|
5.19e-01
|
REGULATION OF PTEN GENE TRANSCRIPTION
|
57
|
3.02e-01
|
3.96e-01
|
0.1830
|
-0.010300
|
-0.101000
|
0.088600
|
-1.12e-01
|
-5.11e-02
|
8.93e-01
|
1.87e-01
|
2.47e-01
|
1.43e-01
|
5.05e-01
|
TICAM1 TRAF6 DEPENDENT INDUCTION OF TAK1 COMPLEX
|
11
|
9.70e-01
|
9.74e-01
|
0.1830
|
-0.083200
|
0.089800
|
-0.029300
|
8.83e-02
|
-9.87e-02
|
6.33e-01
|
6.06e-01
|
8.66e-01
|
6.12e-01
|
5.71e-01
|
FOXO MEDIATED TRANSCRIPTION OF CELL DEATH GENES
|
15
|
7.99e-01
|
8.35e-01
|
0.1810
|
0.011500
|
-0.157000
|
-0.006370
|
8.69e-02
|
2.46e-02
|
9.39e-01
|
2.93e-01
|
9.66e-01
|
5.60e-01
|
8.69e-01
|
EXTENSION OF TELOMERES
|
48
|
4.20e-01
|
5.17e-01
|
0.1810
|
0.014400
|
0.028900
|
-0.000120
|
1.58e-01
|
-8.30e-02
|
8.63e-01
|
7.29e-01
|
9.99e-01
|
5.83e-02
|
3.20e-01
|
ACTIVATION OF ANTERIOR HOX GENES IN HINDBRAIN DEVELOPMENT DURING EARLY EMBRYOGENESIS
|
63
|
2.76e-01
|
3.73e-01
|
0.1810
|
-0.016500
|
-0.045800
|
-0.048300
|
6.34e-02
|
-1.55e-01
|
8.20e-01
|
5.30e-01
|
5.08e-01
|
3.84e-01
|
3.30e-02
|
GOLGI TO ER RETROGRADE TRANSPORT
|
119
|
9.83e-03
|
2.91e-02
|
0.1810
|
-0.038000
|
0.001860
|
0.100000
|
-7.34e-03
|
1.46e-01
|
4.74e-01
|
9.72e-01
|
5.96e-02
|
8.90e-01
|
6.00e-03
|
GENE SILENCING BY RNA
|
81
|
1.40e-01
|
2.25e-01
|
0.1800
|
-0.024100
|
-0.123000
|
-0.041800
|
5.29e-02
|
-1.10e-01
|
7.08e-01
|
5.64e-02
|
5.16e-01
|
4.10e-01
|
8.74e-02
|
PRE NOTCH EXPRESSION AND PROCESSING
|
61
|
4.67e-01
|
5.54e-01
|
0.1800
|
-0.041800
|
-0.039000
|
-0.150000
|
-6.93e-02
|
-4.16e-02
|
5.72e-01
|
5.98e-01
|
4.32e-02
|
3.49e-01
|
5.74e-01
|
DISEASES OF SIGNAL TRANSDUCTION BY GROWTH FACTOR RECEPTORS AND SECOND MESSENGERS
|
358
|
9.66e-05
|
5.59e-04
|
0.1800
|
-0.046000
|
-0.130000
|
-0.039100
|
-1.06e-01
|
2.08e-02
|
1.36e-01
|
2.46e-05
|
2.05e-01
|
6.03e-04
|
5.00e-01
|
SIGNALING BY PTK6
|
50
|
4.92e-01
|
5.80e-01
|
0.1790
|
-0.098100
|
-0.049500
|
-0.105000
|
-6.99e-02
|
6.44e-02
|
2.30e-01
|
5.45e-01
|
1.98e-01
|
3.92e-01
|
4.31e-01
|
TRANSPORT OF SMALL MOLECULES
|
547
|
3.71e-07
|
3.85e-06
|
0.1790
|
0.086900
|
0.027800
|
0.043100
|
-6.04e-03
|
1.48e-01
|
5.43e-04
|
2.69e-01
|
8.60e-02
|
8.10e-01
|
3.70e-09
|
MET PROMOTES CELL MOTILITY
|
38
|
6.71e-01
|
7.24e-01
|
0.1780
|
0.030800
|
-0.051400
|
-0.070000
|
-1.51e-01
|
-2.04e-02
|
7.42e-01
|
5.83e-01
|
4.56e-01
|
1.07e-01
|
8.28e-01
|
INTRA GOLGI AND RETROGRADE GOLGI TO ER TRAFFIC
|
185
|
7.03e-04
|
3.29e-03
|
0.1780
|
-0.023200
|
-0.010100
|
0.069300
|
-1.40e-03
|
1.62e-01
|
5.87e-01
|
8.14e-01
|
1.04e-01
|
9.74e-01
|
1.47e-04
|
MAPK FAMILY SIGNALING CASCADES
|
279
|
2.72e-05
|
1.78e-04
|
0.1770
|
-0.053000
|
-0.149000
|
0.024800
|
-5.81e-02
|
4.92e-02
|
1.29e-01
|
1.94e-05
|
4.76e-01
|
9.57e-02
|
1.58e-01
|
RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES
|
78
|
1.69e-01
|
2.60e-01
|
0.1750
|
-0.010800
|
0.053800
|
0.149000
|
1.49e-02
|
7.36e-02
|
8.70e-01
|
4.12e-01
|
2.32e-02
|
8.21e-01
|
2.62e-01
|
ASPARAGINE N LINKED GLYCOSYLATION
|
279
|
2.39e-06
|
2.10e-05
|
0.1750
|
-0.032700
|
-0.037100
|
0.091200
|
4.73e-02
|
1.33e-01
|
3.48e-01
|
2.88e-01
|
8.93e-03
|
1.75e-01
|
1.35e-04
|
COSTIMULATION BY THE CD28 FAMILY
|
47
|
5.93e-01
|
6.64e-01
|
0.1750
|
0.013200
|
-0.073000
|
-0.056200
|
-1.12e-01
|
9.65e-02
|
8.76e-01
|
3.87e-01
|
5.05e-01
|
1.85e-01
|
2.52e-01
|
TAK1 ACTIVATES NFKB BY PHOSPHORYLATION AND ACTIVATION OF IKKS COMPLEX
|
29
|
5.62e-01
|
6.39e-01
|
0.1740
|
0.039900
|
0.011500
|
-0.144000
|
7.71e-02
|
-4.23e-02
|
7.10e-01
|
9.15e-01
|
1.78e-01
|
4.72e-01
|
6.93e-01
|
NERVOUS SYSTEM DEVELOPMENT
|
537
|
1.01e-08
|
1.39e-07
|
0.1740
|
-0.081800
|
-0.076400
|
0.044500
|
8.54e-03
|
-1.25e-01
|
1.25e-03
|
2.58e-03
|
7.88e-02
|
7.36e-01
|
7.61e-07
|
VESICLE MEDIATED TRANSPORT
|
596
|
5.73e-11
|
1.10e-09
|
0.1740
|
0.004450
|
-0.023800
|
0.051600
|
-4.00e-02
|
1.59e-01
|
8.54e-01
|
3.23e-01
|
3.23e-02
|
9.74e-02
|
3.87e-11
|
METABOLISM OF STEROIDS
|
110
|
6.67e-02
|
1.29e-01
|
0.1740
|
-0.098100
|
-0.065700
|
-0.050100
|
-8.90e-02
|
7.61e-02
|
7.56e-02
|
2.35e-01
|
3.65e-01
|
1.07e-01
|
1.69e-01
|
INTRACELLULAR SIGNALING BY SECOND MESSENGERS
|
274
|
3.10e-04
|
1.58e-03
|
0.1740
|
0.025900
|
-0.140000
|
0.026000
|
-7.25e-02
|
6.36e-02
|
4.62e-01
|
7.21e-05
|
4.60e-01
|
3.94e-02
|
7.07e-02
|
TNFR1 INDUCED NFKAPPAB SIGNALING PATHWAY
|
29
|
6.86e-01
|
7.36e-01
|
0.1730
|
0.081300
|
-0.148000
|
0.028600
|
-1.24e-02
|
-2.56e-02
|
4.49e-01
|
1.68e-01
|
7.90e-01
|
9.08e-01
|
8.11e-01
|
POTENTIAL THERAPEUTICS FOR SARS
|
76
|
3.47e-01
|
4.44e-01
|
0.1730
|
-0.047100
|
-0.081500
|
-0.003730
|
-8.36e-02
|
-1.19e-01
|
4.78e-01
|
2.20e-01
|
9.55e-01
|
2.08e-01
|
7.28e-02
|
JNK C JUN KINASES PHOSPHORYLATION AND ACTIVATION MEDIATED BY ACTIVATED HUMAN TAK1
|
22
|
8.65e-01
|
8.88e-01
|
0.1730
|
0.135000
|
-0.023200
|
-0.022300
|
-8.24e-02
|
6.28e-02
|
2.74e-01
|
8.51e-01
|
8.57e-01
|
5.03e-01
|
6.10e-01
|
TRANSCRIPTIONAL REGULATION BY SMALL RNAS
|
59
|
3.64e-01
|
4.61e-01
|
0.1730
|
-0.077800
|
-0.039800
|
-0.012700
|
1.33e-01
|
-6.59e-02
|
3.02e-01
|
5.97e-01
|
8.66e-01
|
7.70e-02
|
3.82e-01
|
REGULATION OF TNFR1 SIGNALING
|
34
|
6.48e-01
|
7.07e-01
|
0.1720
|
0.022200
|
-0.166000
|
0.010400
|
-1.38e-02
|
-3.87e-02
|
8.23e-01
|
9.48e-02
|
9.17e-01
|
8.89e-01
|
6.97e-01
|
ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION
|
23
|
6.28e-01
|
6.93e-01
|
0.1720
|
0.115000
|
-0.073000
|
-0.099400
|
3.16e-02
|
-1.88e-02
|
3.41e-01
|
5.45e-01
|
4.09e-01
|
7.93e-01
|
8.76e-01
|
METABOLISM OF FAT SOLUBLE VITAMINS
|
30
|
6.05e-01
|
6.73e-01
|
0.1720
|
0.086200
|
0.134000
|
-0.036600
|
1.08e-02
|
-5.35e-02
|
4.14e-01
|
2.06e-01
|
7.29e-01
|
9.18e-01
|
6.12e-01
|
TNF SIGNALING
|
43
|
6.54e-01
|
7.10e-01
|
0.1710
|
0.016600
|
-0.152000
|
0.006770
|
-7.09e-02
|
-3.09e-02
|
8.51e-01
|
8.48e-02
|
9.39e-01
|
4.22e-01
|
7.26e-01
|
ANTI INFLAMMATORY RESPONSE FAVOURING LEISHMANIA PARASITE INFECTION
|
105
|
1.01e-01
|
1.78e-01
|
0.1710
|
-0.048800
|
-0.068100
|
0.014300
|
-1.49e-01
|
3.16e-03
|
3.88e-01
|
2.28e-01
|
8.01e-01
|
8.59e-03
|
9.55e-01
|
LYSOSOME VESICLE BIOGENESIS
|
32
|
6.49e-01
|
7.08e-01
|
0.1710
|
-0.097800
|
0.056100
|
0.070600
|
9.19e-02
|
5.60e-02
|
3.38e-01
|
5.83e-01
|
4.89e-01
|
3.68e-01
|
5.84e-01
|
SIGNALING BY RHO GTPASES MIRO GTPASES AND RHOBTB3
|
620
|
3.19e-08
|
3.95e-07
|
0.1700
|
0.009000
|
-0.069800
|
-0.017800
|
-1.39e-01
|
6.48e-02
|
7.04e-01
|
3.15e-03
|
4.52e-01
|
4.33e-09
|
6.11e-03
|
HCMV LATE EVENTS
|
63
|
2.08e-01
|
3.02e-01
|
0.1690
|
-0.074700
|
-0.031300
|
0.021300
|
1.39e-01
|
4.77e-02
|
3.05e-01
|
6.67e-01
|
7.70e-01
|
5.67e-02
|
5.13e-01
|
DISORDERS OF TRANSMEMBRANE TRANSPORTERS
|
132
|
1.13e-02
|
3.21e-02
|
0.1690
|
-0.055000
|
-0.037500
|
0.036700
|
1.47e-01
|
3.23e-02
|
2.76e-01
|
4.58e-01
|
4.67e-01
|
3.54e-03
|
5.22e-01
|
SEMA4D IN SEMAPHORIN SIGNALING
|
24
|
7.76e-01
|
8.20e-01
|
0.1670
|
0.046700
|
-0.065900
|
-0.121000
|
-1.90e-02
|
-8.09e-02
|
6.92e-01
|
5.77e-01
|
3.05e-01
|
8.72e-01
|
4.93e-01
|
CYTOKINE SIGNALING IN IMMUNE SYSTEM
|
528
|
2.29e-07
|
2.52e-06
|
0.1670
|
-0.052200
|
-0.112000
|
-0.113000
|
-4.67e-03
|
3.84e-03
|
4.10e-02
|
1.22e-05
|
9.89e-06
|
8.55e-01
|
8.80e-01
|
KINESINS
|
48
|
5.08e-01
|
5.94e-01
|
0.1670
|
0.008540
|
-0.027100
|
0.026600
|
-1.61e-01
|
2.54e-02
|
9.18e-01
|
7.46e-01
|
7.50e-01
|
5.43e-02
|
7.60e-01
|
TGF BETA RECEPTOR SIGNALING ACTIVATES SMADS
|
32
|
8.52e-01
|
8.77e-01
|
0.1670
|
-0.132000
|
-0.070500
|
-0.053200
|
-2.75e-02
|
-4.33e-02
|
1.96e-01
|
4.90e-01
|
6.02e-01
|
7.88e-01
|
6.72e-01
|
G ALPHA I SIGNALLING EVENTS
|
184
|
6.30e-03
|
1.98e-02
|
0.1670
|
-0.007140
|
-0.074800
|
0.072200
|
-1.28e-01
|
2.22e-02
|
8.68e-01
|
8.06e-02
|
9.19e-02
|
2.76e-03
|
6.04e-01
|
EGFR DOWNREGULATION
|
27
|
6.62e-01
|
7.15e-01
|
0.1660
|
-0.059900
|
-0.008850
|
0.121000
|
-5.41e-02
|
-7.99e-02
|
5.90e-01
|
9.37e-01
|
2.75e-01
|
6.27e-01
|
4.72e-01
|
MITOTIC SPINDLE CHECKPOINT
|
96
|
3.16e-02
|
7.23e-02
|
0.1660
|
-0.108000
|
-0.077200
|
0.023500
|
4.14e-02
|
8.72e-02
|
6.65e-02
|
1.91e-01
|
6.91e-01
|
4.84e-01
|
1.40e-01
|
DNA DOUBLE STRAND BREAK RESPONSE
|
50
|
6.82e-01
|
7.33e-01
|
0.1660
|
-0.096800
|
0.010200
|
-0.037100
|
7.95e-02
|
-1.01e-01
|
2.37e-01
|
9.00e-01
|
6.50e-01
|
3.31e-01
|
2.15e-01
|
CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION
|
337
|
7.62e-08
|
9.04e-07
|
0.1650
|
-0.099700
|
-0.049400
|
0.020000
|
6.54e-02
|
1.01e-01
|
1.71e-03
|
1.20e-01
|
5.28e-01
|
3.96e-02
|
1.46e-03
|
RHO GTPASES ACTIVATE IQGAPS
|
23
|
7.48e-01
|
7.94e-01
|
0.1650
|
-0.104000
|
-0.026900
|
0.092500
|
8.02e-02
|
2.29e-02
|
3.86e-01
|
8.23e-01
|
4.42e-01
|
5.06e-01
|
8.49e-01
|
VISUAL PHOTOTRANSDUCTION
|
54
|
3.02e-01
|
3.96e-01
|
0.1650
|
0.073400
|
0.139000
|
-0.011800
|
-3.36e-02
|
-3.24e-02
|
3.51e-01
|
7.68e-02
|
8.81e-01
|
6.70e-01
|
6.81e-01
|
ADORA2B MEDIATED ANTI INFLAMMATORY CYTOKINES PRODUCTION
|
81
|
8.85e-02
|
1.61e-01
|
0.1640
|
-0.053200
|
-0.007640
|
0.071700
|
-1.32e-01
|
-3.86e-02
|
4.08e-01
|
9.06e-01
|
2.65e-01
|
3.95e-02
|
5.49e-01
|
TRANS GOLGI NETWORK VESICLE BUDDING
|
69
|
1.61e-01
|
2.50e-01
|
0.1640
|
-0.099100
|
-0.003850
|
-0.009330
|
-5.75e-03
|
1.30e-01
|
1.55e-01
|
9.56e-01
|
8.93e-01
|
9.34e-01
|
6.22e-02
|
M PHASE
|
336
|
3.90e-06
|
3.16e-05
|
0.1640
|
-0.096600
|
-0.007270
|
0.043000
|
1.21e-01
|
2.99e-02
|
2.41e-03
|
8.19e-01
|
1.77e-01
|
1.41e-04
|
3.48e-01
|
INFECTION WITH MYCOBACTERIUM TUBERCULOSIS
|
25
|
8.90e-01
|
9.09e-01
|
0.1630
|
-0.095300
|
-0.005250
|
-0.119000
|
5.44e-02
|
-1.62e-02
|
4.09e-01
|
9.64e-01
|
3.02e-01
|
6.38e-01
|
8.88e-01
|
CYCLIN A B1 B2 ASSOCIATED EVENTS DURING G2 M TRANSITION
|
20
|
9.27e-01
|
9.38e-01
|
0.1620
|
-0.099300
|
-0.089700
|
-0.024100
|
-8.80e-02
|
-1.88e-04
|
4.42e-01
|
4.88e-01
|
8.52e-01
|
4.96e-01
|
9.99e-01
|
TELOMERE EXTENSION BY TELOMERASE
|
21
|
9.05e-01
|
9.20e-01
|
0.1610
|
-0.053200
|
-0.018900
|
0.008320
|
1.13e-01
|
-9.96e-02
|
6.73e-01
|
8.81e-01
|
9.47e-01
|
3.68e-01
|
4.30e-01
|
ACTIVATION OF BH3 ONLY PROTEINS
|
30
|
7.91e-01
|
8.30e-01
|
0.1610
|
-0.009110
|
0.009000
|
0.138000
|
7.99e-02
|
1.26e-02
|
9.31e-01
|
9.32e-01
|
1.90e-01
|
4.49e-01
|
9.05e-01
|
BINDING AND UPTAKE OF LIGANDS BY SCAVENGER RECEPTORS
|
31
|
7.18e-01
|
7.64e-01
|
0.1610
|
0.004220
|
0.018000
|
-0.155000
|
-5.47e-03
|
-3.76e-02
|
9.68e-01
|
8.63e-01
|
1.35e-01
|
9.58e-01
|
7.17e-01
|
SIGNALING BY NUCLEAR RECEPTORS
|
215
|
5.69e-02
|
1.15e-01
|
0.1600
|
-0.090300
|
-0.037200
|
-0.115000
|
-4.14e-02
|
-3.23e-02
|
2.27e-02
|
3.48e-01
|
3.82e-03
|
2.96e-01
|
4.15e-01
|
SENSORY PERCEPTION
|
133
|
1.65e-02
|
4.32e-02
|
0.1590
|
0.121000
|
0.058200
|
-0.008490
|
-7.63e-02
|
-3.79e-02
|
1.65e-02
|
2.47e-01
|
8.66e-01
|
1.29e-01
|
4.51e-01
|
RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES
|
85
|
2.57e-01
|
3.54e-01
|
0.1580
|
-0.009160
|
0.065500
|
0.125000
|
1.94e-02
|
6.83e-02
|
8.84e-01
|
2.97e-01
|
4.64e-02
|
7.57e-01
|
2.77e-01
|
HOMOLOGY DIRECTED REPAIR
|
103
|
2.33e-01
|
3.29e-01
|
0.1580
|
-0.076700
|
-0.019300
|
-0.045600
|
1.07e-01
|
-7.18e-02
|
1.79e-01
|
7.35e-01
|
4.24e-01
|
6.13e-02
|
2.08e-01
|
SARS COV 2 INFECTION
|
65
|
1.97e-01
|
2.89e-01
|
0.1570
|
-0.099000
|
-0.061200
|
0.102000
|
2.38e-02
|
4.42e-03
|
1.68e-01
|
3.94e-01
|
1.56e-01
|
7.40e-01
|
9.51e-01
|
COPI DEPENDENT GOLGI TO ER RETROGRADE TRAFFIC
|
86
|
2.41e-01
|
3.39e-01
|
0.1560
|
-0.001750
|
0.033600
|
0.107000
|
-1.07e-02
|
1.08e-01
|
9.78e-01
|
5.91e-01
|
8.74e-02
|
8.64e-01
|
8.27e-02
|
TRAF6 MEDIATED INDUCTION OF TAK1 COMPLEX WITHIN TLR4 COMPLEX
|
14
|
9.12e-01
|
9.24e-01
|
0.1560
|
0.059300
|
0.014600
|
-0.067900
|
1.25e-01
|
-1.67e-02
|
7.01e-01
|
9.25e-01
|
6.60e-01
|
4.18e-01
|
9.14e-01
|
REGULATION OF LIPID METABOLISM BY PPARALPHA
|
105
|
2.22e-01
|
3.16e-01
|
0.1560
|
0.054500
|
-0.087800
|
0.081500
|
-8.30e-02
|
7.18e-03
|
3.35e-01
|
1.20e-01
|
1.49e-01
|
1.42e-01
|
8.99e-01
|
SIGNALING BY RECEPTOR TYROSINE KINASES
|
449
|
8.65e-05
|
5.06e-04
|
0.1560
|
0.013100
|
-0.083500
|
-0.002390
|
-1.18e-01
|
5.64e-02
|
6.36e-01
|
2.53e-03
|
9.31e-01
|
2.00e-05
|
4.12e-02
|
AURKA ACTIVATION BY TPX2
|
71
|
4.32e-01
|
5.25e-01
|
0.1540
|
-0.010600
|
0.055900
|
0.097100
|
4.09e-02
|
9.66e-02
|
8.77e-01
|
4.16e-01
|
1.57e-01
|
5.52e-01
|
1.59e-01
|
RESOLUTION OF SISTER CHROMATID COHESION
|
100
|
6.61e-02
|
1.28e-01
|
0.1540
|
-0.083800
|
-0.077400
|
0.002790
|
8.02e-03
|
1.03e-01
|
1.48e-01
|
1.81e-01
|
9.62e-01
|
8.90e-01
|
7.57e-02
|
MAP3K8 TPL2 DEPENDENT MAPK1 3 ACTIVATION
|
16
|
9.69e-01
|
9.74e-01
|
0.1530
|
0.081400
|
0.050000
|
0.020500
|
-5.72e-02
|
1.04e-01
|
5.73e-01
|
7.29e-01
|
8.87e-01
|
6.92e-01
|
4.74e-01
|
DISEASES OF METABOLISM
|
194
|
8.03e-02
|
1.49e-01
|
0.1530
|
0.027300
|
0.107000
|
0.040700
|
4.61e-02
|
8.63e-02
|
5.12e-01
|
1.03e-02
|
3.29e-01
|
2.69e-01
|
3.86e-02
|
PLASMA LIPOPROTEIN CLEARANCE
|
25
|
7.56e-01
|
8.02e-01
|
0.1510
|
-0.130000
|
0.027600
|
0.004160
|
-5.63e-02
|
4.55e-02
|
2.61e-01
|
8.11e-01
|
9.71e-01
|
6.26e-01
|
6.93e-01
|
FLT3 SIGNALING
|
36
|
7.91e-01
|
8.30e-01
|
0.1510
|
0.023200
|
-0.098000
|
0.013900
|
-5.83e-02
|
9.48e-02
|
8.10e-01
|
3.09e-01
|
8.86e-01
|
5.45e-01
|
3.25e-01
|
HDR THROUGH HOMOLOGOUS RECOMBINATION HRR
|
62
|
5.98e-01
|
6.67e-01
|
0.1490
|
-0.034200
|
0.041000
|
-0.028200
|
1.14e-01
|
-7.48e-02
|
6.42e-01
|
5.77e-01
|
7.01e-01
|
1.20e-01
|
3.09e-01
|
METABOLISM OF LIPIDS
|
600
|
2.68e-08
|
3.39e-07
|
0.1490
|
0.013300
|
0.003830
|
-0.019000
|
3.20e-02
|
1.44e-01
|
5.80e-01
|
8.73e-01
|
4.28e-01
|
1.83e-01
|
2.09e-09
|
LEISHMANIA INFECTION
|
183
|
3.79e-02
|
8.41e-02
|
0.1490
|
-0.023300
|
-0.060300
|
0.011700
|
-1.27e-01
|
4.17e-02
|
5.87e-01
|
1.60e-01
|
7.84e-01
|
3.08e-03
|
3.32e-01
|
CELL CYCLE MITOTIC
|
468
|
8.42e-07
|
8.22e-06
|
0.1480
|
-0.082800
|
-0.004240
|
0.024200
|
1.17e-01
|
2.92e-02
|
2.23e-03
|
8.76e-01
|
3.71e-01
|
1.61e-05
|
2.80e-01
|
FACTORS INVOLVED IN MEGAKARYOCYTE DEVELOPMENT AND PLATELET PRODUCTION
|
119
|
1.72e-01
|
2.62e-01
|
0.1480
|
0.015100
|
-0.005820
|
0.012200
|
-9.38e-02
|
1.12e-01
|
7.77e-01
|
9.13e-01
|
8.19e-01
|
7.74e-02
|
3.46e-02
|
DEUBIQUITINATION
|
237
|
3.99e-03
|
1.38e-02
|
0.1470
|
-0.078400
|
-0.110000
|
-0.047800
|
3.21e-02
|
1.33e-02
|
3.79e-02
|
3.70e-03
|
2.06e-01
|
3.96e-01
|
7.25e-01
|
SIGNALING BY FGFR4
|
31
|
8.96e-01
|
9.11e-01
|
0.1470
|
-0.024700
|
-0.105000
|
-0.067900
|
-6.20e-02
|
3.86e-02
|
8.12e-01
|
3.14e-01
|
5.13e-01
|
5.50e-01
|
7.10e-01
|
MITOTIC PROPHASE
|
91
|
2.08e-01
|
3.02e-01
|
0.1450
|
0.018900
|
-0.038000
|
0.012000
|
5.37e-02
|
1.27e-01
|
7.55e-01
|
5.31e-01
|
8.43e-01
|
3.76e-01
|
3.64e-02
|
RHO GTPASES ACTIVATE FORMINS
|
117
|
5.28e-02
|
1.07e-01
|
0.1440
|
-0.086000
|
-0.082500
|
0.031900
|
2.29e-03
|
7.38e-02
|
1.08e-01
|
1.24e-01
|
5.51e-01
|
9.66e-01
|
1.68e-01
|
INNATE IMMUNE SYSTEM
|
760
|
1.19e-10
|
2.15e-09
|
0.1440
|
-0.057200
|
-0.030200
|
-0.096400
|
7.10e-02
|
4.58e-02
|
7.65e-03
|
1.59e-01
|
6.96e-06
|
9.43e-04
|
3.30e-02
|
FLT3 SIGNALING IN DISEASE
|
27
|
8.59e-01
|
8.83e-01
|
0.1430
|
0.021100
|
-0.093900
|
-0.033800
|
-1.83e-02
|
9.86e-02
|
8.49e-01
|
3.98e-01
|
7.61e-01
|
8.69e-01
|
3.75e-01
|
SIGNALING BY FGFR IN DISEASE
|
53
|
7.95e-01
|
8.33e-01
|
0.1420
|
-0.057100
|
-0.090000
|
-0.061500
|
5.10e-03
|
-7.13e-02
|
4.72e-01
|
2.57e-01
|
4.39e-01
|
9.49e-01
|
3.70e-01
|
GLUCAGON LIKE PEPTIDE 1 GLP1 REGULATES INSULIN SECRETION
|
38
|
8.72e-01
|
8.92e-01
|
0.1420
|
-0.063200
|
-0.094500
|
-0.006740
|
-8.06e-02
|
-2.65e-02
|
5.00e-01
|
3.13e-01
|
9.43e-01
|
3.90e-01
|
7.77e-01
|
PEPTIDE HORMONE METABOLISM
|
56
|
6.68e-01
|
7.20e-01
|
0.1410
|
-0.102000
|
-0.063300
|
-0.012900
|
-7.25e-02
|
-8.99e-03
|
1.87e-01
|
4.13e-01
|
8.67e-01
|
3.48e-01
|
9.07e-01
|
REGULATION OF TP53 ACTIVITY THROUGH PHOSPHORYLATION
|
86
|
4.37e-01
|
5.29e-01
|
0.1410
|
-0.059800
|
-0.074400
|
-0.014200
|
5.83e-02
|
-8.43e-02
|
3.38e-01
|
2.34e-01
|
8.20e-01
|
3.50e-01
|
1.77e-01
|
RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2
|
102
|
2.90e-01
|
3.85e-01
|
0.1400
|
-0.003280
|
0.092700
|
-0.072800
|
7.52e-02
|
-2.72e-03
|
9.54e-01
|
1.06e-01
|
2.04e-01
|
1.90e-01
|
9.62e-01
|
SIGNALING BY INTERLEUKINS
|
337
|
1.07e-04
|
6.12e-04
|
0.1390
|
-0.034200
|
-0.071600
|
-0.089500
|
4.52e-02
|
5.49e-02
|
2.82e-01
|
2.43e-02
|
4.86e-03
|
1.55e-01
|
8.40e-02
|
NEGATIVE REGULATION OF FGFR4 SIGNALING
|
21
|
9.63e-01
|
9.68e-01
|
0.1380
|
0.067400
|
-0.012900
|
0.051200
|
2.11e-02
|
1.07e-01
|
5.93e-01
|
9.19e-01
|
6.85e-01
|
8.67e-01
|
3.97e-01
|
HCMV INFECTION
|
101
|
1.53e-01
|
2.41e-01
|
0.1380
|
-0.068600
|
-0.069200
|
0.048900
|
8.48e-02
|
-3.25e-03
|
2.34e-01
|
2.30e-01
|
3.96e-01
|
1.41e-01
|
9.55e-01
|
CYTOSOLIC SENSORS OF PATHOGEN ASSOCIATED DNA
|
59
|
5.27e-01
|
6.09e-01
|
0.1380
|
-0.017400
|
-0.021800
|
-0.091100
|
9.23e-02
|
-3.65e-02
|
8.18e-01
|
7.73e-01
|
2.26e-01
|
2.20e-01
|
6.28e-01
|
TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION
|
73
|
5.80e-01
|
6.54e-01
|
0.1380
|
0.042000
|
-0.066400
|
0.067400
|
-9.00e-02
|
1.01e-02
|
5.35e-01
|
3.27e-01
|
3.20e-01
|
1.84e-01
|
8.82e-01
|
SARS COV INFECTIONS
|
139
|
1.44e-01
|
2.29e-01
|
0.1370
|
-0.085000
|
-0.072400
|
0.039000
|
-2.90e-02
|
-6.33e-02
|
8.40e-02
|
1.41e-01
|
4.28e-01
|
5.55e-01
|
1.98e-01
|
SEMA4D INDUCED CELL MIGRATION AND GROWTH CONE COLLAPSE
|
20
|
8.91e-01
|
9.09e-01
|
0.1350
|
0.052400
|
0.028900
|
-0.103000
|
3.37e-03
|
-6.43e-02
|
6.85e-01
|
8.23e-01
|
4.26e-01
|
9.79e-01
|
6.19e-01
|
CELL CYCLE
|
583
|
2.44e-06
|
2.13e-05
|
0.1340
|
-0.073500
|
-0.010600
|
0.021700
|
1.09e-01
|
-7.67e-03
|
2.55e-03
|
6.64e-01
|
3.73e-01
|
7.60e-06
|
7.53e-01
|
HCMV EARLY EVENTS
|
78
|
5.15e-01
|
6.02e-01
|
0.1340
|
-0.058600
|
-0.119000
|
-0.005320
|
-4.81e-03
|
-1.82e-02
|
3.71e-01
|
7.01e-02
|
9.35e-01
|
9.41e-01
|
7.82e-01
|
CELL SURFACE INTERACTIONS AT THE VASCULAR WALL
|
88
|
2.98e-01
|
3.94e-01
|
0.1330
|
0.026300
|
0.069100
|
-0.093100
|
-4.79e-02
|
3.65e-02
|
6.70e-01
|
2.63e-01
|
1.32e-01
|
4.38e-01
|
5.55e-01
|
SUMOYLATION OF DNA DAMAGE RESPONSE AND REPAIR PROTEINS
|
73
|
6.62e-01
|
7.15e-01
|
0.1320
|
0.001420
|
-0.087900
|
0.024500
|
-9.45e-02
|
-1.61e-02
|
9.83e-01
|
1.94e-01
|
7.18e-01
|
1.63e-01
|
8.12e-01
|
HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE
|
40
|
8.73e-01
|
8.93e-01
|
0.1300
|
-0.039600
|
0.012900
|
-0.109000
|
1.50e-02
|
-5.42e-02
|
6.65e-01
|
8.88e-01
|
2.31e-01
|
8.70e-01
|
5.54e-01
|
DEVELOPMENTAL BIOLOGY
|
787
|
5.52e-07
|
5.58e-06
|
0.1300
|
-0.050800
|
-0.060700
|
0.037100
|
-2.21e-02
|
-9.31e-02
|
1.61e-02
|
4.04e-03
|
7.86e-02
|
2.96e-01
|
1.03e-05
|
CARGO RECOGNITION FOR CLATHRIN MEDIATED ENDOCYTOSIS
|
88
|
5.95e-01
|
6.66e-01
|
0.1290
|
0.046200
|
-0.010200
|
0.046100
|
-7.05e-02
|
8.55e-02
|
4.54e-01
|
8.69e-01
|
4.55e-01
|
2.53e-01
|
1.66e-01
|
FOXO MEDIATED TRANSCRIPTION
|
56
|
5.70e-01
|
6.45e-01
|
0.1270
|
-0.021600
|
-0.111000
|
-0.016200
|
2.60e-02
|
4.96e-02
|
7.80e-01
|
1.50e-01
|
8.34e-01
|
7.36e-01
|
5.21e-01
|
TRANSCRIPTIONAL REGULATION BY TP53
|
339
|
1.42e-03
|
5.75e-03
|
0.1260
|
-0.053100
|
-0.027800
|
0.042500
|
1.02e-01
|
-1.43e-03
|
9.37e-02
|
3.81e-01
|
1.80e-01
|
1.29e-03
|
9.64e-01
|
DNA DOUBLE STRAND BREAK REPAIR
|
132
|
2.76e-01
|
3.73e-01
|
0.1250
|
-0.039500
|
-0.018500
|
-0.019200
|
1.00e-01
|
-5.80e-02
|
4.34e-01
|
7.13e-01
|
7.04e-01
|
4.66e-02
|
2.50e-01
|
SIGNALING BY MET
|
74
|
7.20e-01
|
7.66e-01
|
0.1240
|
-0.028900
|
-0.052600
|
-0.030800
|
-9.80e-02
|
3.41e-02
|
6.68e-01
|
4.34e-01
|
6.47e-01
|
1.45e-01
|
6.12e-01
|
NOTCH4 ACTIVATION AND TRANSMISSION OF SIGNAL TO THE NUCLEUS
|
12
|
9.90e-01
|
9.90e-01
|
0.1210
|
-0.030600
|
0.103000
|
0.013000
|
3.05e-02
|
-4.51e-02
|
8.55e-01
|
5.38e-01
|
9.38e-01
|
8.55e-01
|
7.87e-01
|
REGULATION OF TP53 ACTIVITY
|
148
|
1.74e-01
|
2.64e-01
|
0.1210
|
0.027000
|
-0.106000
|
0.037500
|
-5.26e-03
|
3.48e-02
|
5.71e-01
|
2.64e-02
|
4.31e-01
|
9.12e-01
|
4.66e-01
|
ACYL CHAIN REMODELLING OF PE
|
16
|
9.61e-01
|
9.68e-01
|
0.1200
|
-0.040000
|
-0.004430
|
0.059700
|
-6.38e-02
|
7.14e-02
|
7.82e-01
|
9.76e-01
|
6.79e-01
|
6.59e-01
|
6.21e-01
|
INHIBITION OF REPLICATION INITIATION OF DAMAGED DNA BY RB1 E2F1
|
13
|
9.80e-01
|
9.82e-01
|
0.1190
|
-0.099200
|
-0.037100
|
-0.015700
|
6.09e-03
|
5.25e-02
|
5.36e-01
|
8.17e-01
|
9.22e-01
|
9.70e-01
|
7.43e-01
|
TRANSLATION OF SARS COV 1 STRUCTURAL PROTEINS
|
28
|
8.92e-01
|
9.09e-01
|
0.1180
|
-0.111000
|
-0.008190
|
0.034500
|
-1.60e-02
|
-1.52e-02
|
3.10e-01
|
9.40e-01
|
7.52e-01
|
8.84e-01
|
8.89e-01
|
RESPONSE OF MTB TO PHAGOCYTOSIS
|
22
|
9.78e-01
|
9.81e-01
|
0.1160
|
-0.106000
|
-0.021800
|
-0.018400
|
5.52e-03
|
-3.62e-02
|
3.87e-01
|
8.59e-01
|
8.81e-01
|
9.64e-01
|
7.69e-01
|
ADAPTIVE IMMUNE SYSTEM
|
585
|
4.68e-06
|
3.71e-05
|
0.1140
|
-0.042700
|
-0.036700
|
0.005640
|
3.12e-02
|
9.40e-02
|
7.90e-02
|
1.31e-01
|
8.17e-01
|
1.99e-01
|
1.10e-04
|
HATS ACETYLATE HISTONES
|
90
|
5.63e-01
|
6.40e-01
|
0.1110
|
0.011900
|
-0.073200
|
0.077800
|
-7.26e-03
|
-2.82e-02
|
8.45e-01
|
2.30e-01
|
2.03e-01
|
9.05e-01
|
6.44e-01
|
NEGATIVE REGULATION OF MET ACTIVITY
|
20
|
9.88e-01
|
9.89e-01
|
0.1090
|
0.008960
|
-0.094400
|
-0.011400
|
-4.46e-02
|
-2.73e-02
|
9.45e-01
|
4.65e-01
|
9.30e-01
|
7.30e-01
|
8.32e-01
|
G ALPHA Q SIGNALLING EVENTS
|
140
|
4.92e-01
|
5.80e-01
|
0.1070
|
-0.005610
|
-0.056400
|
0.022900
|
-8.55e-02
|
1.73e-02
|
9.09e-01
|
2.50e-01
|
6.40e-01
|
8.12e-02
|
7.25e-01
|
CILIUM ASSEMBLY
|
189
|
9.91e-02
|
1.76e-01
|
0.1060
|
-0.075800
|
0.015200
|
0.045600
|
-3.04e-02
|
-4.82e-02
|
7.27e-02
|
7.19e-01
|
2.81e-01
|
4.71e-01
|
2.54e-01
|
RHOH GTPASE CYCLE
|
37
|
8.95e-01
|
9.10e-01
|
0.1060
|
0.012200
|
0.038900
|
-0.084900
|
-2.85e-02
|
-3.85e-02
|
8.98e-01
|
6.82e-01
|
3.72e-01
|
7.64e-01
|
6.86e-01
|
HDR THROUGH SINGLE STRAND ANNEALING SSA
|
36
|
9.34e-01
|
9.43e-01
|
0.1050
|
-0.003690
|
0.027100
|
-0.053700
|
4.70e-02
|
-7.22e-02
|
9.69e-01
|
7.79e-01
|
5.77e-01
|
6.25e-01
|
4.53e-01
|
RNA POLYMERASE II TRANSCRIPTION
|
1069
|
5.82e-05
|
3.53e-04
|
0.1040
|
-0.054900
|
-0.078100
|
-0.004530
|
-1.83e-02
|
-3.55e-02
|
2.69e-03
|
1.95e-05
|
8.04e-01
|
3.16e-01
|
5.23e-02
|
SIGNALING BY FGFR3
|
34
|
9.71e-01
|
9.74e-01
|
0.1010
|
-0.001750
|
-0.074200
|
-0.046000
|
-4.13e-02
|
2.80e-02
|
9.86e-01
|
4.54e-01
|
6.43e-01
|
6.77e-01
|
7.78e-01
|
MITOTIC PROMETAPHASE
|
175
|
1.97e-01
|
2.89e-01
|
0.0989
|
-0.035500
|
-0.012800
|
0.041600
|
-6.18e-03
|
8.11e-02
|
4.18e-01
|
7.71e-01
|
3.43e-01
|
8.88e-01
|
6.46e-02
|
HEMOSTASIS
|
463
|
3.19e-02
|
7.28e-02
|
0.0979
|
0.028100
|
0.011300
|
-0.011900
|
-5.35e-02
|
7.53e-02
|
3.01e-01
|
6.78e-01
|
6.62e-01
|
4.96e-02
|
5.70e-03
|
POST TRANSLATIONAL PROTEIN MODIFICATION
|
1184
|
3.21e-07
|
3.39e-06
|
0.0969
|
-0.006020
|
-0.015400
|
0.029200
|
2.58e-02
|
8.72e-02
|
7.30e-01
|
3.77e-01
|
9.44e-02
|
1.38e-01
|
5.66e-07
|
ORGANELLE BIOGENESIS AND MAINTENANCE
|
281
|
1.38e-01
|
2.23e-01
|
0.0920
|
-0.043100
|
-0.045500
|
0.042400
|
3.04e-02
|
-4.25e-02
|
2.15e-01
|
1.90e-01
|
2.22e-01
|
3.82e-01
|
2.22e-01
|
REGULATION OF PLK1 ACTIVITY AT G2 M TRANSITION
|
84
|
8.52e-01
|
8.77e-01
|
0.0909
|
-0.015900
|
0.037400
|
0.062900
|
4.09e-02
|
3.13e-02
|
8.02e-01
|
5.53e-01
|
3.20e-01
|
5.18e-01
|
6.20e-01
|
ANCHORING OF THE BASAL BODY TO THE PLASMA MEMBRANE
|
96
|
5.87e-01
|
6.61e-01
|
0.0889
|
-0.051400
|
0.012800
|
0.053700
|
-3.90e-02
|
-2.63e-02
|
3.84e-01
|
8.28e-01
|
3.64e-01
|
5.09e-01
|
6.56e-01
|
CELLULAR SENESCENCE
|
138
|
8.38e-01
|
8.67e-01
|
0.0879
|
-0.040100
|
-0.037600
|
-0.033300
|
-7.44e-03
|
-5.95e-02
|
4.17e-01
|
4.46e-01
|
5.00e-01
|
8.80e-01
|
2.28e-01
|
RHO GTPASE EFFECTORS
|
243
|
2.55e-01
|
3.53e-01
|
0.0790
|
-0.028200
|
-0.040000
|
0.022200
|
-1.32e-03
|
5.79e-02
|
4.49e-01
|
2.84e-01
|
5.51e-01
|
9.72e-01
|
1.21e-01
|
PLATELET ACTIVATION SIGNALING AND AGGREGATION
|
216
|
5.22e-01
|
6.06e-01
|
0.0737
|
-0.013100
|
-0.021400
|
-0.027400
|
-7.26e-03
|
6.32e-02
|
7.40e-01
|
5.88e-01
|
4.88e-01
|
8.54e-01
|
1.10e-01
|